Factors influencing the analgesic effects and clinical efficacy of transcutaneous electrical nerve stimulation (TENS) by Johnson, Mark Ian
FACTORS INFLUENCING THE 
ANALGESIC EFFECTS AND 
CLINICAL EFFICACY OF 
TRANSCUTANEOUS 
ELECTRICAL NERVE 
STIMULATION (TENS). 
By 
Mark Ian Johnson 
A thesis submitted for the degree of PhD 
July 1991 
tNIEwCAs-r*LE UNIVERSITY L. I ERARY 
09 : I. 5 C?; '7 6,9 8 
MEQ ýrýesls L SS5(ö . 
Short Abstract 
Short Abstract 
Factors influencing the analgesic effects and clinical efficacy of TENS have been 
examined in this thesis. 
Clinical Studies: It was found that since the introduction of TENS into the 
Newcastle Pain Relief Clinic in 1979,1582 patients have been given a trial of TENS to 
control chronic pain, of which 927 (58.6%) continue to use the therapy on a long-term 
basis. The clinical use of TENS by 179 of these patients was examined in-depth and it 
was found that any type of pain may respond to TENS although a lack of relationships 
between patient, stimulator and treatment outcome variables was observed. However, 
over half of the patients using TENS on a long-term basis achieve less than'50% relief 
of pain, therefore, an investigation to identify the optimal electrical characteristics of 
TENS on cold-pressor pain in healthy subjects was performed. 
Electrical characteristics of TENS: Differential analgesic effects were observed 
between a range of pulse frequencies, pulse patterns and stimulating modes. It was 
suggested that continuous mode stimulation at 80Hz producing a 'strong but 
comfortable' electrical paraesthesia within the site of pain should be the primary choice 
when using TENS treatment in the clinic. However, acupuncture-like TENS produced 
powerful analgesic effects during and after TENS. A number of improvements in 
stimulator design are suggested. 
EEG variables: Further studies, aimed at elucidating TENS mechanisms, showed 
that TENS altered electroencephalographic (EEG) variables in healthy subjects and 
pain patients. Moreover, chronic pain patients with small baseline peak-to-peak 
amplitudes of the somatosensory evoked potential (SEP) and low spontaneous EEG 
activity, showed poor response to TENS. It is suggested that an individual's intrinsic 
central response pattern to external stimuli may influence response to TENS. 
The clinical implications of these findings are discussed. 
Long Abstract 
Long Abstract 
Transcutaneous electrical nerve stimulation (TENS) is a simple, non-invasive 
technique used in the control of chronic pain. Despite the success of TENS and its 
continued use for over twenty years, some patients either fail to respond or show only 
a partial response. Furthermore some patients respond initially to TENS but then 
become tolerant to its analgesic effects. The reasons for poor response to TENS are 
unknown; different clinics report widely differing success rates, and information on 
long-term efficacy is sparse. Furthermore, TENS is still administered on an empirical 
basis in which the patient determines by trial and error the most appropriate stimulator 
settings (i. e. electrical characteristics of TENS) to treat his or her particular pain. It is 
impossible to predict whether an individual patient will respond to TENS or which 
stimulator settings will be optimal. In an attempt to elucidate these problems, the 
clinical, electrophysiological, neuropharmacological, psychological and sociological 
factors that influence the analgesic effects and clinical efficacy of TENS have been 
examined in this thesis. 
Three clinical studies were performed. The first (Study 2.1) reviewed the use of TENS 
since its introduction to Newcastle Pain Relief Clinic in 1979. It was found that 1582 
patients have been given a trial of TENS of which 927 (58.6%) continue to use a 
stimulator on a long-term basis (Study 2.1). The clinical use of TENS by 179 of these 
patients was examined in-depth (Study 2.2). Although previous literature suggests that 
TENS is most efficacious for pains of neurogenic (neuropathic) origin, it was found 
that any type of pain may respond. No relationships were found to exist between the 
electrical characteristics of TENS (i. e. stimulator settings) used by patients during 
TENS treatment and the cause and site of pain. However, patients utilised specific 
pulse frequencies and patterns and consistently used these settings on subsequent 
treatment sessions (Study 2.3). 
These clinical studies showed that in this population, 41.4% of patients failed to 
respond to TENS and half using TENS on a long-term basis achieved less than 50% 
relief of pain. Thus, a systematic investigation to determine optimal electrical 
characteristics of TENS was performed. 
Three experiments were undertaken to examine separately the analgesic effects of 
different electrical characteristics of TENS (pulse frequency, pulse pattern and 
stimulation mode) on cold-pressor pain in healthy subjects. The effects of a range of 
Long Abstract 
pulse frequencies (10Hz to 160Hz) applied to produce a 'strong but comfortable' 
electrical paraesthesia within the painful site were measured (Exp. 3.1). It was found 
that frequencies between 20-80Hz were most effective. However, no differential 
effects were observed between a range of pulse patterns (continuous, burst, 
modulation, random; Exp. 3.2). When TENS was applied in burst mode at an intensity 
sufficient to produce phasic muscle twitches at a site distant yet myotomally related to 
the site of pain (acupuncture-like TENS) a powerful analgesic effect was observed 
during and post-stimulation (Exp. 3.3). It is suggested that continuous mode 
stimulation at 80Hz, producing a 'strong but comfortable' electrical paraesthesia within 
the painful site, should be the primary TENS treatment choice in the clinic but that in 
selected cases AL-TENS may be more effective. A number of improvements in 
stimulator design are suggested. 
Further experiments were aimed at elucidating the mechanism of TENS effects by 
investigating the influence of TENS on electrophysiological and neuropharmacological 
variables. It was found that TENS reduced peak-to-peak amplitudes of the late 
waveform components (N1P2) of somatosensory evoked potentials (Exp. 4.1) and 
increased alpha, beta and theta activity of spontaneous EEG in healthy subjects (Exp. 
4.2) and/or pain patients (Exp. 4.3). As TENS produced changes in SEPs elicited 
from non-painful stimuli, and also changes in spontaneous EEG in pain-free subjects, 
it is suggested that the effects of TENS may be due in part to changes in sensory 
processing at several levels in the nervous system which may not specific for the 
perception of pain. The surprising finding that TENS increased peripheral circulating 
met-enkephalin in chronic pain patients was attributed to a stress-like release although 
this observation remains to be confirmed using a larger population sample (Exp. 5.1). 
The results of these experiments suggest that baseline electrophysiological and 
neuropharmacological variables may be important determinants of individual response 
to TENS. Thus, a prospective investigation was undertaken on 29 patients who were 
undergoing a trial of TENS to control chronic pain, in an attempt to identify predictors 
of patient response. Patient response to TENS was related to baseline SEP amplitudes 
and spontaneous EEG but was not related to biochemical, psycho-social, personality 
or pain related factors (Exp. 6.1). Thus, patients with small peak-to-peak amplitudes 
of the SEP, and low power spectrum of spontaneous EEG showed poor response to 
TENS (Exp. 6.1). It is suggested that an individual's intrinsic central response pattern 
to external stimuli may influence response to TENS. 
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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
Pain is one of the world's most costly health problems. It is financially expensive 
in terms of medical consultations, treatments and time lost from work, and 
immeasurably costly in terms of personal suffering and impaired quality of life. 
Nevertheless the medical management of pain, especially chronic pain, remains 
unsatisfactory and any potential improvement in pain control is worthy of serious 
study. The relatively recent technique of transcutaneous electrical nerve stimulation 
(TENS) appears to offer such promise in the control of chronic pain and is the 
subject of this investigation. 
TENS is a simple, non-invasive technique, in which electrical currents, generated 
by a portable stimulating unit, are administered via conducting pads (electrodes) 
placed on the intact surface of the skin (Fig. 1.1). 
Fig. 1.1 Nurse applying TENS to treat a patient with 
back pain. Electrodes are attached to surface of skin by adhesive 
tape. Electrical pulses from the TENS unit (next to the patient on the 
bed) are delivered to the electrodes via a lead to produce a tingling 
sensation (electrical paraesthesia). 
Chapter 1: Introduction 2 
In its simplest (conventional) form TENS produces a'tingling' sensation (electrical 
paraesthesia) within the painful area. The intensity and quality of electrical 
paraesthesia can be varied and controlled by the patient according to his/her 
requirements. TENS has been shown to produce useful analgesic effects in patients 
with acute or chronic pain and has gained worldwide popularity. TENS has many 
advantages over conventional treatments for pain. It does not require surgical 
intervention and, unlike analgesic drugs, has no serious adverse effects. It can be 
used long-term and does not interfere with other analgesic treatments. However 
some patients fail to respond to TENS; others respond initially but then become 
tolerant; still others show only a partial response. The reasons for poor response to 
TENS are unknown; different clinics report widely differing success rates, and 
information on long-term efficacy is sparse. 
Furthermore, there have been few detailed studies into the stimulator settings 
(electrical characteristics) utilised during TENS which may influence efficacy. In 
practice TENS is usually administered on an empirical basis where the patient 
determines by trial and error the most appropriate electrical characteristics of 
stimulation to control the pain condition. It is likely that TENS efficacy could be 
improved if the electrical characteristics of stimulation were optimised. 
This investigation is aimed at elucidating some of the factors which determine the 
analgesic efficacy of TENS, with a view to predicting patient response to TENS 
and possible improvements in stimulator design. 
PAIN 
The working definition of pain as described by the Taxonomy Committee of The 
International Association of the Study of Pain (IASP) is : 
"... an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage. " 
Some additional points of clarity accompany the definition: 
"Pain is always subjective. Each individual learns the application of the word 
through experiences related to injury in early life. It is unquestionably a 
sensation in a part of body but is also unpleasant and therefore an emotional 
experience. " 
A detailed explanation of this definition can be found in Merskey [1979] and IASP 
[1986]. 
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Three aspects of pain perception arise from this definition: 
(i) The sensory components of pain, e. g. location, intensity and quality of pain. 
(ii) The affective components of pain, e. g. distress and anxiety associated with 
pain. 
(iii) The evaluative components of pain, e. g. significance and importance of 
pain. 
Thus, the sensation of pain, like any other sensory modality, depends upon the 
activation of a discrete set of neural pathways, which in turn evoke a complex 
reflex and motivational-affective experience associated with emotional reactions 
such as suffering, anxiety, depression and an evaluation of what the pain means 
[Fields 1991]. Consequently inter-individual reactions to painful stimuli are 
variable. 
ACUTE AND CHRONIC PAIN 
Pain is most commonly produced by either (i) injury or (ii) stimuli that are intense 
enough to be potentially damaging (noxious). Along with the subjective experience 
of pain, noxious stimuli elicit a variety of behavioural responses which serve to 
protect uninjured tissues, i. e. withdrawal reflexes, escape, immobilisation of the 
injured part and avoiding future encounters with such stimuli. Thus in its acute 
state, pain serves as a warning signal or protective mechanism and is associated 
with acute disease or traumatic injury. If diagnosed and treated comprehensively 
acute pain can usually be resolved. 
It is when a pain condition becomes chronic, persisting longer than the expected 
time after illness or injury, that the pain appears to lose its biological importance as 
a warning signal and the body may cease to react with appropriate protective 
reflexes. Four types of chronic pain have been described by Chapman and Bonica 
[1985]: 
(i) Pain persisting beyond the normal healing time for acute injury or disease. 
(ii) Pain related to chronic degenerative disease or a persisting neurological 
condition. 
(iii) Pain without any identifiable organic cause. 
(vi) Advanced cancer. 
Often the diagnosis and treatment of chronic pain is difficult, and the failure of 
ineffective medication and surgery can leave patients seriously debilitated. 
Consequently chronic pain is often associated with severe depression since the 
patient may lose hope for prospects of relief. 
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To achieve adequate treatment of both acute and chronic pain, it is important to 
understand the basic neuroanatomical and neuropharmacological systems which 
lead to the sensation of pain. 
NEUROANATOMY OF PAIN 
Between the stimulus of tissue injury and the subjective experience of pain a series 
of complex electrical and chemical events take place. A schematic diagram of the 
major neural pathways that contribute to pain sensation is shown in Fig. 1.2. There 
is no single pathway or brain centre devoted to pain transmission and processing 
but rather an elaborate neurobiological system in which many interacting processes 
convert the noxious stimulus into the subjective sensation of pain. These processes 
include, transduction, transmission, modulation and perception of nociceptive 
information. 
Transduction: Refers to the process by which noxious stimuli is converted to 
electrical activity in the appropriate sensory nerve endings. This is achieved by 
nociceptors, which can be defined as: 
"receptors preferentially sensitive to noxious or potentially noxious stimuli or 
to a stimulus which would become noxious if prolonged" [IASP 1986]. 
Two main classes of cutaneous nociceptors are known: 
(i) High threshold mechanoreceptors connected to myelinated A-delta fibres, 
which conduct at 5-10ms-1, 
(ii) Polymodal nociceptors connected to unmyelinated C-fibres, which conduct 
at 0.5-2ms-1. 
Both groups of nociceptors begin to respond at stimulus intensities below those that 
evoke pain [Wall & McMahon 1986]. 
Transmission: Refers to the neural events subsequent to transduction. There 
are two major components of the nociceptive transmission system. 
Peripheral: Small diameter A-delta and C-fibres (2.0-5.0µm and 0.4-1.2µm 
respectively) transmit nociceptive information from nociceptors to the dorsal horn 
of the spinal cord (the majority via the dorsal root ganglia), where they branch 
profusely in the marginal zone and substantia gelatinosa, and form synapses with 
intemeurones and second order neurones. 
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Fig. 1.2 Schematic diagram of the main nociceptive pathways. Non-noxious 
information is transmitted in large A-alpha/beta diameter fibres (thick line) which ascend ipsilateral 
via the dorsal column to synapse in the cuneate and gracile nuclei. Second order neurones originate 
here and cross the spinal cord to run in the contralateral medial lemniscus to the ventrobasal nuclei 
of the thalamus and the somatosensory cortex. Nociceptive information is transmitted from the 
periphery to the dorsal horn of the spinal cord via small diameter fibres (thin line) which synapse 
with second order transmission (T) cells either directly or via interneurones (white circle). The 
transmission cells are located in the deeper layers of the dorsal horn (lamina V) and project to the 
contralateral thalamus in spinoreticular and spinothalamic tracts. Diffuse projections to the whole 
cortex produce the affective - evaluative components of pain and projections to the specific (Areas 
SI & SII) somatosensory cortex produce the sensory - discriminatory components of pain. The 
transmission of nociceptive information is modulated by (i) a gate control system and (ii) 
descending pain inhibitory pathways. The gate control system modulates the firing of transmission 
cells via inhibitory interneurones (black circle) located in the Substantia Gelatinosa (SG). These 
inhibitory interneurones can by activated by either (i) collaterals from the large diameter fibres 
(activated by TENS) or (ii) descending pain inhibitory pathways. These descending pain inhibitory 
pathways originate in the periaqueductal grey matter of the brainstem and are activated by (i) 
collaterals from spinothalamic tract and (ii) higher centres of the brain. All synapses excitatory 
unless otherwise stated. (Adapted from Thompson [1984); Bowsher [1988); Fields [1987a]; Bonica 
[1990]). 
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Central: The most important pathways in the human spinal cord which relay 
nociceptive information to the brain and thalamus, ascend via second order 
neurones in the contralateral anterolateral white matter in the following nerve tracts: 
(i) Spinoreticular -a multi-synaptic tract which ascends to the medullary reticular 
formation and intralaminar nuclei of the thalamus. 
(ii) Spinothalamic - which ascends directly to the ventrobasal nuclear complex of 
the thalamus. 
The spinothalamic tract has been subdivided into: 
(i) the neospinothalamic tract, responsible for pricking or localised sharp pain 
associated with A-delta fibre stimulation: 
(ii) the paleospinothalamic tract, responsible for slow burning pains associated 
with C-fibre stimulation. 
Evidence suggests that the spinoreticular and the paleospinothalamic tracts serve as 
a single functional entity [Fields 1987b]. 
From its respective nuclei in the thalamus, the neospinothalamic tract projects to the 
somatosensory cortex (areas SI and SII) and sub-serves the sensory-discriminative 
aspects of pain. The spinoreticular pathway projects from the thalamus. to 
widespread areas of the brain, and underlies the motivational-affective aspects of 
pain (Fig. 1.2). Thus, diffuse projections from the thalamus to the hypothalamus, 
limbic system and cortex, account for the autonomic, emotional and cognitive 
processes associated with the perception of pain. 
Modulation: Refers to the neural activity leading to control of the nociceptive 
transmission system. An antinociceptive system operates via (i) 'spinal gating 
mechanisms', where the further transmission of incoming nociceptive information 
is regulated by collaterals of primary afferent neurones (both large (primarily A- 
beta, 5-12µm) and small diameter) and interneurones, and (ii) supraspinal 
descending pain inhibitory pathways, extending from the periaqueductal grey to the 
spinal cord, where they impinge upon incoming nociceptive information. 
Pain perception: Unfortunately knowledge is severely lacking in the 
understanding of the process of pain perception. A recent study by Jones et al. 
[1991] which used positron emission tomography (PET) to measure changes in 
regional blood flow during pain in healthy subjects, suggests that the cingulate 
cortex may play an important role in the perception of pain. However, pain is 
perceived in terms of injury in the context of the afferent barrage in fibres 
transmitting nociceptive and non-nociceptive information, and of analytical 
processes in the brain. Moreover, the peripheral and central nervous systems 
Chapter 1: Introduction 
change progressively with time, particularly after injury. Thus changes in neuronal 
connectivity and excitability resulting from injury may alter the way in which the 
nervous system responds to stimuli and may even evoke pain from innocuous 
stimuli. 
NEUROPHARMACOLOGY OF PAIN 
It is clear that many substances play a role in the transmission and modulation of 
nociceptive information. Endogenous algesic agents produced peripherally during 
noxious stimulation include serotonin (5-Hydroxytryptamine (5-HT)), histamine, 
and bradykinin. In addition prostaglandins play an important role in sensitising 
sensory nerve endings to nociceptive substances such as kinins. These peripherally 
acting substances will not be considered further. Neuropeptides (non-opioid and 
opioid), monoamines and amino acids appear to play important roles in the central 
transmission and modulation of nociceptive information, as shown in Fig. 1.3. 
These central agents will now be discussed. 
Non-opioid neuropeptides: Substance P has been shown to act as an 
excitatory neurotransmitter at primary nociceptive nerve endings in the dorsal horn 
[Hökfelt et al. 1975]. It may be co-released with other transmitters, possibly 
glutamate or ATP, and its release may be controlled by the pre-synaptic action of 
short enkephalinergic interneurones. In addition to substance P, other non-opioid 
polypeptides including somatostatin, neurotensin, angiotensin II and 
cholecystokinin (CCK) may be involved in pain modulation in the spinal cord and 
brain. 
Opioid neuropeptides: Since the isolation of opioid peptides from the pig 
brain by Hughes et al. [1975], a wide distribution of multiple opioid peptides and 
opioid receptors have been found [for review see Mansour et al. 1988]. Many of 
these are closely associated with systems subserving pain modulation [for review 
see Clement-Jones & Besser 1983]. Three classes of endogenous opioid peptides 
appear to be of major physiological importance: dynorphin, endorphins and 
enkephalins. Enkephalins appear to control the response of dorsal horn neurones 
and modulate pain at higher sites in the central nervous system, although the 
analgesic effects of enkephalins are short lived due to their rapid degradation by 
enkephalinases. 
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Fig. 1.3 Simplified diagram of the neuropharmacology of antinociceptive 
pathways. Substance P (SP), and Vasoactive Intestinal Polypeptide (VIP) are released from 
primary afferent nociceptive neurones originating from the skin and viscera and terminate in the 
substantia gelatinosa (SG) of the dorsal horn. SG interneurones excite second order transmission 
cells (T) primarily in lamina V which ascend in multisynaptic spinoreticular tracts to the thalamus 
and produce the conscious sensation of 'slow aching' pain. Waldeyer cells (W) in lamina I of the 
dorsal horn can be excited by impulses generated in A-delta afferents and transmit noxious 
information conveying 'fast sharp' pain to consciousness via the spinothalamic tract and the 
somatosensory cortex. Spinal antinociception: Enkephalinergic interneurones (ENK, dark circle) 
operate on the borders of lamina I and II and inhibit onward transmission of noxious information 
generated by C-fibre activity. Low intensity TENS and dorsal column stimulation (DCS) inhibit 
SG, possibly by the release of GABA, to produce segmental inhibition of nociceptive 
transmission. Supraspinal antinociception: Descending pain inhibitory pathways are activated via 
collaterals of the spinothalamic tract by high intensity TENS or acupuncture, and originate in the 
periaqueduatal grey (PAG). The PAG is rich in opioid peptides (OP) and receives input from a 
variety of sources including the hypothalamus. Neurones from the PAG project to the nucleus 
raphe magnus (nRM) and nucleus reticularis gigantocellularis (nRG). Serotonergic (5-HT) and 
noradrenergic (NAd) neurones arising form the nRM and nRG, project to ENK to inhibit onward 
transmission of nociceptive information. All synapses excitatory unless otherwise stated. From Thompson and Filshie [in press]. 
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Endorphins are less rapidly degraded in the body and have longer lasting analgesic 
effects. A rise of concentration in cerebrospinal fluid (CSF) concentrations of beta- 
endorphin have been shown to occur during acupuncture [Clement-Jones et al. 
1980b], electrical stimulation of the periaqueductal grey and associated nuclei [Akil 
et al. 1976], and during certain forms of TENS [Sjölund et al. 1977]. The role of 
dynorphin in pain modulation remains unclear. 
Monoamines: Monoamine neurotransmitters appear to play a role in the 
modulation of nociceptive transmission via supraspinal descending pain inhibitory 
pathways terminating in the spinal cord [Akil & Liebeskind 1975]. Analgesia 
produced by electrical stimulation of the periaqueductal grey and raphe nuclei, is 
accompanied by the release of 5-HT and noradrenaline in the spinal cord in the cat 
[Belcher et al. 1978]. Histamine, acetylcholine, and dopamine, may also mediate 
pain suppression pathways [for review see Fitzgerald 1986]. 
Amino acids: Several amino acid transmitters have been shown to play a role 
in nociception. Glutamate is contained within three quarters of dorsal root ganglia 
cells and may be an excitatory neurotransmitter for primary afferent nociceptive 
afferents. Recently, the N-methyl d-aspartate (NMDA) receptor has been implicated 
in the amplification and prolongation of an ongoing nociceptive afferent barrage (C- 
fibre dependent facilitation, or 'wind-up') [Dickenson 1990]. Gamma-amino 
butyric acid (GABA) may be involved in central antinociceptive systems within the 
spinal cord and brainstem nuclei. Glycine, beta-alanine, and taurine, may also play 
a role. 
MEASUREMENT OF PAIN IN MAN 
One of the most difficult and critical aspects in the investigation of pain is its 
quantitative documentation. As pain is a subjective experience, the basic expression 
of pain in humans is the verbal report. Various methods on the scaling of subjective 
pain have been established. 
Pain rating scales: Common approaches to the rating of pain sensation are 
category and analogue scales. The category scale is classified by a set of given 
descriptors to measure sensory (e. g. sharp, dull, burning, aching), affective (e. g. 
exhausting, sickening, gruelling, nagging), and evaluative (e. g. annoying, 
unbearable), components of pain as shown in the McGill Pain Questionnaire 
[Melzack 1975a]. The analogue scale translates different strengths or sensations 
into units of length, and although scales can vary in presentation, a 10 cm visual 
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analogue line labelled at ends with words and numbers (for example 'no pain' =0 
to'worst pain imaginable' = 10) is commonly used in clinical research. The subject 
indicates the intensity of the pain by marking the line at the appropriate point. 
Despite problems with the reliability of the analogue scale in measuring inter- 
individual pain variables (i. e. intensity), and its ability to record only one 
component of the multi-dimensional pain sensation, it proves a most useful and 
simple means of comparing treatment effects within the laboratory setting. 
Objective pain measures: To quantify objectively the verbal report of 
pain, physiological reactions accompanying pain can be recorded, such as 
peripheral nerve activity, withdrawal reflexes, skin resistance reactions, evoked 
potentials (EPs) and the electroencephalogram (EEG). It has been claimed that the 
cerebral evoked potential (the stimulus induced change in the electroencephalogram) 
can provide a stable and reliable correlate between brain activity and the subjective 
report of pain [for reviews see Chapman et al. 1979; Bromm 1985]. Many studies 
have utilised EPs to quantify pain and analgesic effects in man. With recent 
improvements in technology and methodology, it is also possible to monitor 
changes in spontaneous (ongoing) electroencephalographic activity during pain and 
analgesia, although few studies have been performed. 
Experimental and clinical pain: Experimentally-induced pain in the 
laboratory differs from pain seen by the physician in the clinic because experimental 
pain can always be interrupted or stopped on request by the subject. Measurement 
of experimental pain is characterised by the sensory-discriminative rather than 
affective-evaluative components of pain, and is reflected by nocifensive motor 
reactions. By contrast, a patient's pain is characterised by aversive, emotional and 
vegetative components producing a feeling of illness, and ultimately causing the 
patient to visit the doctor. 
TREATMENT OF PAIN 
Until the 50's, many physicians had worked on the assumption that the brain had a 
hard-wired pain transmitting system, and that to stop pain one had to irreversibly 
block these transmitting pathways by either surgical (i. e. cordotomy) or chemical 
means (i. e. neurolytic block). Such treatment failed and at present analgesic 
medications are the mainstay of pain control as they have a proven efficacy, are 
widely available, and are convenient for patients to use and physicians to 
administer. Primary analgesic agents include antipyretics (non-steroidal anti- 
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inflammatory drugs), narcotics (opioids) and local and general anaesthetics. 
Secondary analgesic agents include anxiolytics, neuroleptics, antidepressants and 
anticonvulsants [Thompson 1984]. Nevertheless, patients and physicians are often 
dissatisfied with the long-term use of analgesic drugs for non-malignant pain as 
patients often report inadequate pain relief, experience intolerable side effects and/or 
are intimidated with the problems associated with long-term use. 
Consequently a variety of non-drug treatment techniques have been developed and 
are gaining acceptance in the medical profession. These include cognitive 
behavioural methods (hypnotherapy, biofeedback, relaxation), ablative procedures 
(neurolytic blocks), neuroaugmentative surgery, acupuncture and transcutaneous 
electrical nerve stimulation (TENS). Unfortunately administration of most of these 
treatments requires specialised training and is labour intensive and thus expensive. 
TENS remains the exception to the rule, yet the value of the technique is still 
questioned due to contradictory reports on efficacy and the difficulty of designing 
good clinical studies [Deyo et al. 1990a; 1990b]. 
TENS came into widespread use following the prediction by Melzack and Wall in 
1965 that stimulation of large diameter afferent fibres in a peripheral nerve would 
alleviate pain [Melzack & Wall 1965]. Over the last few decades TENS has been 
established as an efficacious therapeutic modality in the treatment of both acute and 
chronic pain, yet the technique is not really new. 
HISTORY OF ELECTROANALGESIA 
Long before the technology existed to generate electricity, man has used 'naturally 
occurring' electricity for the treatment of ailments. Stone carvings dating from the 
Egyptian Fifth Dynasty (2500BC) indicate that Malapterurus electricus, a species of 
electric fish found in the Nile, was used to treat pain conditions [Kane & Taub 
1975]. The earliest known reference to acupuncture was also reported at this time 
in the Yellow Emperor's Classic of Internal Medicine. Hippocrates (400BC) 
referred to the use of electric torpedo fish (Torpedo marmorata) for the treatment of 
headache and arthritis, and Scribonius Largus (46 AD), the Roman Physician, 
recorded the use of such fish to treat gout. The first english language book on 
medical electricity was published by Richard Lovett in 1756, following the 
classification of the phenomenon of electricity by William Gilbert (1544-1603). 
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2500 B. C. Egyptian Fifth Dynasty Stone carvings showing the use of electric 
fish to treat pain 
400 B. C. 
AD. 48 
1756 
1759 
1772 
1800+ 
1850's 
1875 
c1900 
1965 
1967 
1967 
1969 
1973-74 
1977 
1979 
Hippocrates 
Scrlbonius Largtts 
Richard Lovett 
Dr John Wesley 
John Birch 
Barlandiere 
W. J. Oliver 
Rockwell et al. 
R. Melzack and P. W. Wall 
P. Wal and W. Sweet 
C. N. Shealy et al. 
D. V. Reynolds 
D. M. Long and C. N. Shealy 
LE. Augu. stinsson et aL 
M. B. E. Ftiisson et al 
Electric Fish used for headache and arthritis 
Treated gout with electrical ray fish 
Subtil Medium Proved 
First textbook on medical electricity in 
English language 
Electricity made plain and useful by a lover 
of mankind and common sense" 
Sciatica hysteria headache kidney stone gout 
etc. 
English surgeon who used electrotherapy 
extensively 
Used electric discharge from Leyden bottles 
via acupuncture needles 
Electrical stimulation of muscle used to 
produce surgical and obstetric analgesia 
A practical treatise on the medical and 
surgical uses of electricity 2nd ed. 
'Electreat' apparatus sold direct to public 
with claims to cure many diseases including 
cancer. Banned by FDA in early 50's 
Cate Control theory 
High-frequency (50-100Hz) percutaneous 
electrical nerve stimulation for chronic 
neurogenic pain 
First dorsal column implantation 
Stimulation of periaqueductal grey produces 
surgical anaesthesia 
Report results of transcutaneous electrical 
nerve stimulation (TENS) 
Obstetric analgesia with TENS 
Increased analgesic efficacy of acupuncture- 
like TENS 
1982 B. Saada High-intensity muscle stimulating TENS 
promotes healing of chronic ulceration 
Table 1.1 History of electroanalgesia. From Thompson 
[1987a]. 
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A multitude of reports, describing the use of electricity in medicine, termed 
electrotherapy, and for reducing pain, termed electroanalgesia, followed in the 
1800's (Table 1.1). Of note was the finding of Berlioz (1816) that the effects of 
acupuncture were increased when administered in combination with electricity 
(electro-acupuncture). Nevertheless electrotherapy fell out of favour at the turn of 
the 20th century and, until recently, electroanalgesia has had little use in mainstream 
medicine. 
The proposal of the gate control theory of pain mechanisms by Melzack and Wall 
re-awakened interest in pain treatment by electrical stimulation. The theory states 'A 
gate control system modulates sensory input from the skin before it evokes pain 
perception and response. ". Thus in short, the model suggests that the action system 
responsible for pain perception and response, is triggered after sensory information 
arriving from the periphery has been modulated in the spinal cord by sensory 
feedback and influences from the central nervous system. It was therefore inferred 
that activity in large diameter afferent nerve fibres, mediating non-noxious 'touch' 
messages, could block the transmission of nerve signals from small diameter 
afferent fibres, mediating noxious 'pain' messages, (Fig. 1.4). 
CENTRAL CONTROL. 
GATE CONTROL SYSTEM 
L 
INPUT 
S 
ACTION 
SYSTEM 
Fig. 1.4 The original schematic diagram of the gate 
control theory of pain mechanisms as proposed by 
Melzack and Wall [1965]. Large (L) and small (S) diameter 
fibres project to the Substantia Gelatinosa (SG) and first 
Transmission cells (T) in the spinal cord. The inhibitory effect exerted 
by the SG on the T-cell is increased by activity in large diameter 
fibres and decreased by small diameter fibres. Thus, large diameter 
fibres reduce the increase in T-cell activity produced by the small 
diameter fibres. (+), excitation; (-), inhibition. 
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Consequently, generation of extra touch messages in the periphery, either naturally 
(i. e. rubbing) or artificially (i. e. electrical stimulation), would relieve pain. 
Although the experimental basis for the precise gating mechanism has been the 
subject of criticism [Nathan 1976], the concept of large fibre suppression of the 
transmission of nociceptive information by a spinal gating mechanism still remains 
largely intact, and has been amply verified experimentally [Wall 1978]. 
Wall and Sweet [1967] confirmed a prediction of the gate control theory when they 
showed that high-frequency (50-100Hz) percutaneous electrical nerve stimulation 
relieved chronic neurogenic pain. Shealy et al. [1966; 1967] reported the first 
clinical use of dorsal column stimulation to relieve pain via electrodes implanted 
into the spinal cord. Stimulation of the skin was used by Long [1974] and Shealy 
[1974] as a means to predict which patients would respond to dorsal column 
implantation. However they found that such skin stimulation proved successful as a 
free standing treatment. This finding coupled with the advent of solid state 
electronic devices resulted in the rapid development of portable battery powered 
stimulators for the relief of pain. Many reports followed which established the 
clinical use of TENS and this was followed by attempts to improve its efficacy. In 
1976, Eriksson and Sjölund [1976] developed a form of stimulation which they 
termed "Acupuncture-Like TENS" (AL-TENS) because they felt it encompassed 
the mechanisms of both acupuncture and TENS. AL-TENS was found to reduce 
pain in patients who did not normally respond to conventional TENS. 
To date, an overwhelming number of reports relating to the clinical use of TENS 
have been published, and it has been established that TENS can play a major role in 
the relief of a wide range of chronic pain conditions. However, its clinical efficacy 
is still questioned. This may be due in part to the difficulty in designing double 
blind controlled clinical trials, and thereby attributing TENS effects to placebo 
response [Deyo et al. 1990a]. 
MECHANISM OF TENS ACTION 
It is generally accepted that TENS acts predominantly via segmental inhibition of 
nociceptive input in the spinal cord, as proposed in the gate control theory 
although, a number of interactive mechanisms may also play a role. During high- 
frequency (above 10Hz) electrical stimulation of cutaneous afferents, a sensation of 
electrical paraesthesia is produced, with a concurrent rise in the threshold for 
noxious and non-noxious stimuli and a reduction in clinical pain, which may persist 
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for hours post-stimulation. It has been suggested that these effects may be 
produced by peripheral, spinal and supraspinal mechanisms. These will now be 
discussed. 
Peripheral: It has been claimed that the reduction in pain observed during 
TENS treatment is primarily due to changes in peripheral transmission of 
nociceptive information [Campbell & Taub 1973; Torebjork & Hallin 1974; Ignelzi 
& Nyquist 1979]. Ignelzi and Nyquist [1976] studied the effects of percutaneous 
neurostimulators used clinically on isolated peripheral nerve evoked activity in the 
cat. They found that electrical stimulation of the sural nerve altered nociceptive 
transmission in the same nerve by slowing conduction velocity or raising excitation 
threshold, thereby preventing nociceptive information from reaching the spinal 
cord. Strong stimulus intensities and the activation of both large and small diameter 
fibres, were required to achieve this effect, which was in contrast to the non-painful 
low intensity stimulation used by patients. Furthermore, Swett and Law [1983] in a 
study applying stimulation characteristics used by patients who were obtaining pain 
relief to the peripheral nerve of the cat, reported that the intensities used by patients 
were insufficient to activate small diameter fibres and found no evidence of small 
diameter nerve block. 
Spinal: The bulk of experimental evidence supports a central mechanism of 
TENS action. It is possible that both spinal and supraspinal antinociceptive systems 
may operate during TENS, and the influence of each system may ultimately depend 
upon the mode of stimulation used. Conventional TENS, which activates large 
diameter fibres (predominantly A-alpha and A-beta, although activation of A-delta 
may also occur [Chung et al. 1984b]), is likely to inhibit incoming nociceptive 
information at a segmental level in the spinal cord, as suggested by the gate control 
theory. Electrophysiological studies have shown that segmental activation of 
cutaneous A fibres by peripheral conditioning stimuli, inhibits C-fibre and noxious- 
evoked activity in the dorsal horn of spinalised animals [Woolf et al. 1980; Woolf 
& Wall 1982; Chung et al. 1984a; Sjölund 1985]. Such stimulation has also been 
found to reduce noxious-induced flexion reflexes in man [Willer et al. 1982; Chan 
& Tsang 1987]. Both pre- and post-synaptic inhibition of nociceptive transmission 
has been shown to occur during TENS [Fitzgerald & Woolf 1981; Woolf & King 
1987]. However the precise neuronal circuitry producing this inhibition is still 
largely unknown. The large density of enkephalinergic interneurones located in the 
substantia gelatinosa of the dorsal horn [Bennett et al. 1982], and the finding by 
Duggan and Foong [1985] that dorsal column stimulation in cats releases GABA 
within the cord, suggests important roles for these substances in the mechanism of 
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TENS action. The post-stimulation hypoaesthesia associated with conventional 
TENS has been attributed to a long-lasting depression of central synaptic 
transmission, possibly at the level of the cuneate nucleus [Macefield & Burke 
1991]. 
Supraspinal: There is evidence that supraspinal descending pain inhibitory 
pathways originating in the brainstem, may also play a role in TENS analgesia. It is 
likely that these pathways are only activated by stimulus intensities greater than that 
achieved during conventional TENS. The concept of a supraspinal network 
modifying pain transmission was originally suggested by Reynolds et al. [1969], 
who found that electrical stimulation of the midbrain in rats selectively suppressed 
responses to painful stimuli. This 'Stimulation Produced Analgesia' (SPA) was 
found to reduce clinical pain in humans with electrodes implanted into the 
periaqueductal grey (PAG) [Mayer & Liebeskind 1974]. It was confirmed that 
stimulation of a variety of midbrain, medullary, and pontine sites produced SPA, 
and that neurones originating from these areas projected spinally (via dorsolateral 
funiculus) to inhibit dorsal horn neurones in lamina I, II, and V, which contain 
terminals of nociceptive primary afferents [Bovie & Meyerson 1982]. 
Acupuncture-like TENS (AL-TENS) is a TENS technique originally developed by 
Eriksson and Sjölund [1976] to improve TENS efficacy by encompassing the 
mechanism of acupuncture and TENS. A requirement of AL-TENS is the 
production of phasic muscle contraction by high intensity stimulation, with 
concurrent activation of deep muscle afferents myotomally related to the pain. It has 
been suggested that stimulation of small diameter sensory and muscle afferents by 
acupuncture, activates descending pain inhibitory pathways via a supraspinal loop 
[for review see Bowsher 1987]. Thus, by implication, AL-TENS may activate 
supraspinal descending inhibitory pain control pathways with the release of opioid 
peptides and monoamines (see Fig. 1.3). This is supported by the naloxone- 
reversibility (naloxone is an opiate receptor antagonist) of the pain reduction 
achieved during AL-TENS, but not conventional TENS [Sjölund & Eriksson 
1979]. It seems unlikely that a pituitary and/or hypothalamic release of opioid 
peptides into the peripheral circulation would account for this naloxone- 
reversability [Facchinetti et al. 1984], but rather that segmental inhibition in the 
spinal cord is supplemented by the local release of opioid peptides activated by 
signals transmitted via the descending pain inhibitory pathways. 
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Further evidence for a central rather than peripheral mechanism of action of TENS 
has been provided by human studies using somatosensory evoked potentials 
(SEPs) [Golding et al. 1986; Nardone & Schieppati 1989]. These will be discussed 
in detail in Chapter 4. 
Other actions of TENS, involving the activation of sympathetic reflexes, have been 
suggested. Thus, Kaada et al. [1982] reported an increase in blood flow during 
TENS in patients with Raynaud's syndrome, although Dean and Leijon [1990] 
found a decrease in blood flow during TENS in healthy subjects. Furthermore, 
Owens et al. [1979] and Abram et al. [1980] have observed increases in skin 
temperature during TENS in both healthy subjects and pain patients, although 
conflicting reports exist [Ebersold et al. 1977]. Abram et al. [1980] suggested that 
TENS may reduce sympathetic tone in certain patients and prove successful in 
treating chronic pain states associated with sympathetic hyperactivity. However, 
work in this field is still incomplete. 
In summary, evidence suggests that the analgesic effects of TENS are produced by 
segmental inhibition in the spinal cord, and under certain stimulating conditions 
(i. e. AL-TENS) with the activation of descending pain inhibitory pathways and the 
release of opioid peptides. 
PRINCIPLES OF USE 
TENS has been used successfully in the treatment of a wide range of both acute and 
chronic pain conditions, although certain conditions are less likely to respond to 
TENS (Table 1.2a and 1.2b). In its conventional form, TENS is generally applied 
to produce a 'strong but comfortable' electrical paraesthesia within the site of pain. 
Electrical pulses generated from the stimulating unit are passed across the surface of 
the skin to activate underlying nerves via two electrodes (Fig. 1.5). Conductive gel 
is used to decrease resistance across the skin-electrode interface, and the electrodes 
can be hidden or concealed under clothing if necessary. Patients can then administer 
stimulation as required and the electrical characteristics of stimulation varied via 
appropriate dials [Long & Hagfors 1975]. 
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DISORDER 
PERIPHERAL NERVE DISORDERS 
Peripheral nerve injury 
Traumatic neuromas 
Causaigia 
Trigeminal nerve section 
Amputation pain 
Phantom limb pain 
Intercostal neuritis 
Trigeminal neuralgia and 
Atypical facial pain 
Post-herpetie neuralgia 
Mono and polyneuritis 
Nerve compression injury 
SPINAL CORD AND SPINAL ROOT 
DISORDERS 
Dorsal root compression and 
spinal nerve compression 
Brachial avulsion injury 
Syringomyelia and postcordotomy 
Spinal cord injury 
Arachnolditis 
PAIN ASSOCIATED WITH NEOPLASTIC 
LESIONS 
Metastatic bone pain 
Neoplastic pain 
REFERENCE 
Wall & Sweet 1967 
Bates & Nathan 1980 
Richardson et al. 1980 
Meyer & Fields 1972 
Bates & Nathan 1980 
Gyory et aL 1977 
Miles & Lipton 1978 
Bates & Nathan 1980 
Ericsson et al. 1984 
Ericsson et at. 1979 
Nathan & Wall 1974 
Picaza et al. 1975 
Magora et aL 1978 
Andersson et al. 1976 
77iorsteinsson et al. 1977 
Eriksson ei al. 1984 
Wynn-Parry 1980 
Picaza et al. 1975 
Bates & Nathan 1980 
Rachen 1978 
Richardson et al. 1980 
Picaza et al. 1975 
Magora et aL 1978 
Bates & Nathan 1980 
Picaza et al. 1975 
MUSCLE PAIN 
Secondary muscle spasm 
Spastic torticollis 
Musculoskeletal disorders 
JOINT PAIN 
Rheumatoid arthritis 
Osteoarthritis 
ACUTE PAIN 
Obstetric pain 
Acute trauma 
Acute orofacial pain 
Post-operative pain 
MISCELLANEOUS CONDITIONS 
Itch 
Raynauds 
Angina 
Functional abdominal pain 
Magora et aL 1978 
Ersek 1977 
Wolf et aL 1981 
Mannheimer & Carlsson 1979 
Taylor et al. 1981 
Augustinsson et al. 1977 
Nielzen et al. 1982 
Hanson & Ekblom 1983 
Hymes et al. 1974 
Cooperman et al. 1977 
Pike 1978 
Solomon et al. 1980 
Augustinsson et al. 1976 
Kaada et aL 1984 
Mannheimer et al 1982 
Sylvester et aL 1986 
Table 1.2a Clinical conditions successfully treated with 
TENS. Adapted from Woolf [1989]. 
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DISORDER 
PERIPHERAL NERVE DISORDERS 
Metabolic peripheral neuropathies 
Post-herpetic intercostal neuralgia 
Occipital neuralgia 
Nerve injury and neuralgia 
SPINAL CORD AND SPINAL ROOT 
DISORDERS 
Partial cord transection 
Myelodysplasia 
Spondyloarthrosis 
CENTRAL PAIN STATES 
Thalamic pain 
MISCELLANEOUS CONDITIONS 
Headache 
Vascular headache 
Atypical facial pain 
Pain scars 
Coccydynia 
Visceral pain 
Ischaemic pain 
Industrial injury 
Psychogenic pain 
REFERENCE 
Long et aL 1979 
Cauthen & Renner 1975 
Cauthen & Renner 1975 
Magora et aL 1978 
Cauthen & Renner 1975 
Rtcharson et aL 1980 
Picaza et aL 1975 
Picaza et al. 1975 
Bates & Nathan 1980 
Long & Hagfors 1975 
Loeser et aL 1975 
Picaza et al. 1975 
Cauthen & Renner 1975 
Bates & Nathan 1980 
Bates & Nathan 1980 
Cathen & Renner 1975 
Eriksson et al. 1979 
Eriksson et aL 1979 
Long et al. 1979 
Long & Hagfbrs 1975 
Nielzen et aL 1982 
Johansson et aL 1980 
Table 1.2b Clinical conditions reported to be 
unsuccessfully treated with TENS. Adapted from Woolf 
[1989]. 
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Stimulator Brain Sensory 
Frequency, Strength ;; ' ''ýý:: ý" Cortex Controll Control 
.14 
Spinoreticular 
(multi-synaptic) 
and 
spinothalamic tracts 
Touch /Nociceptive 
transmitting /Itransmitting 
A-beta fibre `ý ý- ,P 
A-delta and C-fibre 
Fig. 1.5 Simplified mechanism of TENS. Pulses of electrical 
current from the stimulator excite (via skin electrodes) touch 
receptors. These electrically-excited nerve impulses then pass to the 
spinal cord where they synaptically inhibit (by the release of 
transmitters) incoming nociceptive information which would 
normally be conveyed to the reticular formation, thalamus and cerebral 
cortex. From Thompson [1987b] 
TENS units were designed on theoretical grounds to activate selectively large 
diameter fibres, without concurrent activation of small diameter nociceptive fibres. 
However, studies examining optimal stimulation characteristics for TENS remain 
sparse. Li and Bak [1976] examined the excitability of A- and C-fibres in cat 
saphenous nerves, by creating strength/duration curves for activation by electrical 
stimulation. They found that small unmyelinated'nociceptive' axons were virtually 
unexcitable by pulse widths below 200µs. Howson [1978] also created 
strength/duration curves during TENS to his own ulnar nerve on the forearm, and 
suggested that a good separation between motor responses, the perception of pain, 
and sensory detection was achieved at 100µs. Pulse widths greater than 
1000µs(lms) were found to activate simultaneously all fibres even at low 
stimulation amplitudes. Thus pulse widths between 20-1000µs are ideal to 
selectively activate large (and not small) diameter afferents. Although the optimal 
frequency of electrical stimuli to produce maximal firing of large diameter fibres 
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(A-alpha/beta) in human nerve has not been defined, frequencies above 100Hz have 
been suggested to be no more effective [Buchthal & Rosenfalck 1966]. 
Consequently frequency ranges of 40-100Hz are generally suggested for clinical 
use of TENS [Woolf 1989]. 
Commercial stimulator specifications vary between companies, although 
stimulators used at Newcastle Pain Relief Clinic are similar (Table 1.3). In general, 
stimulators have facilities to vary pulse amplitude, pulse frequency, and pulse 
patterns (Fig. 1.6). 
Output Waveform 
200pS 
(Fixed) 
10Hz 
Lr ý 
PULSE PATTERNS 
IIIIIIIIIIIIIIIilllllilllllllllllllllllllllllllllllllllllillllillllllllllllllllilllillllll 
Continuous mode 
1ll1IDlim uiimmii mumme nuuunn 
Bust mode (2.3Hz hales of pulses) 
Fig. 1.6 The control functions of a Microtens 
stimulator. The stimulator has facilities to control (i) pulse 
amplitude (intensity) - left hand dial, (ii) pulse frequency - right hand 
dial and (iii) pulse patterns (either continuous or burst) - right hand 
switch. The output waveform is biphasic with a fixed pulse width of 
200µs. 
Pulse frequency, ranges between 1-200Hz and a variety of pulse patterns are 
usually available (i. e. continuous, burst and random). A biphasic wave (where the 
area of the positive wave portion is equal to the the area of the negative) is most 
commonly used, since this reduces polarisation which may produce adverse skin 
reactions [Lampe & Mannheimer 1988]. The current amplitude (i. e. intensity or 
strength of stimulation) usually ranges between 0-50 volts, equating approximately 
to 0-50 mA across the skin (whose impedance range = 500-2000 ohms). This 
intensity range can produce sufficient current strength to twitch underlying 
musclature. Constant-current rather than constant-voltage design is preferred to 
compensate for variations in impedance at the electrode-skin interface. Variations in 
stimulator design (with pulse width control, dual channels, different pulse patterns 
and waveforms) have been introduced to optimise clinical efficacy, but have met 
with limited success. 
0 
2ooHz 
I 
PULSE FREQUENCY 
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AIM OF PROJECT 
Although TENS has been used successfully for a variety of acute and chronic pain 
conditions, some patients either fail to respond, or respond initially and then 
develop tolerance to TENS analgesia. It has been estimated that over 70 % of 
patients initially respond to TENS, but only a third of these continue to obtain relief 
after two years [Bates & Nathan 1980]. The degree of pain relief obtained by 
patients responding to TENS proves variable; some patients report total relief of 
pain, whereas others, with a similar pain condition, report less than 20% relief 
(unpublished observations). 
Despite its use for over twenty years, TENS is still administered on an empirical 
basis because it is impossible to determine whether a patient will respond prior to 
treatment. Prediction of response would not only be of value in the clinic, but may 
help understand treatment failure and the development of tolerance to TENS 
analgesia. The optimal electrical characteristics of TENS for various pain conditions 
remains unknown, and the patient is usually advised to experiment with stimulator 
settings until satisfactory relief is obtained. Few studies have systematically 
investigated the analgesic effects of different TENS characteristics. Therefore some 
patients may not be utilising the optimal electrical characteristics of TENS for their 
particular pain condition. Furthermore, information on the electrical settings used 
by patients successfully controlling pain is limited. 
Hence, the aims of the project were to investigate: 
(i) The clinical factors which optimise TENS efficacy by studying, in depth, the 
use of TENS by patients successfully controlling chronic pain. 
(ii) The analgesic effects of different electrical characteristics of TENS in healthy 
subjects. 
(iv) The effect of TENS on electrophysiological and neuropharmacological 
variables. 
(v) The factors related to patient response to TENS. 
It was hoped that the results of this work would improve TENS`efficacy by: 
'(i) optimising the electrical characteristics of TENS used by patients, 
(ii) elucidating the mechanisms of TENS analgesia and treatment failure, 
(iii) designing new and therapeutically more powerful electrical stimulators. 
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CHAPTER 2 
THE CLINICAL USE OF TENS 
INTRODUCTION 
Despite the large number of clinical trials which confirm the effectiveness of TENS in 
the treatment of a wide range of acute and chronic pain conditions (Table 1.2a and b), 
information on the long-term clinical efficacy of TENS is limited (for summary see 
Table 2.1). Thus, uncertainty remains as to the number of patients who either fail to 
respond, or drop out of TENS treatment after a period of time. 
Long-term efficacy of TENS 
Bates and Nathan [1980] examined TENS efficacy in 235 patients with a variety of 
chronic pain conditions and found that approximately 30% of patients initially failed to 
respond to treatment. After 32 weeks, only one third of the patients who initially 
responded to treatment continued to use TENS, the proportion dropping to one fifth 
after 2 years. Similarly, Loeser et al. [1975] found that while 68% of patients (out of a 
total of 198) obtained short-term relief with TENS, this proportion fell to 12.5% after 
one year. Eriksson et al. [1979; 1984] found that patient response to TENS depended 
upon the type of pain, and that varying proportions of patients (18-82%) had effective 
relief after 2 months and 18-60% after a year. However, approximately 55% of 
patients obtained short-term relief of pain with TENS (2 month follow-up); 41% at the 
1 year follow-up and 30% at the 2 year follow-up. These studies suggest that a 
significant proportion of patients drop out of TENS treatment between 2-12 months. 
Furthermore, Eriksson et al. [1979] found that acupuncture-like TENS (AL-TENS) 
produced analgesia in some patients who did not respond to conventional TENS. 
The treatment of acute pain by TENS often takes place in a hospital ward (during 
labour or post-operative pain), where staff trained in TENS techniques are available to 
ensure correct TENS administration, and to monitor progress. For the treatment of a 
chronic pain condition the situation is different, as the patient needs to administer 
treatment away from the clinic (Sjölund et al. 1990). 
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Thus, after instruction on the principles of TENS use by a therapist in a clinic, patients 
must learn to master the TENS technique themselves, and administer the treatment as 
appropriate. Information on the treatment regimes used by patients controlling a 
chronic pain condition with TENS is limited. 
Criteria for deciding to use TENS 
Patients attending Newcastle Pain Relief Clinic (NPRC) have usually been referred by 
their general practitioner (GP), and many have tried a variety of treatments to control 
the pain condition. Two main criteria are used in deciding whether to administer TENS 
[Thompson personal communication]: 
(i) The patient's pain has failed to respond to other treatments, e. g. non-steroidal 
anti-inflammatory drugs (NSAIDS), weak opioids, antidepressants. 
(ii) The patient's pain is difficult to treat by other methods, e. g. deafferentation, 
post-herpetic neuralgia, phantom and stump pain. 
Instruction to new patients 
At Newcastle Pain Relief Clinic new TENS patients undergo an hour's trial of TENS 
in the clinic for three reasons: 
(i) to observe any immediate response to TENS, 
(ii) to observe any adverse reactions (including aggravation of the pain condition), 
(iii) to fully instruct the patient on stimulator use. 
Nurses trained in TENS techniques instruct the patient on stimulator use as follows: 
1. Apply electrodes to produce electrical paraesthesia ('tingling') within the painful 
area. Occasionally, for reasons of non-response, pain aggravation, or sensitive 
skin, this is not possible and electrodes are then applied: 
(a) immediately proximal to the painful site, 
(b) at the contralateral ('mirror image') site, 
(c) straddling the spinal cord at the dermatome related to the painful region. 
2. Initially use continuous mode TENS. 
3. Set all controls (pulse amplitude (current intensity) and pulse frequency) to 
minimum setting. 
4. Increase pulse amplitude (intensity) to a'strong but comfortable' level. 
5. Increase pulse frequency to maximal comfortable level. 
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6. If insufficient pain relief is obtained, try increasing pulse intensity, or use burst 
mode TENS. 
7. Patients are encouraged to experiment with all stimulator settings and hunt for the 
most appropriate setting during each treatment session. 
Under certain circumstances, burst mode TENS utilised as acupuncture-like TENS 
(AL-TENS) may be the first treatment choice (see Chapter 3 and Sjölund et al. 
[1990]). After this hour's trial, the patient administers TENS at home, prior to 
returning to the clinic (usually within two months) for further assessment. Patients not 
responding to TENS treatment return the stimulator, and a different treatment is tried. 
Those responding to TENS treatment are provided with a stimulator on loan from the 
clinic. 
TENS variables related to treatment outcome 
When TENS is used to treat a patient's pain, a number of important variables related to 
the patient, and to the stimulator, may influence treatment outcome. These include: 
(i) Patient variables: age, sex, cause and site of pain, personality, use of drugs and 
TENS treatment regime (i. e. how often TENS is administered). 
(ii) Stimulator variables: model of stimulator, site of electrodes, pulse waveform, 
pulse frequency (Hz), pulse pattern, pulse amplitude (current intensity) and pulse 
width (µs). 
(iii) Outcome variables: TENS analgesic efficacy, onset of analgesia, post-TENS 
analgesia and adverse effects. 
Although it has been well documented that TENS efficacy is dependent upon the 
electrical characteristics of stimulation (i. e. pulse frequency, pulse pattern, pulse 
width, stimulating mode and electrode placement; for review see Woolf [1989]), there 
have been few reports of the actual electrical characteristics of TENS used by patients. 
Linzer and Long [1976] were able to monitor the electrical characteristics of TENS in 
only 23 patients suffering from chronic pain who obtained satisfactory TENS 
analgesia. They found that 74% of patients utilised pulse frequencies below 60Hz, 
74% of patients utilised pulse widths between 50-100µs and all patients who achieved 
relief produced a 'tingling' electrical paraesthesia within the area of pain. Thus the 
group concluded that the success rate with TENS could be improved by careful 
attention to electrode placement, stimulating variables and patient education. 
Mannheimer and Carlsson [1979] found that 'conventional' TENS delivered at a 
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frequency of 3 Hz, was less effective in suppressing pain than 'conventional' TENS at 
70 Hz for patients with rheumatoid arthritis. However, the delivery of low frequency 
(3Hz) trains or'bursts' of pulses at high intensity (acupuncture-like TENS), has been 
shown to be beneficial for patients not responding to conventional TENS [Eriksson et 
al. 1979] . 
Wolf et al. [1981] attempted to determine optimal electrode placements and stimulating 
parameters while treating chronic pain patients with conventional TENS, administered 
at the clinic in 30-45 minute sessions. No clear correlations between electrode 
placements, stimulating parameters and pain relief were found, although TENS did 
reduce pain intensity scores. The group concluded that a patient's psychological profile 
may help to determine who would benefit from TENS. Johansson et al. [1980] found 
that the Eysenck Personality Questionnaire (EPQ) which records traits in personality 
(i. e. psychoticism, extroversion, neuroticism and an internal consistency 'lie' 
measure), may be predictive of outcome to TENS treatment. Recently Houlton et al. 
[1990] assessed the use of TENS in a population of chronic pain patients who had last 
attended the clinic over 3 years prior to the study. Of 189 questionnaires mailed, 68 
were returned; of these, 57 patients had been given a trial of TENS and 29 (51% of 
those given a trial) were still using stimulators. Average daily use in these patients was 
4.3 h/day. Although there appeared to be no comprehensive study of the electrical 
characteristics of TENS in these patients, pulse frequencies between 80-100 Hz were 
reported to be most beneficial. 
To date, no comprehensive investigation has examined the electrical characteristics of 
TENS utilised by patients using the technique on a long-term basis to control chronic 
pain. Consequently TENS is administered on an empirical basis where the patient 
determines by trial and error the most appropriate electrical characteristics to control his 
or her pain. 
Aims of Chapter 2 
Because of the lack of information on the clinical use of TENS by both pain clinics, 
and patients successfully controlling chronic pain with TENS, it was decided to 
conduct a fact finding survey. Thus, the overall aim of Chapter 2 was to examine, in 
depth, the clinical use of TENS. This was achieved in three studies: 
Study 2.1. Long-term use of TENS at Newcastle Pain Relief Clinic. 
Study 2.2. An in-depth study of long-term users of TENS. 
Study 2.3. The consistency of pulse frequencies and pulse patterns of TENS used 
by chronic pain patients. 
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THE STUDIES 
Study 2.1 
Long-term use of TENS at Newcastle Pain Relief Clinic. 
The aim of this study was to assess long-term efficacy of TENS in a heterogeneous 
population of chronic pain patients, by examining administrative records of stimulators 
issued by Newcastle Pain Relief Clinic. 
Patients and Procedure 
Newcastle Pain Relief Clinic (NPRC) records containing names and addresses of 
patients, and the date of issue and return of stimulating units (up to 1st January 1991) 
were examined. All patients had attended NPRC for a follow-up appointment to assess 
TENS treatment. Although the records contain only sparse clinical information, it was 
possible to classify patients according to Anatomical Region, as described by the 
International Association for the Study of Pain Classification of Chronic pain 
conditions [for full description see IASP 1986]. 
Results of Study 2.1 
The first stimulator, a Stimtech EP, was issued to a patient in October 1979. Since 
then, 1582 patients have received stimulators on loan, of which 655 (41.4%) have 
returned the stimulator and 927 (58.6%) continue to use TENS (Fig. 2.1, pie chart). 
The clinic has progressively increased the use of TENS, and over the last five years 
approximately 180 stimulators were issued each year (3-4 stimulators/week), as shown 
in Fig. 2.1. Although 655 stimulators were returned, the dates of return of 132 of these 
were not recorded. The majority of stimulators (368) were returned within the first 6 
months, usually during the first follow-up appointment at the clinic. Only a small 
proportion of patients returned stimulators after the first year (Fig. 2.2). 
Of patients still in possession of stimulators, 28 have used TENS successfully for over 
10 years (Fig. 2.3). A wide range of pain conditions have been treated with TENS and 
the distribution of pain conditions treated reflect the distribution of complaints 
presenting at the clinic [Davies & Crombie 1990]. No particular pain condition 
responded better than another, and over 50% of patients continue to use stimulators in 
most groups (Fig. 2.4). Of note is the large proportion of lower back problems, 67% 
of which were treated successfully with TENS. 
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Fig. 2.1 The number of stimulators issued by Newcastle 
Pain Relief Clinic per year (Study 2.1). Pie chart shows the 
number of patients still in possession of a stimulator. 
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Fig. 2.4 The number of stimulators loaned to patients 
classified according to the anatomical region of the 
patient's pain (Study 2.1, n=1582). 
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Main findings of Study 2.1 
(i) TENS was introduced into NPRC in 1979. 
(ii) TENS has been used in an attempt to control chronic pain in 1582 patients. Of 
these 1582 patients, 927 (58.6%) continue to use TENS. 
(iii) The majority of patients who return stimulators do so within the first six 
months (during the first follow-up assessment). 
(iv) No particular pain condition appears to respond better than another. 
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Study 2.2 
An in-depth study of long-term users of TENS. 
The aim of Study 2.2 was to examine the relationships between patient, stimulator, and 
outcome variables, in patients who were successfully using TENS on a long-term 
basis to control a chronic pain condition. 
Patients and Procedure 
One hundred and seventy nine patients drawn randomly from NPRC files (female 
n=82, male n=97; age range=24-85, mean±SD=55.2±12.9 years of age), and with a 
variety of chronic pain conditions participated in the study. All had been in possession 
of a TENS unit for at least three months (on loan from Newcastle Pain Relief Clinic 
after a successful trial session), although the majority had been using TENS for a 
number of years. 
TENS Questionnaire 
All patients completed a specially designed TENS Multiple Choice Questionnaire 
either: (i) by postal correspondence, or (ii) on attendance to the research unit (for 
TENS questionnaire see Appendix A). The questionnaire collected data regarding site 
and cause of pain, the model of stimulator, frequency of stimulator use and degree of 
pain relief. Personality variables were also measured using the Eysenck Personality 
Questionnaire (EPQ) [Eysenck & Eysenck 1975]. 
All patients were classified according to the International Association for the Study of 
Pain (IASP) classification of chronic pain conditions [IASP 1986] into: 
(i) anatomical region of pain (IASP Axis I), 
(ii) aetiology of pain, (IASP Axis V), 
(iii) a third group termed 'Diagnostic clusters' designed by Johnson et al. [1991 a]. 
Determination of Electrical Characteristics of TENS 
Of the 179 patients, 107 (female n=58, male n=49; age range=24-85 years of age) 
attended the research unit so that the electrical characteristics of TENS could be 
assessed. This was achieved by recording peak voltage (Volts), pulse width (µs), 
pulse frequency (Hz), pulse amplitude (current intensity) and electrode impedance 
(Kohm), on a Frye Electronics Type 4000 TENS Analyser (Frye Analyser) supplied 
by RDG Electro-Medical (Fig. 2.5a). 
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Fig. 2. Sa Frye Electronics Type 4000 TENS Analyser, Frye Analyser. 
Patients applied TENS to the 'usual' anatomical site to achieve analgesia for their 
particular chronic pain condition. They were asked to adjust both pulse amplitude and 
pulse frequency (via the appropriate control dials) to the settings they routinely used to 
treat their pain. Patients free of pain during the visit (n=10 who rated <1 on a visual 
analogue scale where O=no pain and 10=worst pain imaginable) were asked to adjust 
the stimulator to its 'normal therapy setting'. 
Electrical characteristics were recorded at sensory threshold, therapy level and pain 
threshold to TENS electrical pulses at the site of electrode application (Fig. 2.5b). 
Patients found their respective thresholds after a small amount of "hunting", and the 
mean of three repetitions was calculated. Pulse amplitude (current intensity) recordings 
were taken at the patient's preferred pulse frequency, and repeated at high frequency 
(100Hz) and low frequency (20Hz) stimulation. If stimulators possessed a burst mode 
facility, the entire procedure was repeated in burst mode. 
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Fig. 2.5b Determination of the electrical characteristics of TENS. 
Patients were in possession of one of the following types of stimulator ( Fig. 2.5c): 
1. Tiger Pulse (Polarity reversal facility. RDG Medical) 
2. Tiger Burst (Burst mode facility. RDG Medical) 
3. Spembly 9000 (Burst mode facility. Spembly) 
4. Microtens 7757 (Burst mode facility. NEEN Pain Management Systems) 
Fig. 2.5c Stimulators issued by Newcastle Pain Relief 
Clinic. 
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Follow-up 
Twenty-four patients (female n=12, male n=12; age range=39-79, mean=54.2 years of 
age) returned for a follow-up assessment. A four month period elapsed between the 
two visits. 
Statistical Analysis 
Data was plotted to check for normal distribution prior to statistical analysis. 
Parametric statistical procedures were employed for continuous data (after logarithmic 
transformation for skewed distributions), and non-parametric procedures for 
categorical data. A detailed explanation of the statistical procedures used in this and 
future experiments is provided in Appendix B. 
Results of Study 2.2 
A wide range of chronic pain conditions, among which low back pain was 
predominant, was represented in the patient population ( Fig. 2.6a, b and c). The 
results of the 179 questionnaires are summarised in Table 2.2. 
a. ANATOMICAL REGION 
IASP Classification: Axis I 
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Fig. 2.6a Long-term users of TENS classified according to 
Anatomical region (IASP Axis I, Study 2.2, n=179). For full 
details of terms see IASP [ 1986]. 
Chapter 2: The clinical use of TENS 37 
b. AETIOLOGY 
IASP Classification: Axis V 
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Fig. 2.6b Long-term users of TENS classified according to 
Aetiology, (IASP Axis V, Study 2.2, n=179). For full details 
of terms see IASP [1986], degen/mech=degenerative/mechanical. 
c. DIAGNOSTIC CLUSTERS 
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Fig. 2.6c Long-term users of TENS classified according to 
Diagnostic clusters (Author's classification, Study 2.2, 
n=179). For full details of terms see Johnson et al. [1991a]. 
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QUESTION n Median (range) 
Age of study population (years) (a)female (a) 82 (a) 55.7(24-82) 
(b)male (b) 97 (b) 54.8(30-85) 
(c)all (c) 179 (c) 55.2(24-85) 
Length of use (years) 179 3.7(0.25-9) 
Degree of pain relief 168 5.0(0-10) 
(0 no relief ---- > 10 total relief) 
Duration of treatment (a)days / week 152 (a) 7.0(1.00- 7.0) 
(b)h / week (b)35.0(0.75-63.0) 
Time to onset of analgesia (min) 150 30 (0-->2h) 
Time to offset of analgesia (min) 150 60(0-->2h) 
n No of patients 
Pulse pattern preference (a) fast 128 (a)72(56) 
(b) slow (b)29(23) 
(c) none (c)27(21) 
Pulse frequency preference (a) fast 48 (a)28(58) 
(b) slow (b)15(31) 
(c) none (c) 5(11) 
Reset frequency button on each treament 48 35(73) 
session 
Change of TENS efficacy (a) increase 129 (a)13(10) 
with use (b) unchanged (b)75(58) 
(c) decrease (c)41(32) 
Outdoor use (a) regularly 162 (a)85(53) 
(b) occasionally (b) 31(19) 
(c) never (c)46(28) 
Use TENS in combination with other drugs 147 110(75) 
Incidence of skin reactions 143 45(31) 
(ie irritation or rash) 
Table 2.2 Summary of answers to TENS Questionnaire by 
long-term users of TENS. (See Appendix A for details of the 
questionnaire). 
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Questionnaires 
As patients were instructed to omit any questions that they did not understand, the n 
values varied for different results. Sixty-seven (37%) patients were using a Microtens 
7757,49 (28%) a Tiger Burst, 44 (25%) a Tiger Pulse and 17 (10%) a Spembly 
9000. The analgesic efficacy of TENS, assessed by a visual analogue scale (VAS; 
where 0= no relief of pain and 10=total relief of pain), is shown in Fig. 2.7. Seventy- 
nine (47%) patients reported that TENS reduced their pain by half or more; 23 (13.7%) 
of patients reported that TENS did not produce any relief (between 0-1 VAS) and 26 
(15.5%) reported total relief of pain (between 9.1-10 VAS) whilst using TENS. A 
clustering effect was observed around the columns representing total relief of pain 
(VAS=10), no relief of pain (VAS=O), and relief of pain by half (VAS=5). This may 
be due in part to a psychological biasing of patient response to visual analogue scales. 
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of pain Visual Analogue Scale (VAS) of pain 
Fig. 2.7 Pain relief obtained by long-term users of TENS 
(Study 2.2, n=168). Patients marked with a cross a point on the 
visual analogue scale to represent the 'average' relief of pain obtained 
when using TENS. 
All the patients who achieved no analgesic benefit from TENS (VAS <1) nevertheless 
expressed a desire to continue TENS treatment. In fact, two thirds of the patients who 
reported complete failure of TENS analgesia continued to use the stimulator on a daily 
basis! No significant differences (one-way Analysis of Variance (one-way ANOVA)) 
were found between the degree of pain relief achieved with TENS when patients were 
classified according to anatomical region of pain, aetiology of pain or diagnostic 
clusters (Fig. 2.8). 
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Fig. 2.8 Mean±SE pain relief obtained by long-term users 
of TENS classified into: (a) Anatomical region, (b) 
Aetiology, (c) Diagnostic cluster (Study 2.2, n=168). See 
Fig. 2.6 for respective n values for each group. For full details of terms 
see IASP [1986] 
Although 117(75%) patients reported daily stimulator use (Fig. 2.9), only 61 of these 
had used TENS on the previous day. This discrepancy may be due in part to an 
overestimate by certain patients of their daily use of TENS. Over 30% of patients used 
TENS for over 49 h/week (Fig. 2.9 inset), calculated from the number of days used per 
week, and hours used per day. 
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Days of use per month 
Fig. 2.9 Duration of TENS treatment by long-term users 
(Study 2.2, n=152). 
The onset of TENS analgesia occurred within half an hour in 115 (77%) patients and 
within an hour in 144 (over 95%) patients (Fig. 2.10a). Post-TENS analgesia lasted 
over an hour in 50 (33%) patients, and less than thirty minutes for 77 (51%) of 
patients (Fig. 2.10b). No significant differences (Kruskal-Wallis - categorical data) 
were found between the time to onset or offset of TENS analgesia between burst and 
continuous modes of stimulation. 
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Fig. 2.10a Time to onset of TENS analgesia in long-term 
users (Study 2.2, n=150). 
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Immediately > 0.5 0.5-1.0 1.1-2.0 
Time of post-TENS analgesia (h) 
> 2.0 
Fig. 2.10b Time to offset of TENS analgesia in long-term 
users (Study 2.2, n=150). 
Of the patients who had the availability of both burst and continuous stimulation, 72 
(56%) preferred using continuous, 29 (23%) preferred burst and 27 (21%) alternated 
between the two. No significant differences (Kruskal-Wallis - categorical data) were 
found between the mode of stimulation and the anatomical region of pain, aetiology of 
pain or diagnostic clusters. 
Forty-one (32%) patients reported a decline in TENS efficacy since the time of issue, 
although 75 (58%) continued to achieve the same degree of analgesia and 10 (13%) an 
increased effect. Forty-five (31%) patients had encountered skin reactions (i. e. rash or 
irritation) to either the tape, gel, or electrodes (Table 2.2). 
No significant differences (unpaired t-tests (continuous data) and Mann-Whitney U- 
test (categorical data)) were observed between males and females for any of the 
parameters measured through the questionnaire. No relationships (measured using 
Pearson (continuous data) and Spearman (categorical data) correlation coefficient and 
one-way ANOVA) were detected between personality traits (EPQ) and any of the 
patient, stimulator, or outcome variables. 
Seventy-five percent of patients were using TENS in combination with a variety of 
drugs, including analgesics, antidepressants, anxiolytics, antihypertensives, and 
antiepileptics. Although it was impossible to separate the effects of these drugs from 
the effects of TENS, no significant differences were noted in the degree of pain relief 
achieved in the drug versus non-drug patients (Mean±SD pain relief (VAS units); 
patients using drugs=5.0±3.2 (n=105), Patients not using drugs=4.5±2.4 (n=34), 
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P>0.05, unpaired t-test). Patients commonly reported that TENS reduced their drug 
intake, but TENS was less effective than drugs when the pain was at its worst. 
Electrical Characteristics of TENS 
Pulse Frequency: Fig. 2.11 shows the pulse frequency used by patients when using 
continuous mode stimulation. Pulse frequencies between 1-70 Hz were utilised by 68 
(75.5%) of patients, with a small cluster of patients, 12 (13%), choosing 111-140Hz. 
Median frequency of pulse delivery was found to be 32Hz (mean±SD=53±48 Hz; 
mode=24Hz). In patients using burst mode stimulation, the frequency of pulse 
delivery for burst (measured as pulse delivery within the 'burst' or 'train' of pulses) 
and continuous modes of stimulation were found to be highly correlated (r=+0.743, 
df=89, P<0.01, Pearson correlation coefficient) and not significantly different 
(P>0.01, paired t-test). 
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Fig. 2.11 Pulse frequencies and pulse patterns used during 
stimulation by long-term users of TENS (Study 2.2). Pulse 
frequencies were recorded on a Frye Analyser when TENS was set to 
contnuous mode (n=90). Pie chart shows preferred pulse patterns (n=128). 
As all stimulators used by the patients were constructed with a frequency control dial 
with logarithmic characteristics, it is difficult for patients to adjust the instrument to 
specific pulse frequencies above 40Hz (Fig. 2.12). Such frequencies lie on the steep 
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part of the frequency output curve, so that small turns of the frequency control dial 
result in large changes in frequency [Johnson et al. 1989]. As a consequence, the 
distribution of pulse frequencies used by patients may directly follow the 
characteristics of the frequency dial. All patients utilising pulse frequencies between 
111-140 Hz were using Tiger Pulse or Tiger Burst stimulators, and had reached the 
maximum possible frequency available. 
No significant differences in pulse frequency were found across anatomical region, 
aetiology and diagnostic clusters (one-way ANOVA). No correlations (Pearson 
correlation coefficients) were observed between pulse frequency (after log 
transformation to allow for the skew distribution) and (i) the present pain rating, (VAS; 
r=+0.001, df=89, P>0.05), (ii) the degree of pain relief achieved using TENS (VAS; 
r=+0.132, df=89, P>0.05), or (iii) any of the personality variables measured by the 
EPQ. 
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Fig. 2.12 Calibration of the frequency control dial of 
stimulators issued by Newcastle Pain Relief Clinic. 
Corresponding pulse frequencies were recorded on a Frye TENS Analyser 
(1Kohm internal load) to incremental changes on the frequency control 
dial. Mean±SE (n=5). 
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Intensity of Stimulation 
Sensory detection threshold: The mean±SD sensory detection threshold (SDT), 
measured at the site of application of TENS, was found to be 11.04±6.6mA (n=87) at 
the pulse frequency used by the patient. No relationship (r=+0.2, df=86, P>0.05, 
Pearson correlation coefficient) was found between sensory detection threshold and 
pulse frequency. Males were found to have a significantly higher sensory detection 
threshold than females (Mean±SD; female=9.2±5.9, male=12.9±6.9, P<0.01, 
unpaired t-test). No significant differences in sensory detection threshold (one-way 
ANOVA) were observed across regions, aetiology or diagnostic clusters. 
Therapy level: The intensity of stimulation required to achieve the therapeutic analgesic 
effect, was corrected for individual variations in sensory detection threshold (SDT) by 
simple subtraction: 
Therapy Level (mA above SDT)=Absolute therap ly evel(mA) - SDT (mA) 
The intensity of TENS to achieve analgesia is shown in Fig. 2.13. Sixty-one (71%) 
patients utilised therapy settings below lOmA above SDT, although a small number of 
patients exceeded current settings of 40 mA above SDT. No significant differences in 
therapy levels were found across anatomical region, aetiology and diagnostic clusters 
respectively (one-way ANOVA). 
Current Intensity (mA above SDT) 
Fig. 2.13 Current intensity of the therapy settings of 
stimulation utilised by long-term users of TENS (Study 
2.2, n=87). 
i 
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The mean±SD therapy level was found to be 9.1±9.1 mA above SDT (n=87). No 
relationship (r=+0.2, df=86, P>0.05, Pearson correlation coefficient) was found 
between therapy level and pulse frequency. Males utilised a significantly higher 
therapy level (Mean±SD (mA above SDT); female 7.0±6.4, male 11.4±11.1, P<0.05, 
unpaired t-test ). 
Pain threshold: Pain threshold measurements, taken at the site of TENS electrodes, 
were also corrected for sensory detection threshold in each individual. Mean±SD pain 
threshold for all patients was found to be 18.20±15.2 mA above SDT (n=87). No 
relationships (r=+0.2, df=86, P>0.05, Pearson correlation coefficient) were found 
between pain threshold and pulse frequency. Males showed significantly higher pain 
thresholds (Mean±SD (mA above SDT); females=14.4±11.6, males=22.5±17.6, 
P<0.05, unpaired t-test), and no significant differences in pain threshold were found 
across anatomical region, aetiology or diagnostic clusters (one-way ANOVA). 
Percentage Therapy level: Therapy levels were re-calculated as a percentage falling 
within a window between sensory detection threshold and pain threshold. Thus: 
%Therapy level = Absolute Therapy level(mA) - SDT (mA) Pain threshold(mA) - SDT(mA) x 100 
No relationships (examined by plotting data, Pearson and Spearman correlation 
coefficients, and ANOVA and Kruskal-Wallis tests) were found to exist between 
percentage therapy level and any of the patient, stimulator, or outcome variables 
recorded. 
Comparison of low frequency (fixed at 20 Hz) and high frequency 
stimulation (fixed at I00Hz) 
Patients required significantly more current to attain sensory detection threshold, 
therapy level and pain threshold at the low frequency (20Hz) of pulse delivery as 
shown in Table 2.3. Males were found to have significantly higher sensory thresholds, 
therapy levels, and pain thresholds, for both high and low frequencies of stimulation. 
i 
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MEAN ± SD CURRENT Low Frequency High Frequency Paired t-test 
INTENSITY (mA) (20Hz) (100Hz) 
Sensory detecton threshold [mA] (n=88) 11.6± 8.1 8.7± 5.4 p<0.001 
Therapy level [mA above SDT] (n=87) 11.1±11.3 8.3± 9.9 p<0.001 
Pain threshold [mA above SDT] (n=83) 21.6±16.9 16.7±16.3 p<0.001 
Table 2.3 Comparison of current intensity achieved during 
TENS administered at low and high pulse frequencies 
(continuous mode) in long-term users of TENS. Recordings 
were taken at the site of pain. Data was logarithmically transformed prior 
to statistical analysis (SDT=sensory detection threshold). 
Follow-up 
Pulse frequency remained consistent over the 4 month follow-up period (r =+0.66, 
df=23, P<0.01, Pearson correlation coefficient; paired t-tests showed no significant 
differences between visits, P=0.93). Therapy settings declined between visit 1 and 2 
(Mean±SD (mA above SDT); visit 1=10.2±10.6; visit 2=6.1±6.2, P<0.01, paired t- 
test) although no significant differences were observed for sensory detection threshold 
over the two visits (Mean±SD (mA); visit 1=12.7±6.5; visit 2=12.2±8.9, P=0.55, 
paired t-test: Pearson correlation coefficient: r=+0.82, df=23, P<0.01) 
Main findings of Study 2.2 
(i) No relationships were observed between region, aetiology or the diagnosis of 
pain, with any patient, stimulator, or outcome variable. 
(ii) Patients applied TENS to produce a'strong but comfortable electrical 
paraesthesia within the painful area. 
(iii) In 47% of patients, TENS reduced (on average) the intensity of their chronic 
pain by more than half. 
(iv) The onset and offset of analgesia was reported to be rapid, within 30 minutes in 
the majority of patients. 
(v) Seventy-five per cent (75%) of patients reported to use TENS on a daily basis, 
and 30% use TENS for over 49 h/week. 
(vi) Forty-four per cent (44%) of patients benefitted from the availability of burst 
mode stimulation. 
(vii) Seventy-five per cent (75%) of patients used frequencies below 70 Hz, 
although this may be due in part to stimulator design. 
Chapter 2: The clinical use of TENS 48 
Study 2.3. 
The consistency of pulse frequencies and pulse patterns of 
TENS used by chronic pain patients. 
Study 2.2 found that 75% of patients utilised frequencies between 1-70 Hz and 
although no relationships were shown to exist between TENS pulse frequency and 
either the cause and site of pain, or TENS efficacy, the results implied that patients 
utilised specific pulse frequencies which were unique to the individual. Patients also 
expressed strong preferences for specific pulse patterns and 23% of patients reported 
burst mode TENS to be the most beneficial pulse pattern to reduce their pain. The aim 
of Study 2.3 was to investigate the consistency of TENS pulse frequencies and pulse 
patterns used by chronic pain patients over a one year period. 
Patients and Procedure 
Thirteen patients (female n=8, male n=5; age range=39-66, mean±SD=54.1± 9.8 
years of age) attended the research unit on three separate occasions (approximately 4 
months apart over a one year period) to participate in the study. Of these 13 patients, 
10 returned for a fourth visit. Patients were instructed to apply TENS as they would to 
treat their chronic pain condition. All patients applied electrodes directly over, or 
immediately proximal to, the site of pain. Patients set their stimulators to a'strong but 
comfortable' intensity level and hunted for the most suitable pulse frequency. The 
electrical characteristics of TENS were recorded using the Frye Analyser as described 
in Study 2.2. Patients were in possession of one of four types of stimulator (i. e. Tiger 
Pulse, Tiger Burst, Microtens, or Spembly). Pulse width was fixed at 200µs in all 
stimulators, and electrode impedance was below 1.5 Kohms. 
Patients were categorised according to the classification of chronic pain, prepared by 
the International Association for the Study of Pain [IASP 1986]. The patient 
population had a range of chronic pain conditions, including deafferentations (n=2), 
nerve entrapments (n=3), neuralgias (n=3), spondylosis (n=3), sympathetic (n=1) and 
'other' (n=1). Five of these patients had low back pain of either 'traumatic' or 
'degenerative/mechanical' aetiology. 
All patients had been successfully controlling their pain condition with TENS for over 
one year prior to this study. Twelve of the 13 patients found that TENS generally 
reduced their pain by over half, as measured on a visual analogue scale. 
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Results of Study 2.3 
The results of Study 2.3 are summarised in Table 2.4. Of the 13 patients, 4 were in 
possession of a Tiger Pulse stimulator (no burst mode option available), 3a Tiger 
Burst, 3a Spembly 9000 and 3a Microtens 7577. Patients utilised pulse frequencies 
between 3-200 Hz (range=3-176Hz, mean=60Hz, median=47Hz, n=39; 3 visits per 
subject). All stimulators possess a frequency control dial with logarithmic output 
characteristics, therefore logarithmic transformation of pulse frequency data was 
performed before statistical analysis (see Appendix B). 
PATIENT PULSE FREQUENCY(Hz) [Pattern] 
1St visit 2nd visit 3rd visit 4th visit 
(A) 12 [C] 28 [C] 12 [Cl 35 [C] 
B 140 [B] 136 [B] 176 [C] 200 [C] 
(C) 124 [C] 72 [C] 124 [C] [x] [x] 
D 47 [B] 56 [B] 56 [B] 60 [B] 
(E) 8 [C] 17 [C] 3 [C] [x] [x] 
F 92 [C] 100 [B] 26 [C] 112 [C] 
G 16 [Cl 16 [C] 16 [C] 18 [C] 
H 104 [B] 29 [B] 29 [C] 26 [B] 
I 24 [C] 32 [C] 33 [C] 29 [C] 
J 58 [C] 43 [C] 50 [C] 16 [C] 
(K) 10 [C] 18 [C] 23 [C] 16 [C] 
L 55 [C] 92 [C] 80 [C] 32 [C] 
M 136 [B] 112 [B] 124 [B] [x] [x] 
Table 2.4 The consistency of pulse frequencies and pulse 
patterns of TENS in long-term users (Study 2.3). Pulse 
pattern; [B] = burst mode, [C] = continuous mode, [X] = patients not 
returning for 4th visit=[X]. Patients without the availability of burst 
mode stimulation = (A), (C), (E), (K). 
One-way ANOVA for repeated measures showed no significant differences between 
the frequency of pulse delivery used between visits. Pulse frequencies used by 
individual patients were found to be highly correlated between visits (Visit 1v2, 
r=+0.84, df=12, P<0.01: Visit 1v3, r=+0.82, df=12, P<0.01: Visit 2v3, r=+0.81 
df=12, P<0.01, Pearson Correlation coefficient, see Table 2.4). Analysis of the 10 
patients who returned for a fourth visit also revealed no significant differences in pulse 
frequency between visits (one-way ANOVA). 
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Of the patients with the option of burst mode stimulation, 6 out of 9 patients utilised 
the same pattern of stimulation on 3 visits. Thus, 4 utilised continuous mode only, 2 
patients utilised burst mode only, and 3 alternated between the two modes. All of the 
patients utilising either burst or continuous mode TENS alone, continued to do so if 
they returned for the fourth visit. 
As in Study 2.2 no relationships were found between pulse frequency or pulse pattern, 
with the site or cause of pain. However, the patient sample was small in the present 
study. 
Main findings of Study 2.3 
(i) Patients show individual preferences for pulse frequencies and patterns, and 
consistently turn to such settings on subsequent treatment sessions. 
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DISCUSSION 
The clinical use of TENS in the treatment of chronic pain conditions has been 
examined in depth by three studies. Since the introduction of TENS to NPRC, 1582 
patients with a wide variety of pain conditions have been given a trial of TENS, and 
927 (58.6%) continue to use stimulators on a long-term basis (Study 2.1). No 
relationships between patient, stimulator and outcome variables were found in patients 
who successfully use TENS on a long-term basis to control a chronic pain condition 
(Study 2.2). However, patients prefer specific pulse frequencies and pulse patterns, 
and turn to such settings on subsequent TENS treatment sessions (Study 2.3). 
Furthermore, Study 2.2 revealed much information of importance to clinicians 
involved in pain control by means of TENS. These findings will now be discussed in 
detail. 
Long-term use of TENS at Newcastle Pain Relief Clinic 
(Study 2.1) 
The clinical importance of TENS as an analgesic technique in the treatment of chronic 
pain has been demonstrated. At present, approximately 180 stimulators are issued to 
patients by NPRC each year (3-4 per week), and since its introduction to the clinic in 
1979, TENS has been issued on loan to 1582 patients. Of these 1582 patients, 927 
(58.6%) continue to use stimulators. Although it was not possible to assess the degree 
of pain relief obtained by patients continuing with TENS treatment, nor to confirm that 
all were using stimulators regularly, the policy in the clinic was to stress that 
stimulators should be returned if not being used so that they could be issued to other 
patients. It may therefore be inferred that the majority of those not returning stimulators 
were obtaining some benefit from TENS. An investigation is planned to assess TENS 
use (by postal questionnaire) in all patients possessing stimulators. 
Eriksson et al. [1979; 1984] found that varying proportions (18-60%) of patients 
continued to benefit from TENS after one year, depending upon the type of pain 
condition. Bates and Nathan [1980] reported 27% of patients to benefit after a year 
(Table 2.1). A wide range of chronic pain conditions (reflecting the distribution of 
pains presenting at NPRC [Davies & Crombie 1990]) were successfully treated with 
TENS, and no particular pain appeared to respond better than another. Thus, any type 
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of pain may benefit from TENS. This finding was confirmed by the results of Study 
2.2 and by previous investigations [Loeser et al. 1975; Bates & Nathan 1980; Wolf et 
al. 1981]. However, it is clear that certain pain conditions are less likely to respond 
than others (see Table 1.2). 
Most patients who returned their stimulators did so within the first six months, usually 
at the first follow-up appointment at NPRC. Such patients may be classified as non- 
responders, to TENS because: 
(i) it was ineffective, 
(ii) it aggravated the pain, 
(iii) it was too difficult or inconvenient to use. 
Hence, patients responding to TENS for over 6 months usually continue with 
treatment, a finding consistent with Eriksson et al. [1984]. Reasons for patients 
returning stimulators after this time may include resolution of the pain problem, simple 
forgetfulness, and the development of tolerance to TENS analgesia [Pomeranz & 
Niznick 1987]. 
Long-term use of TENS by chronic pain patients (Study 2.2) 
Study 2.2 is the first in-depth study of a large number of patients who successfully use 
TENS on a long-term basis for the relief of a variety of chronic pain conditions. 
Despite the wide range of conditions treated, no relationships were observed between 
patient (i. e. cause and site of pain), and stimulator variables (i. e. TENS settings used). 
This result is consistent with previous reports [Loeser et al. 1975; Bates & Nathan 
1980; Wolf et al. 1981]. However, the patients examined in Study 2.2 were 
responding to TENS, and comparisons with TENS non-responders may provide more 
valuable information (see Chapter 6). Nevertheless, Study 2.2 revealed much 
information of importance to clinicians involved in pain control by means of TENS. 
The following findings are of clinical relevance: 
(i) Patients applied TENS to produce a'strong but comfortable' electrical 
paraesthesia within the painful site. 
(ii) Forty-seven per cent (47%) of patients found that TENS reduced their pain by 
more than half. 
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(iii) The onset of TENS analgesia occurred immediately in 30% of patients, within 
less than 1/2 hour in 75% of patients, and within one hour in 95% of patients. 
(iv) Post-TENS analgesia lasted less than 30 minutes in 51% of patients and more 
than an hour in over 30% of patients. 
(v) Seventy-five per cent (75%) of patients reported to use TENS on a daily basis, 
52% of patients used TENS for up to 28 hours per week, whilst 30% used it for 
over 49 hours per week. 
(vi) Forty-four per cent (44%) of patients benefitted from the availability of burst 
mode stimulation. 
(vii) Seventy-five per cent (75%) of patients utilised pulse frequencies between 
lHz-70Hz (median=32 Hz) although this may be in part due to stimulator design. 
Some of these points are discussed below. 
TENS Questionnaires 
In a study of patients with chronic facial pain, Eriksson et al. [1984] found that men 
attained greater benefit from TENS than women. By contrast, Johansson et al. [1980] 
found that neither age nor sex had predictive value. The latter finding is confirmed in 
the present investigation, in which there was no correlation between these factors and 
the degree of response to TENS across any of the chronic pain conditions. Moreover 
examination of the administrative records revealed no differences in the proportion of 
stimulators returned to the clinic by males and females. 
Degree of analgesia: Long-term results of peripheral conditioning stimulation as 
reported by Eriksson et al. [1979], indicated that three-quarters of chronic pain patients 
who obtain successful analgesia reach over 50% pain relief (measured on a VAS). 
Approximately half of the patients in the present study reported over 50% relief of pain 
during TENS use. Surprisingly 11 of the 23 patients who reported no TENS analgesia 
continued to use the stimulator on a daily basis, thus posing an interesting anomaly. 
Patients who report no pain relief on a VAS may not necessarily represent failures of 
TENS treatment because some of them still receive benefit, evidenced by their 
statements that: "TENS does not reduce my pain, but it distracts, or takes my mind off 
it". Such patients may produce idiosyncratic VAS scores and reveals a deficiency in 
such ratings which record only one component of the pain sensation (i. e. pain 
intensity). Our patients utilised a wide range of treatment regimes. Some used TENS 
for over 7 hours daily, proclaiming the success of the "Wonderful black box"!. 
However, despite the experience of long-term stimulator use, some patients still 
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showed anxiety on using TENS, possibly reducing efficacy, as suggested by Nathan 
and Wall [1974]. 
Onset of analgesia: The rapid onset of TENS analgesia (within 30 mins of 
stimulator'switch on' for 75% of patients), and also rapid offset (within 30 minutes of 
stimulator 'switch off for over 50% of patients), was noted by Hansson and Ekblom 
[1983]. This rapid'on-off analgesic effect accords with a neuronal gating mechanism 
as proposed by Melzack and Wall [1965]. However, Eriksson et al. [1979] using 
bursts mode TENS at an intensity sufficient to produce muscle contraction, as utilised 
in AL-TENS, found that the induction time of analgesia to be 20-30 minutes, and 
slower than the induction time of low intensity continuous mode TENS which was 2- 
10 minutes. In the present study, the time to onset of analgesia with burst or 
continuous mode did not differ. This may be due to the different intensities of burst 
stimulation used by the patients in Study 2.2 and those in the Eriksson et al. study. 
Thus the group of patients examined in Study 2.2 used burst mode TENS at intensities 
below that required to induce muscle contraction. 
Post-TENS analgesia: In over 50% of patients, post-TENS analgesia lasted less 
than 30 minutes, as observed previously by Andersson et al. [1976]. However, a third 
of patients achieved post-TENS analgesia of over one hour, possibly as a result of 
activating descending pain inhibitory pathways and the release of opioid peptides. 
Nevertheless such patients were not observed to be using high intensity TENS or 
producing AL-TENS, which has been proposed to be a requirement to activate opioid 
release [Sjölund et al. 1977]. Over half of the patients preferred continuous mode 
TENS alone to treat their chronic pain, and a quarter used the burst facility alone. No 
significant differences were found between the duration of post-TENS analgesia 
obtained with burst or continuous stimulation. 
TENS tolerance: The declining response to TENS with time, often termed tolerance 
to TENS analgesia, has remained a fundamental problem for clinicians and patients 
alike. Although the mechanism of this tolerance is far from understood, it may be due 
to an adaptative change by the nervous system to regular repetitive stimuli produced by 
TENS [Cheng & Pomeranz 1987]. In the present study, 32% of patients reported a 
decline in TENS efficacy from the time the stimulator was issued, although for the 
majority (58%) TENS efficacy remained unchanged. This finding is consistent with 
that of Study 2.1 in which few patients returned stimulators after one year. Attempts to 
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prevent or delay the occurrence of tolerance have led to the development of TENS units 
with 'random' pulse delivery facilities (i. e. Xenos), and a new generation of non- 
portable stimulators such as the Codetron [Pomeranz & Niznick 1987] and the Likon 
[Likon 1990]. Such devices remain to be fully validated. 
Personality (EPQ): The possibility that personality might be correlated with 
response to TENS has been investigated by several workers. Nielzen et al. [1982] and 
Johansson et al. [1980] reported that psychiatric and personality assessments may have 
a predictive value for TENS outcome. However Andersson et al. [1976] found no 
relationships between the EPQ and patient response to TENS. Similarly in Study 2.2 
no relationships were observed between EPQ ratings and any patient, stimulator, or 
outcome variables. 
Adverse effects: The only common problem associated with TENS was skin 
irritation, and this was encountered by a third of patients, probably due to either, (i) 
drying out of electrode jelly [Mason & Mackay 1976; Yamamoto et al. 1986], or (ii) 
irritation from tape. Some patients reported using TENS for over 7 hours without 
replenishing electrode gel because of inconvenience. More severe allergic reactions to 
electrodes, gel or tape are occasionally encountered in the clinic, although the problem 
is usually overcome by changing the type of electrode used, for example, from carbon 
rubber with saline gel to a self-adhesive non-gel type. 
Electrical characteristics of TENS 
Site of stimulation: When patients were first issued with a stimulator, they were 
instructed to apply electrodes directly over, or immediately proximal to the site of pain 
[Wolf et al. 1981; Sjölund & Eriksson 1985]. Patients were also encouraged to 
experiment with electrode positions in order to find the optimal site for pain relief. 
Subsequently, most patients had carried out an exhaustive trial of different electrode 
positions, and were generally using sites to produce an electrical paraesthesia within 
the site of pain, rather than stimulating remote body sites. This finding is consistent 
with previous reports [Loeser et al. 1975; Linzer & Long 1976]. 
Pulse frequency: Andersson et al. [1976] found that the degree of pain relief was 
related to the frequency of stimulation, so that for example, 2 Hz was insufficient to 
produce analgesia. It is generally stated that frequencies between 40-100 Hz are the 
most beneficial for patients [Woolf 1989]. Linzer and Long [1976] reported that 74% 
of patients used frequencies between 1-60 Hz, although it is possible that this was due 
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to the logarithmic output characteristics of the frequency control dial on some 
stimulators. 
The patients in Study 2.2 favoured frequencies between 1-70Hz, with an additional 
cluster at 111-140Hz. Unfortunately, specific frequencies above 40Hz are usually 
difficult to attain on commercially available stimulators, because these lie on the steep 
part of the frequency output curve, which has a logarithmic function. Hence a small 
turn of the control dial results in a big change in frequency (Fig. 2.12). The distribution 
of pulse frequency used by patients in Study 2.2, reflected the characteristics of the 
frequency control dial. Different models of stimulators had different frequency output 
characteristics, and these probably influenced the patients choice of stimulation 
frequency. Thus, the cluster of patients using frequencies between 111-140 Hz were 
all using Tiger Pulse and Tiger Burst stimulators whose maximum frequency setting 
lies in this range. Moreover, analysis of the questionnaire indicates that patients prefer 
to use faster frequencies of stimulation. This fact, coupled with the lack of use of 
frequencies between 41-110 Hz, strongly suggests that patients were not always able 
to attain the maximal preferred frequency to achieve the largest analgesic effect. It is 
clear that there is considerable scope for improved design of commercially available 
stimulators. 
The results of Study 2.2 suggest that each patient prefers a particular pulse frequency 
and pulse pattern to treat his or her pain condition because: 
(i) Patients inevitably returned to their preferred pulse frequency after completing 
the Frye Analysis recording session. 
(ii) Patients reported regularly resetting pulse frequency before use. 
(iii) Patients chose similar frequencies at the 4 month follow-up period. 
These findings were confirmed in Study 2.3 where it was found that patients utilise 
specific pulse frequencies and pulse patterns (unique to the individual) to control their 
chronic pain condition. After experimenting with stimulator settings, patients find the 
most beneficial pulse frequency and pulse pattern and use these on subsequent 
treatment sessions. 
The reason of why patients prefer certain pulse frequencies and patterns remains to be 
determined. Sjölund [1985] found that stimulation of peripheral nerves at a frequency 
of 80 Hz, produced the most profound suppression of the C-fibre-evoked reflex in 
rats. Theoretically, high frequency (often reported as between 40-100 Hz) low 
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intensity TENS should produce optimal conditions for selectively activating large 
diameter afferent fibres (A-beta), a prerequisite for closing 'pain gates' in the spinal 
cord. 
In Study 2.2,59 (65%) patients used frequencies below 50 Hz and in Study 2.3,6 
(46%) patients utilised frequencies below 50 Hz. The large variability in pulse 
frequencies used between individuals, and the lack of relationships between the pulse 
frequency and the cause and site of pain, or any of the many variables recorded, 
suggests that pulse frequency preference may be for reasons of comfort, unconnected 
with specific pain control mechanisms. Thus, it appears that patients experiment with 
frequency settings to 'tune in' to a favourite pulse frequency. 
Pulse Pattern: Study 2.2 found that 72 (56%) patients used continuous TENS 
alone, 29 (23%) burst TENS alone, and 27 (21%) regularly alternated between the 
two. A similar distribution was observed in Study 2.3 where 4 out of 9 (44%) patients 
preferred to use continuous mode TENS alone, 2 (22%) preferred burst TENS alone, 
and 3 (33%) regularly alternated between burst and continuous. Furthermore, patients 
favoured pulse patterns on subsequent treatment sessions. All patients under study 
applied burst mode TENS at an intensity insufficient to activate deep muscle afferents 
which would be requirement to achieve AL-TENS. Therefore it seems probable that 
patients were utilising burst mode TENS in a similar manner to continuous mode 
TENS and for reasons of comfort [Mannheimer & Lampe 1988a]. Nevertheless some 
patients reported discomfort while using the burst mode, possibly due to the 
occurrence of phasic muscle contractions, and consequently preferred continuous 
mode stimulation. 
Intensity of stimulation: Patients report stimulating at the highest possible 'strong 
but comfortable' (non-painful) level, without concurrent muscle contraction, during 
treatment. Wolf et al. [1981] reported a positive relationship between higher intensity 
TENS and increased analgesia, although this was not substantiated in the present 
investigation. In Study 2.2, males needed a higher current to achieve therapy level. 
When pulse frequency was fixed by the experimenter, the lower frequency of pulse 
delivery (20Hz) required a higher intensity of current to achieve sensory threshold, 
therapy level, and pain threshold. No differences in sensory threshold, therapy level 
and pain threshold, whether measured at high or low fixed frequencies, were found 
over the different anatomical regions stimulated. It seems likely that the intensity of 
Chapter 2: The clinical use of TENS 58 
therapeutic stimulation used during TENS is dependent upon a combination of both 
physiological (i. e. site and cause of pain) and psychological (i. e. personality) factors. 
Clinical Implications 
A number of findings from these investigations have direct clinical implication. 
Perhaps the most important is that clinicians cannot assume that any particular pain will 
not respond to TENS, because a wide range of chronic pain conditions have been 
treated successfully in the patient populations under study. As suggested previously 
TENS should be tried for a minimum of one hour in the clinic in order to: 
(i) observe any immediate response to TENS - some patients may take one hour to 
show a response, 
(ii) observe adverse reactions (i. e. skin irritation, or aggravation of pain by TENS), 
(iv) provide adequate instruction on stimulator use. 
In most patients pain relief only occurs during stimulation and only 20% of patients 
will benefit from the bonus of post-TENS analgesia for more than 2 hours. Thus, 
patients may need to apply TENS over the entire day on a daily basis in order to 
control their pain condition successfully. Therefore, a two month home trial is 
necessary to fully assess response to treatment. Other patterns of stimulation (e. g. 
burst) should always be considered (and available), as some patients fail to respond to 
continuous mode TENS. Although patients need to determine their own optimal pulse 
frequency, it is possible that frequencies between 1-70Hz may be of benefit. 
Nevertheless, stimulator design may seriously hinder patient choice. The only common 
adverse effects of TENS is skin irritation in one third of patients, which could be 
reduced by careful instruction on electrode technique. The use of TENS outdoors by 
72% of patients also implies that TENS may vastly improve patient mobility. It is 
important that attention be given to all these factors during the clinical use of TENS. 
Summary 
The importance of TENS as an analgesic technique especially in the control of chronic 
pain has been confirmed. Doubts about the clinical efficacy of TENS have been 
dismissed, as 58.6% of patients given a trial of TENS continue to use the technique to 
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control a wide range of chronic pain conditions. Approximately half of the patients 
using TENS successfully to control a chronic pain condition obtain over 50% 
reduction in their pain during treatment. For the majority of patients, the onset and 
offset of pain relief is rapid and only occurs during stimulation, thus to control the pain 
problem, patients use stimulators over the entire day. In general, patients apply TENS 
to produce a 'strong but comfortable' electrical paraesthesia within the painful area, 
and have specific preferences on pulse frequencies and pulse patterns, turning to these 
frequencies and patterns on subsequent treatment sessions. Nevertheless, these pulse 
frequencies and patterns were not related to the cause and site of pain, implying that 
patients turn to such frequencies and patterns for reasons of comfort, which may not 
be related to mechanisms specific to the pain system. 
Despite the relative success of administering TENS on an empirical basis, in which the 
patient determines by trial and error the setting which best controls the pain condition, 
41.4% of patients fail to respond to treatment, and half using TENS on a long-term 
basis achieve less than 50% relief of pain. It is therefore likely that improvements in 
TENS techniques can be made. Patients may not be utilising the most beneficial 
stimulator settings because of stimulator design. Furthermore, the electrical 
characteristics often suggested for TENS (high frequency 40-100Hz, low intensity 
'strong but comfortable') are largely derived on theoretical grounds to selectively 
activate large diameter skin afferents. However, experimental evidence examining the 
effects of different electrical characteristics of TENS remains sparse. Thus a systematic 
investigation was performed to examine the analgesic effects of different electrical 
characteristics of TENS, as described in Chapter 3. 
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CHAPTER 3 
THE ANALGESIC EFFECTS OF DIFFERENT 
ELECTRICAL CHARACTERISTICS OF TENS 
IN HEALTHY SUBJECTS 
INTRODUCTION 
Chapter 2 has shown that patients who successfully control a chronic pain condition 
with TENS, apply TENS to produce a'strong but comfortable' electrical paraesthesia 
within the painful area. This paraesthesia is achieved using low intensity electrical 
pulses delivered at a range of pulse frequencies and pulse patterns dependent upon the 
patient's preference. In this conventional form of TENS, the electrodes are generally 
placed around the painful area, or over the same dermatome (i. e. the area of skin 
sending afferent nerve fibres to the same spinal nerve root) as the painful area. 
Stimulation in the contralateral dermatome at the same level may enhance the beneficial 
effect. Several variations in TENS techniques have been introduced in an attempt to 
increase efficacy, reduce the incidence of non-response and prevent the development of 
tolerance to TENS analgesia [for review see Mannheimer & Lampe 1988a]. However, 
these variations in TENS techniques have met with only modest success, and in 
practice the electrical characteristics of TENS used by individual patients are usually 
found by trial and error. Furthermore, the results presented in Chapter 2 have shown 
that this 'trial and error' method may not provide the most efficacious electrical 
characteristics of TENS as 41.4% of patients fail to respond, and half of the patients 
responding achieve less than 50% relief. Therefore, a systematic investigation was 
performed to examine the analgesic effects of different electrical characteristics of 
TENS in healthy subjects. 
The electrical characteristics of TENS 
In general, TENS units have dials to control: 
(i) pulse amplitude (current intensity), 
(ii) pulse frequency, 
(iii) pulse pattern, 
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as shown in Fig. 1.5, although some stimulators have pulse width control. Few studies 
have systematically examined the effects of varying pulse frequency, pulse pattern or 
stimulation mode (i. e. 'conventional' or AL-TENS) on the degree of pain relief 
obtained with TENS. 
Pulse Frequency 
It has been well documented in clinical studies that TENS efficacy is dependent upon 
pulse frequency [Andersson et al. 1976; Linzer & Long 1976; Mannheimer & Carlsson 
1979; Hansson & Ekblom 1983]. Animal studies performed by Sjölund [1985] found 
that within a range of stimulating frequencies between 10-160Hz, 80Hz produced the 
maximal suppression of the C-fibre evoked flexion response in lightly anaesthetised 
rats. Hansson and Ekblom [1983] reported significant relief of acute oro-facial pain in 
patients who were administered TENS at frequencies of 2Hz and 100Hz, although 
patients preferred to use the higher frequency. In contrast, an earlier study by Ashton 
et al. [1984a] carried out in this laboratory suggested that 8Hz rather than 100Hz was 
more effective in reducing experimental pain in healthy volunteers. However, many 
studies have been restricted to the investigation of only 2 stimulating frequencies. 
The results of Study 2.2 and 2.3 have shown that patients have preferences toward 
specific pulse frequencies although such preferences do not appear to be related to the 
cause and site of pain [Johnson et al. 1991a; 1991b]. Furthermore, it is generally 
reported that pulse frequencies between 40-100Hz [Woolf 1989] are most beneficial. 
Nevertheless the majority of patients using TENS on a long-term basis administer 
pulse frequencies below 70Hz (Study 2.2). This has been attributed in part to the 
difficulty in obtaining specific frequencies above 40Hz because of the logarithmic 
output characteristics of the frequency control dial. 
Pulse Pattern 
The importance of the pattern of pulse delivery in TENS analgesia was shown in 
Chapter 2 (Studies 2.2 and 2.3) where 23% of patients required burst mode 
stimulation to reduce pain. A variety of pulse patterns have been incorporated into 
stimulator design in an attempt to improve efficacy (including burst, modulation and 
random), but few of these have been systematically investigated. 
Eriksson et al. [1979] has shown that trains of pulses delivered in "bursts" at high 
intensity (sufficient to produce muscle twitch) and low frequency (AL-TENS) were 
sometimes more effective in pain relief than continuous (conventional) TENS. This 
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observation led to the incorporation of 'burst mode' on stimulators. Nevertheless, 
Study 2.2 revealed that many patients utilise burst mode stimulation at an intensity 
insufficient to produce muscle twitch. This low intensity burst mode TENS is thought 
to be similar to continuous TENS and is preferred by patients for reasons of comfort 
[Mannheimer & Lampe 1988a]. 
Preliminary observations in this laboratory showed that some patients found burst 
stimulation uncomfortable (even at low intensity) and disliked the 'stabbing' sensation 
it produced. Consequently a stimulator was developed by RDG Electro-Medical in 
which the amplitude of the pulses (current intensity) within each 'train' or 'burst' was 
gradually increased (or ramped) as shown in Fig. 3.1. This ramping of output intensity 
has been termed 'modulation' stimulation and the subjective sensation it produces is 
similar to stroking. To date, no studies have investigated the effect of modulating 
current amplitude of TENS on humans. However, Ekström and Sjölund [1988] 
examined the effects of modulating both pulse frequency and pulse duration (width) on 
the C-fibre reflex in anaesthetised rats, and found that neither improved analgesic 
effect. 
Continuous 
jIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Burst 
1111111 1111111 IIIIIII 1111111 1111111 
Modulation 
. ýý11.111: 1i1, 
I ýat1I11 11111, ý1111js, 
Random 
Fig. 3.1 TENS pulse patterns (not drawn to scale). 
Continuous pulse pattern = free running delivery of regular pulses; the 
frequency of these pulses is regulated by the frequency control dial of the 
stimulator. Burst pulse pattern = regular trains or bursts of pulses, 
delivered at a fixed frequency of 2.3Hz. The frequency of pulses within the 
burst can be regulated by the frequency control dial. Modulation pulse 
pattern = similar to burst mode TENS except that pulse amplitude (current 
intensity) is increased to reach a plateau. Random pulse pattern = pulses 
delivered at a random frequency between 14-188Hz. 
The development of tolerance to the analgesic effect of TENS may be in part the result 
of adaptation by the nervous system to regular, repetitive stimuli [Pomeranz & Niznick 
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1987]. The exact number of patients developing tolerance is not known. Bates and 
Nathan [1980] found that a significant number of patients dropped out of TENS 
treatment between the 1st and 2nd year (Table 2.1), suggesting the development of 
tolerance rather than placebo effects which are generally shorter lasting. In contrast, the 
findings of Study 2.1 that few patients return stimulators later than one year from 
issue, suggest that the proportion of patients developing tolerance may be small. 
Nevertheless, a prototype stimulator was specifically designed (by Neen Pain 
Management Systems) in an attempt to minimise TENS tolerance by delivering pulses 
in a random manner at frequencies between 14-188Hz. 
Stimulation mode 
Acupuncture-like TENS (AL-TENS), was developed by Eriksson and Sjölund [1976] 
and requires forceful phasic muscle contractions. Electrodes are placed over mixed 
nerves that supply muscles whose innervation arises from the same spinal root as the 
sensory nerves that innervate the area of pain (i. e. a related myotome, found using 
myotome tables). The delivery of single pulses at a low frequency and sufficient 
intensity to produce such phasic muscle twitches was found to be uncomfortable to 
patients, but this discomfort was reduced when pulses were delivered in low frequency 
'trains' or 'bursts'. Consequently 'burst mode' was incorporated into stimulator 
design. 
A major advantage of AL-TENS is that it can be applied at distant sites, but 
myotomally related to the site of pain, important in patients where electrical 
paraesthesia cannot be achieved in the painful area. Such cases include hyperaesthesia, 
in patients with highly sensitive skin (burns), projected pain (sciatica) and deep pain 
(myalgia) [Sjölund et al. 1990]. Since acupuncture achieves a sustained post-treatment 
analgesia (sometimes up to several weeks) it has been suggested that AL-TENS could 
prolong the rather short post-TENS analgesia associated with conventional stimulation. 
Despite the clarity of Sjölund's and Eriksson's work, Chapter 2 has shown that the 
burst mode facility is usually utilised for reasons of comfort rather than the production 
of AL-TENS. As a consequence patients may not be obtaining the maximum benefit 
from their stimulator. Furthermore, patients who do not respond to conventional 
TENS may be lost as TENS failures, although a trial of AL-TENS (and other modes of 
stimulation) may prove successful. 
Other modes of TENS have also been described [for review see Mannheimer & Lampe 
1988a], including "Brief Intense" TENS [Melzack 1975b; Jeans 1979], where TENS 
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is administered as a continuous pulse pattern at the highest possible intensity tolerable 
to the patient. Such stimulation produces fasciculatory or tetanic muscle contraction 
and it has been suggested that the analgesic effects produced by intense TENS are due 
primarily to the peripheral blockade of ongoing nociceptive transmission in small 
diameter peripheral afferents [for review see Mannheimer & Lampe 1988b]. Although 
there are relatively few reports in the literature documenting clinical usage of intense 
TENS Strassburg et al. [1977] have used such stimulation to produce adequate 
analgesia for minor surgical procedures including muscle biopsies and median nerve 
decompressions. Thus it is apparent that there is a lack of controlled trials assessing the 
analgesic effects of AL-TENS (and other modes) in comparison to conventional 
TENS. 
Finally, increasing electrode size might be expected to enhance TENS analgesia, since 
stimulation of a larger area of skin would activate a greater number of large diameter 
cutaneous afferents, and so lead to greater inhibition of nociceptive transmission in the 
spinal cord. 
It was decided to examine the analgesic effects of different electrical characteristics of 
TENS on experimental pain in healthy subjects, rather than clinical pain in patients, 
because of difficulties in measuring clinical pain in heterogeneous patient populations 
(i. e. inter-individual variation in the intensity and quality of clinical pain in a group of 
patients, coupled with overlying psychological problems including depression, may 
reduce the reliability of recordings). Therefore it was necessary to produce a suitable 
experimental pain stimulus in order to investigate the analgesic effects of TENS. 
Cold-Pressor Pain 
The development of pain models capable of evaluating analgesic efficacy under 
standard conditions has proved to be one of the most challenging objectives in the 
study of pain. The important requirements of an experimental pain model in man 
include that the stimulus should: 
(i) be controllable, measurable and reproducible, 
(ii) provide a clear cut identification and perception of pain threshold, 
(iii) show a relation between stimulus and pain intensity, 
(iii) cause minimal tissue damage or lasting psychological or physical effects, 
(iv) be convenient to apply and rapidly tenninated on demand by the subject. 
For review see Gracely [1989]. 
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Immersion of a limb in cold water has long been known to induce pain and the 
accompanying pressor response has been used as a stress test in the study of cardiac 
function. On immersion of the hand in cold water there is an initial sensation of cold, 
followed by pain which rapidly increases in intensity to reach a maximum within about 
one minute. This pain then plateaus or even subsides in a process known as 
adaptation, as described by Wolf and Hardy [1941]. Cold-pressor pain has been used 
extensively to study the effects of analgesics because it can allow for a variety of 
measurements relating to the pain response. Posner et al. [1985] measured pain 
intensity ratings on a visual analogue scale to immersion of the hand in 2°C water and 
found the technique a sensitive model for measuring opiate-induced analgesia in 
healthy volunteers. Hodes et al. [1990] allowed for two response measures, (i) the 
sensory-discriminative response to pain measured by ratings of pain intensity at fixed 
time intervals, and (ii) the affective-reactive response to pain measured by time to 
tolerance. 
Ashton et al. [1984a] in an earlier study conducted in this laboratory, examined the 
effects of acupuncture, TENS and aspirin on pain threshold and pain tolerance to cold- 
pressor pain. They found that TENS at a frequency of 8Hz raised ice pain threshold in 
some normal subjects although this was accompanied by large inter-individual 
variation in response to TENS. TENS at 100Hz was ineffective. 
Aim of Chapter 3 
The aim of the present chapter was to examine the analgesic effects of different 
electrical characteristics of TENS by investigating the effects of: 
(i) pulse frequencies (Exp. 3.1), 
(ii) pulse patterns (Exp. 3.2), 
(iii) stimulation modes (Exp. 3.3). 
on cold-pressor pain in healthy subjects. 
Time to pain threshold and pain tolerance were used as measures of analgesic activity. 
However, because of the unreliability of pain tolerance in Exp. 3.1 and Exp. 3.2, pain 
intensity rating (recorded on a visual analogue scale) was recorded in Exp. 3.3. 
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THE EXPERIMENTS 
General Methods 
Subjects were recruited by advertising on departmental noticeboards and those taking 
part in the experiment were rewarded with a book token (value £3.50). Prior to the 
start of the experiment the nature of the experiment was explained to each subject, and 
in addition he or she was given a small printed protocol. 
Pain Induction 
Pain threshold and tolerance measurements were taken during 6 experimental cycles 
each lasting 15 minutes (see Fig. 3.2). The non-dominant hand was immersed in warm 
water (37°C) for 5 minutes, and then plunged (up to the first wrist crease) into water 
maintained at 0°C in a cold water bath. Subjects silently observed sensations in the 
immersed hand until it became definitely painful, i. e. 'physically hurts', when they 
made the statement 'Pain'. The hand remained immersed until the sensation became 
'unbearable', but not numb, at which point the statement'Out' was made and the hand 
withdrawn. Pain threshold was recorded as the time from immersion in the cold water 
to the statement 'Pain' and pain tolerance as the time from 'Pain' to 'Out'. 
HAND IN HAND IN "PAINI" "OUTI" 
HAND OUT 
(Intolerable) 
I WARM WATER BATH ICE WATER . REST PERIOD AT 37°C IZ 
PAIN THRESHOLD I 
' PAIN 
TOLERANCE _ 
ý5 minutes 10 minutes 
ý 
I , ii 
1 
'ý1 
Fig. 3.2 Cold-pressor pain (one cycle). 
Subjects were requested to withdraw the hand if tolerance had not been reached by 5 
minutes or the hand became numb. Subjects rested while filling in an Eysenck 
Personality Questionnaire (EPQ) or relaxed with light reading material until the start of 
the next cycle. Two pre-treatment cycles were followed by four treatment cycles. A 
familiarisation session was conducted prior to the start of the experiment. 
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TENS Treatment 
A Microtens battery powered portable stimulator was used to produce TENS. Pulse 
width (fixed at 200µs), electrode impedance, current intensity and pulse frequency 
were monitored with a Frye Electronics Type 4000 TENS Analyser (Frye Analyser). 
TENS was delivered via two 2 cm2 disposable electrodes, placed 1 cm apart (cathode 
proximal) on the ventral surface of the arm overlying the median nerve, 3 cm above the 
first wrist crease. Prior to immersion in warm water, the intensity of TENS was raised 
until the subject rated it as 'strong but comfortable', and appropriate adjustments to 
maintain this intensity level were made during the course of the experiment. A plateau 
of subjective sensation was usually reached by 20 minutes. 
Sham TENS (no stimulation) was administered using a modified stimulator (no current 
output), with a flashing 'on' light and a coloured suggestion that 
"The TENS unit is stimulating at a level that is expected to produce a response 
even though you may not feel it. ". 
This was reinforced by a digital display on the Frye Analyser. Subjects rarely 
questioned this procedure. Control TENS subjects were aware that TENS was not 
switched on. 
Statistical analysis 
Data obtained from each experiment was analysed by calculating mean±SD for each 
cycle. As results showed marked heteroscedascity (i. e. increasing variance (SD) with 
increasing pain threshold/tolerance) data was logarithmically transformed prior to 
parametric statistical analysis [Matthews et al. 1990]. Differences between the two pre- 
treatment cycles were examined using a paired t-test. A mean pre-treatment baseline 
was calculated for each individual from the two pre-treatment measures. Differences in 
pre-treatment mean between groups were tested using one-way ANOVA. During- 
treatment changes were calculated by subtracting pre-treatment mean from each of the 
during-treatment cycles. Total change in ice pain threshold/tolerance was calculated for 
each group as the area under the curve (change in ice pain threshold/50minutes). 
Differences between active TENS (TENS) groups and sham TENS (sham) were 
examined using unpaired t-tests and differences between active TENS groups using 
one-way ANOVA (for further details see Appendix B). 
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Experiment 3.1. 
Analgesic effects of different frequencies of TENS on cold- 
pressor pain in healthy subjects 
This investigation was undertaken to determine the effects of a range of frequencies of 
continuous mode TENS on cold-pressor pain. 
Subjects and procedure 
Eighty three TENS-naive healthy subjects (female n=36, male n=47; age range 18-35 
years of age), were randomly allocated to one of seven TENS treatment regimes (pulse 
pattern=continuous); 10Hz TENS, 20Hz TENS, 40Hz TENS, 80Hz TENS, 160Hz 
TENS, sham TENS and control TENS. Experimental procedures have been described 
previously (see Pain Induction). During TENS, subjects were requested to increase the 
intensity (pulse amplitude) of stimulation to produce a 'strong but comfortable' 
paraesthesia. 
Mean±SD TENS intensity levels were: 
lOHz=5.4±1. OmA above SDT 
20Hz=5.7±2.7mA above SDT 
40Hz=4.9±1.5mA above SDT 
80Hz=5.0±2.5mA above SDT 
160Hz=4.6±1.6mA above SDT 
No significant differences in intensity were found across the treatment groups (one- 
way ANOVA). Because of equipment unavailability no intensity data was obtained for 
22 subjects. Control and sham stimulators were not switched on. 
Results of Experiment 3.1 
The mean±SD results for ice pain threshold and ice pain tolerance are shown in Table 
3.1. 
Ice Pain Threshold: Marked heteroscedascity (increasing variance (SD) with 
increasing time to pain threshold and tolerance) was observed (Table 3.1), thus, data 
was logarithmically transformed prior to statistical analysis. No significant differences 
were found between the two pre-treatment observations (paired t-test), and mean pre- 
treatment threshold was calculated for each individual. One-way ANOVA showed no 
significant differences in pre-treatment mean across the treatment groups; thus, change 
in pain threshold during treatment for each cycle, and total change (area under curve), 
was calculated by subtracting pre-treatment mean for each individual from successive 
'during treatment' observations. 
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TENS significantly increased ice pain threshold (Fig. 3.3), with a rapid onset of 
analgesia occurring within 5 minutes of 'switch on'. 
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Fig. 3.3 Mean±SE change in ice pain threshold during 
TENS in healthy subjects (Exp. 3.1). (*=P<0.05, unpaired t-test, 
TENS v sham). 
0 
Total increase in ice pain threshold across the 50 minute treatment session was 
calculated for each treatment group as the area the under curve of change in pain 
threshold against the 50 minute session. No significant differences were found 
between the control and sham TENS (unpaired t-test). 
A bell-shaped relationship was observed in which increased frequency (above 10Hz) 
produced greater analgesia up to a maximum between 20 and 80Hz, but analgesic 
effect declined at higher frequencies. A quadratic trend with log frequency across the 
actively treated groups (i. e. 10Hz, 20Hz, 40Hz, 80Hz, 160Hz) was found although 
just failing to reach significance (F1: 75 =2.30 P=+0.1, one-way ANOVA) due to the 
large increases in variance accompanying increases in threshold (Fig. 3.4). 
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a 50 minute treatment session for different TENS pulse 
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scale for pulse frequency; (n=12 for each group except sham where n=1 1). 
Unpaired t-test total change TENS v sham, *=p<0.05, **=p<0.01. 
Ice Pain Tolerance: Eleven subjects were excluded from the data as they tolerated 
cold immersion of the hand up to the 5 minute limit, making it impossible to assess the 
magnitude of subsequent changes. One-way ANOVA showed no significant difference 
across the treatment groups; thus change in ice pain tolerance during treatment and total 
change (area under curve), was calculated for each individual. No significant 
differences were found between the combined mean of the active TENS treatment and 
sham (unpaired t-test, Fig. 3.5) 
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No significant differences in the total change in ice pain tolerance were found between 
different active TENS groups (one-way ANOVA on total change in ice pain threshold 
across active TENS groups, Fig. 3.6). Large variations in inter-individual response 
was observed. 
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Personality Variabilities: Mean±SD EPQ fell within the norms for students (Table 
3.2). No significant differences were found between males and females. Relationships 
between personality variables and baseline threshold, tolerance and the magnitude of 
response to TENS were also small and non significant (Pearson correlation 
coefficient). 
PENL 
(Psychoticism) (Extroversion) (Neuroticism) (Lie) 
Experimental results 
Female (n=36) 3.6±2.8 14.3±5.1 11.6±5.1 6.0 ±2.7 
Male (n=47) 4.6±3.1 14.7±4.3 10.0±5.7 6.1 ±4.1 
Both (n=83) 4.2±3.0 14.5±4.7 10.7±5.4 6.0±3.6 
Medical student norms* 
Female (n = 27) 3.4 t 2.8 13.3 t 4.7 9.7 t 5.3 7.2 t 3.8 
Male (n = 57) 4.8 ± 3.1 14.0 ± 4.0 9.1 ± 4.4 6.5 ± 3.8 
Both (n - 84) 4.1 ± 2.9 13.7 ± 4.4 9.4 ± 4.8 6.8 ± 3.8 
All correlations between personality variables and baseline Ice Pain Threshold and Tolerance were 
small and non significant. 
('Values taken from Eysenck HJM Eysenck SBG, (1975). Manual of the Eysenck Personality 
Questionnaire (Junior and Adult). Essex: Hodder and Stoughton). 
Table 3.2 Mean±SD Eysenck personality questionnaire scores (Exp. 3.1). 
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Main findings of Experiment 3.1 
(i) TENS produced a rapid and significant increase in ice pain threshold, but not ice 
pain tolerance when compared to sham TENS and control TENS. 
(ii) Large inter-subject variability in response to TENS accompanied such changes. 
(iii) Pulse frequencies between 20-80Hz produced the greatest elevation of ice pain 
threshold, although frequencies above and below also produced significant 
increases in ice pain threshold but of lesser magnitude. 
(iv) A pulse frequency of 80Hz produced a large and reproducible (due to small 
inter-subject variability in response) increase in ice pain threshold. 
(v) No significant effects of TENS on ice pain tolerance were observed due to the 
large inter-subject variability in response. 
(vi) No relationships between EPQ and baseline threshold, tolerance or response to 
TENS were observed. 
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Experiment 3.2 
Analgesic effects of different pulse patterns of TENS on 
cold-pressor pain in healthy subjects. 
The aim of Experiment 3.2 was to compare the effects of burst, modulation, random, 
continuous and double-sized electrode TENS, delivered at a fixed pulse frequency 
(80Hz) and fixed intensity ('strong but comfortable') on cold-pressor pain in healthy 
subjects. 
Subjects and procedure 
Eighty four TENS-naive healthy university students (female n=40, male n=44; age 
range=17-35 years of age) were randomly allocated to one of five TENS treatment 
regimes referred to as: 
burst TENS 
modulation TENS 
random TENS 
continuous TENS 
double-sized electrode continuous TENS (doub. size. elec. ). 
The respective pulse patterns in each of the groups are shown in Fig. 3.1. All 
stimulators were preset to deliver a pulse frequency of 80Hz, except random TENS in 
which the frequency ranged between 14-188Hz. TENS was delivered via two 2 cm2 
disposable electrodes (double sized electrode group used 4 cm2) placed 1 cm apart on 
the ventral surface of the arm overlying the median nerve, 3 cm above the first wrist 
crease. Experimental procedures have been described previously (see Pain Induction). 
During treatment cycles, TENS was maintained at a'strong but comfortable' level. The 
results previously reported (Exp. 3.1) for sham and control TENS (in which the 
stimulator was not switched on) were used to demonstrate generalised treatment 
effects, and statistical comparisons between active TENS treatments (burst, 
modulation, random, continuous and double sized electrodes) were made. 
Mean±SD TENS intensity levels were: 
burst TENS 5.1±1.7 mA above SDT 
modulation TENS 18.7±9.7 mA above SDT 
random TENS 6.7±5.6 mA above SDT 
continuous TENS 5.9±4.0 mA above SDT 
doub. size. elect. TENS 4.8±3.0 mA. above SDT 
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The intensity of modulation TENS was found to be significantly higher than other 
treatment groups (P<0.001, unpaired t-test). No significant differences (one-way 
ANOVA) were found across the remaining active treatment groups. 
Results of Experiment 3.2 
The mean±SD results for ice pain threshold and ice pain tolerance are shown in Table 
3.3. 
Ice Pain Threshold: Marked heteroscedascity was observed and the data was 
logarithmically transformed prior to statistical analysis. Changes in ice pain threshold 
during treatment cycles, and total change across the 50 minute treatment session, were 
calculated as described in Exp. 3.1 (paired t-test showed no significant differences 
between the two pre-treatment cycles, and one-way ANOVA showed no differences 
across the treatment groups). 
A significant increase in ice pain threshold occurred within five minutes of 'switch on' 
when the mean of all active TENS treatment groups combined, were compared to sham 
(Mean±SD 'during' cycle 1 (+5min): sham (Exp. 3.1)=1.7±6.8 s (n=11), all active 
TENS (Exp. 3.2)=6.2±6.5 s (n=60), P<0.05, unpaired t-test). All active TENS 
groups showed a significant elevation in total change in ice pain threshold over the 50 
minute treatment session when compared to sham TENS (Fig. 3.7). 
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Fig. 3.7 Mean±SE total change in ice pain threshold during 
a 50 minute treatment session for different TENS pulse 
patterns in healthy subjects (Exp. 3.2). (**=P<0.01, unpaired t- 
test, TENS group v sham; n=12 for each group except sham where n=11). 
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Continuous TENS produced the greatest magnitude of response but the response was 
reduced when the size of electrode was doubled. Random TENS produced the smallest 
increase in ice pain threshold but also the least inter-individual variation in response. 
One-way ANOVA on the total change in pain threshold between the active TENS 
group showed no significant differences between active TENS groups (F4: 55=0.79). 
No significant differences in total change in ice pain threshold were found between the 
continuous TENS group used in the present study and those found in Exp. 3.1 
(Mean±SD total change (s/50min): Exp. 3.1=+712±582, Exp. 3.2=+601±696, 
P=0.48, unpaired t-test). 
Ice Pain Tolerance: Three subjects were excluded from the data as they tolerated 
cold immersion of the hand up to the 5 minute limit. Changes in ice pain tolerance were 
calculated in an analogous manner to ice pain threshold data. Differences were 
observed between the combined mean of active TENS groups and sham TENS 
(Mean±SD total change (s/50min): combined active TENS=+407±1372, sham=- 
43±378, P<0.05, unpaired t-test). One-way ANOVA showed no significant 
differences in the change in pain tolerance between active TENS groups (F4: 52=1.13, 
see Fig 3.8). 
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Fig. 3.8 Mean±SE total change in ice pain tolerance during a 
50 minute treatment session for different TENS pulse 
patterns in healthy subjects (Exp. 3.2). (P value = unpaired t-test, 
TENS group v sham; n=12 for each group except sham where n=11). 
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Continuous TENS produced the largest increase in ice pain tolerance but increasing the 
size of the electrodes reduced the magnitude of this response (Fig. 3.8). As in Exp. 
3.1, large inter-individual response were observed across the treatment groups. 
Personality: Mean±SD Eysenck Personality Questionnaire results fell within the 
norms for students (Table 3.2) but no relationships were observed with baseline ice 
pain threshold, baseline ice pain tolerance and the magnitude of response (total change) 
to TENS over the 4 treatment cycles. 
Main findings of Experiment 3.2 
(i) Active TENS groups produced a significant elevation in ice pain threshold when 
compared to sham TENS. 
(ii) No significant differences in the magnitude of increase in ice pain threshold 
were observed across the active TENS groups, although continuous TENS 
produced the largest magnitude of response. 
(iii) The increase in ice pain threshold achieved during continuous TENS was 
reduced (non-significantly) when the size of the electrodes were doubled. 
(iv) A significant increase in ice pain tolerance was observed when all active TENS 
groups were combined and compared to sham TENS. 
(v) No significant increases in ice pain tolerance were observed in any of the active 
treatment groups, although continuous, random and burst TENS produced an 
elevation. 
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Experiment 3.3 
Analgesic effects of different modes of TENS on cold- 
pressor pain in healthy subjects. 
The aim of Experiment 3.3 was to compare the effects of 4 stimulation modes of 
TENS: 
(a) continuous mode TENS, applied to produce electrical paraesthesia within the 
painful area at: 
(i) low ('conventional' TENS) intensity, 
(ii) high ('intense' TENS) intensity 
(b) burst mode TENS, applied to a muscle mass distant to the site of pain but 
myotomally related to the painful area at: 
(iii) low ('burst' TENS) intensity, 
(iv) high (AL-TENS) intensity. 
Subjects and procedures 
Sixty TENS-naive healthy university students (female n=30, male n=30; age 
range=19-35 years of age) were randomly allocated to one of five TENS treatment 
groups referred to as; conventional TENS, intense TENS, burst TENS, AL-TENS, 
sham TENS. Stimulating characteristics and site of electrode application are described 
in Table 3.4. 
STIMULATING 
MODE 
ELECTRODE 
PLACEMENT 
PULSE 
PATTERN 
PULSE 
FREQUENCY 
PULSE INTENSITY 
(Amplitude) 
MUSCLE 
ACTIVITY 
Slam Wrist & arm None None None None 
Conventional Wrist/Median nerve Continuous 80Hz Strong but comfortable None 
Intense Wrist/Median nerve Continuous 80Hz Intense Tetanic/fasciculatory 
Blast Arm/Brachloradialls Burst (2.3Hz) 80Hz Strong but comfortable None 
Acupuncture-Like Arm/Brachloradialis Burst (2.3Hz) 80Hz Intense Twitching/phasic 
Table 3.4 Modes of TENS. The different electrical characteristics of TENS 
used in Exp. 3.3. Electrodes were applied to the ipsilateral arm with respect to the 
'painful' hand. 
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Appropriate adjustments in pulse amplitude (intensity) were made by the subject during 
the course of the experiment to maintain the appropriate intensity level. Mean±SD 
TENS intensity levels were: 
conventional TENS 2.4±1.4mA above SDT 
intense TENS 8.9±8.0mA above SDT 
burst TENS 2.7±0.9mA above SDT 
AL-TENS 14.2±8.4mA above SDT 
One-way ANOVA found significant differences between these groups (F3: 43 =11.25, 
P<0.01). 
Pain Induction: Slight modifications were made to the procedure. Pain threshold 
and pain intensity rating measurements were taken during 8 experimental cycles each 
lasting 10 minutes (Fig. 3.9). Pain threshold was recorded as previously described 
(Exp. 3.1 and 3.2). After the report of 'pain' the subjects hand remained immersed in 
cold water for a further 20 seconds, and on removal of the hand subjects placed a cross 
on a visual analogue scale (VAS; where 0=no pain and 10=the worst pain imaginable) 
to rate the intensity of the pain immediately prior to removal from the cold water. No 
subjects requested to withdraw the hand before the 20 second period elapsed. Two 
pre-treatment cycles were followed by 3 during-treatment cycles (TENS on) and three 
post-TENS (TENS off) cycles. Thus the effects of post-TENS analgesia could be 
examined. 
Hand Hand Hand End of 
in in out cycle 
'Pain' 
Warm water 37°C 
20 secs 
Cold water CPC 
010-1 
Pain 
intensity 
Rating 
Rest period 
5 minutes 5 minutes 
Fig. 3.9 Cold-pressor pain (one cycle - modified for Exp. 3.3). 
Results of Experiment 3.3 
The mean±SD results for ice pain threshold and pain intensity ratings are shown in 
Table 3.5. 
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Ice Pain Threshold: Mean pre-treatment threshold was calculated for each 
individual (no significant differences were found between the two pre-treatment 
observations; paired t-test). One-way ANOVA found no significant differences in pre- 
treatment mean across the treatment groups, and changes in pain threshold from pre- 
TENS baseline were calculated by subtracting pre-treatment mean (for each individual) 
from successive during-treatment observations. Total increase in ice pain threshold 
compared to pre-treatment mean was calculated as the area under the curve for changes 
in pain threshold; (i) during-TENS (30 minutes) and (ii) post-TENS (30 minutes). 
Comparisons were made on the total change in pain threshold between during- and 
post-TENS cycles. 
The mean change in pain threshold (from pre-TENS baseline) for the three during- and 
three post-TENS cycles is shown in Fig. 3.10. 
15-1 
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0 ý 
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ö%11ý 10 
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Fig. 3.10 Mean change in ice pain threshold during different 
modes of TENS in healthy subjects (Exp. 3.3, n=12). 
Pain threshold changed little over the course of the experiment in the sham TENS 
group. Conventional, intense and AL-TENS groups showed a rapid (within 10 
minutes) increase in pain threshold when compared to sham TENS. A significant 
increase in ice pain threshold occurred in the conventional, intense and AL-TENS 
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groups when compared to sham (Fig. 3.11). The rise in ice pain threshold observed in 
the burst TENS group failed to reach significance (P=0.14). No significant differences 
in the increase in ice pain threshold was observed between the active TENS groups 
(one-way ANOVA on total change between conventional, intense, burst and AL- 
TENS). Nevertheless, intense TENS showed the largest, and burst TENS the 
smallest, increase in ice pain threshold. 
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Mode of TENS 
Burst AL-TENS 
Fig. 3.11 Mean±SE total change in ice pain threshold 
during TENS (30 minute treatment session) for different 
modes of TENS in healthy subjects (Exp. 3.3). (*=P<0.05, 
**=P<0.01, unpaired t-test, TENS group v sham; n=12). 
The elevation in pain threshold produced by conventional TENS reached a plateau 
within thirty minutes whereas the elevation produced by intense and AL-TENS was 
still rising (Fig. 3.10). A rapid and significant decrease in pain threshold occurred with 
TENS switch off (within 10 minutes) in both the conventional and intense TENS 
groups. By contrast, the increase in pain threshold in the AL-TENS group was 
sustained for over thirty minutes after TENS switch off. One-way ANOVA 
(F3: 44=2.53, P 0.05>0.1) just failed to show any significant differences in the post- 
TENS change in pain threshold between the active TENS groups. However, intense 
and AL-TENS produced a significant elevation in ice pain threshold post-TENS when 
compared to sham (Fig. 3.12). 
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Furthermore, AL-TENS (and to a lesser extent intense TENS) produced a significant 
elevation in ice pain threshold when compared to conventional TENS (Mean±SD total 
change post-TENS (s/30mins): AL-TENS v conventional TENS, P<0.05, intense 
TENS v conventional TENS, P=0.06, unpaired t-test). 
E 
300-1 
bc 250 
.Cö 200 
. ý, a .ý 
Cd 
** 
** 150 
ýý100ý 
ý 
cz 50 
F-, ä 0- 
-50 
ý ýý 
ý ý: 
il 
Sham Conventional Intense Burst AL-TENS 
Mode of TENS 
Fig. 3.12 Mean±SE total change in ice pain threshold post- 
TENS (30 minute treatment session) for different modes of 
TENS in healthy subjects (Exp. 3.3). (**=P<0.01 unpaired t-test, 
TENS group v sham; n=12). AL-TENS and intense TENS were found to 
produce a significant increase in ice pain threshold post-TENS when 
compared to sham. Furthermore, a significant decline in ice pain threshold 
occurred between, during and post-treatment cycles for continuous and 
intense groups (P<0.05, paired t-test). 
Pain intensity rating: Similar statistical analysis were performed on pain intensity 
rating scores. No significant differ 'aces were found between pre-treatment cycles 1 
and 2. Pre-treatment means were calculated and one-way ANOVA showed no 
significant differences between the TENS groups. Total change in pain intensity rating 
during TENS cycles was calculated and the results shown in Fig. 3.13. No significant 
differences between sham TENS and any of the active TENS treatment groups were 
observed. 
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Fig. 3.13 Mean±SE change in pain intensity rating during a 
30 minute treatment session for different modes of TENS 
in healthy subjects (Exp. 3.3). 
Main findings of Experiment 3.3 
(i) Burst TENS, when applied over a muscle mass myotomally related to the site of 
pain, produced an increase in ice pain threshold only when the intensity of 
stimulation was sufficient to produce phasic muscle contraction (i. e. AL-TENS). 
(ii) Continuous TENS, when applied to produce electrical paraesthesia within the 
painful area, produced an increase in ice pain threshold at both low and high 
intensity stimulation. 
(iii) A significant post-TENS increase in ice pain threshold was achieved by AL- 
TENS, and to a lesser extent by intense TENS. 
(iv) TENS produced no significant effects on pain intensity ratings as measured on 
a VAS. 
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DISCUSSION 
A systematic investigation into the analgesic effects of a range of electrical 
characteristics of TENS in alleviating cold-pressor pain in healthy subjects has been 
performed. The results show that TENS, when producing a 'strong but comfortable' 
electrical paraesthesia within the site of pain, produces a significant increase in ice pain 
threshold when compared to sham TENS, but has variable effects on both ice pain 
tolerance and pain intensity rating as measured on a visual analogue scale. Large inter- 
individual variation in response to TENS was noted in all studies. 
Different pulse frequencies of TENS, when delivered at a 'strong but comfortable' 
intensity, produced differential analgesic effects. Thus, frequencies between 20-80Hz 
produced the greatest elevation in ice pain threshold. Different pulse patterns, delivered 
at a 'strong but comfortable' intensity and a fixed frequency (80Hz), significantly 
increased ice pain threshold, although no differential effects between pulse patterns 
was found. However when these pulse patterns were utilised at different current 
intensities and different sites, differential analgesic effects were observed. Thus, burst 
mode TENS applied to a muscle mass myotomally related to the site of pain, only 
increased ice pain threshold if the intensity of stimulation was sufficient to produce 
strong forceful contractions i. e. AL-TENS. Moreover, a significant post-TENS 
analgesia was achieved by AL-TENS and intense TENS, but not conventional, or 
burst TENS groups. These findings are discussed in detail below. 
Pulse Frequency 
Experiment 3.1 has shown that different pulse frequencies produce differential 
analgesic effects. Thus, TENS frequencies of 20-80Hz produced the greatest 
analgesia, while frequencies below and above this level (10Hz and 160Hz) although 
still significantly elevating pain threshold, produced effects of lesser magnitude. As no 
significant differences in stimulus intensity were observed across the treatment groups, 
the frequency of pulse delivery was the governing factor under these conditions. 
By contrast to the findings of the present study, an earlier study of Ashton et al. 
[1984], carried out in this laboratory, found TENS at a frequency of 8Hz appeared to 
raise ice pain threshold (although there was a very large variation in response), but 
TENS at 100Hz was ineffective. The discrepancy in results between the present 
investigation and the Ashton et al. study may be due to differences in experimental 
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method. In the present study, smaller electrodes were applied closer to the wrist to 
achieve a strong electrical paraesthesia within the hand rather than the arm as in the 
Ashton et al. study. Different stimulators with slightly different specifications were 
used in the two studies. The use of iced water, as opposed to crushed ice, may have 
reduced temperature variability from pockets of air. 
Small (non-significant) differences in pre-treatment observations across treatment 
groups (Table 3.1), were noted in Experiment 3.1 and the Ashton study. This may 
have been due to the short TENS familiarisation session prior to the start of the 
experiment, since active TENS groups had higher pre-treatment pain threshold and 
tolerance values than control or sham TENS groups. It is not possible to say whether 
this variation was due to chance, psychological effect or a real treatment response. 
Nevertheless such effects were reduced in Experiments 3.2 and 3.3 in which this 
TENS familiarisation session was omitted. 
A stimulus frequency of 80Hz produced a large and reproducible analgesic effect 
shown by the small individual variation (Fig. 3.4a and b). This finding agrees with the 
observation of Sjölund [1985] who found that over a range of peripheral nerve 
stimulating frequencies (10-160Hz), 80Hz produced the maximal suppression of the 
C-fibre evoked flexion response in the rat. Chung et al. [1984b] found that the higher 
the frequency of electrical peripheral conditioning stimuli (within a range of 0.5- 
20Hz), the more powerful the inhibition of primate spinothalamic tract cells. 
Stimulation intensities strong enough to activate C-fibres were used. Therefore the 
results from both animal and human studies suggest that higher frequencies of TENS 
produce a more effective analgesia. However, the results of animal studies can only be 
applied with extreme caution to the treatment of clinical pain, but it is notable that 
frequencies of 40-100Hz are generally reported to be most beneficial in the clinical 
environment [Woolf 1989]. Unfortunately such frequencies are often difficult to attain 
with commercially available stimulators as they lie on the steep part of a logarithmically 
calibrated frequency control dial as shown in Chapter 2. 
As mentioned earlier, TENS may produce analgesia by several interactive mechanisms 
although in its conventional form, high frequency (10Hz and above) low intensity 
('strong but comfortable') TENS is thought to act at a spinal level by closing 'pain 
gates' in the dorsal horn. The exact mechanism by which changing pulse frequency 
alters the effects of TENS is unknown. Nevertheless, the primary aim of conventional 
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TENS is to selectively activate large diameter sensory nerve fibres. Factors which 
influence the firing of peripheral nerve fibres include pulse width, pulse amplitude and 
pulse frequency [Woolf 1989]. Thus, the greater the pulse width or the higher the 
pulse frequency, the lower amplitude (current intensity) required to excite the nerve 
(Fig. 3.14). 
Amplitude 
(mAmp) 
Fig. 3.14 A three-dimensional surface indicating the theoretical 
relationship between pulse-width and frequency in determining the 
amplitude of a pulse necessary to activate a nerve. From Woolf 
[1989]. 
At low pulse frequencies insufficient peripheral nerves may be activated to produce an 
analgesic effect. Recently Macefield and Burke [1991] recorded a reduction in the 
peak-to-peak amplitudes of early latency waveform components of somatosensory 
evoked potentials (SEPs) following prolonged activation of cutaneous afferents by 
vibration. The group attributed such changes to a depression in central excitability 
possibly reflected by changes in synaptic transmission at the cuneate nucleus and 
thalamo-cortical levels. Thus the reduction in TENS analgesic effects observed at very 
high rates of stimulation in the present study (160Hz) may be due in part to synaptic 
fatigue, possibly at second and higher order neurone sites in the central nervous 
system. 
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Pulse Pattern 
Of the different pulse patterns of TENS used in Experiment 3.2, all significantly 
increased ice pain threshold in healthy subjects when applied to produce a 'strong but 
comfortable' paraesthesia within the site of pain. The increase in ice pain threshold was 
of a similar magnitude to that observed in Experiment 3.1, and large inter-individual 
variation in response to TENS was noted. Although no significant differences in the 
magnitude of increase in ice pain threshold between different pulse patterns was 
observed, random TENS produced the smallest increase and continuous TENS the 
largest increase in ice pain threshold. 
Eriksson et al. [1979] suggested that a requirement of AL-TENS, produced by high 
intensity burst mode stimulation, is the activation of deep muscle afferents. However it 
is unlikely that the subjects using burst mode TENS in Experiment 3.2 achieved AL- 
TENS, as no observable muscle twitching occurred at the wrist in any subjects, and 
the intensity of stimulation required to achieve a 'strong but comfortable' level in the 
burst TENS group was no greater than that in other groups. Recently Field et al. 
[1990] reported no significant differences between burst and continuous mode TENS 
in the treatment of chronic back pain. Although the intensity of stimulation used by the 
patients was not reported, it was found that patients applied both modes of TENS at a 
'strong non-painful' level. This low intensity burst TENS is thought to be similar to 
conventional TENS and is sometimes preferred by patients for reasons of comfort 
[Mannheimner & Lampe 1988a]. 
Subjects using modulation TENS required a higher intensity of stimulation, as 
measured by the Frye Analyser, to reach a 'strong but comfortable' level, although no 
muscle twitching was observed in any subjects. Variation in stimulator design may 
have accounted for this difference since the pulse wave form delivered by modulation 
TENS was found to differ slightly from that of the other types of TENS. Ekström and 
Sjölund [1988], examined the effects of modulating pulse frequency and pulse 
duration (width) on the C-fibre reflex in anaesthetised rats and found that neither 
improved analgesic effect. The present study has shown that modulation of pulse 
amplitude (current intensity) when presented at a 'strong but comfortable' intensity 
was no more efficacious than other patterns of stimulation. 
With regard to random stimulation, Cheng and Pomeranz [1987] reported a successful 
trial using a new stimulator called a Codetron which randomly switches stimuli among 
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six electrode channels, activating each site for 10 seconds. They found that 90% of 
patients obtained benefit with such a device. Although the mechanism by which 
tolerance occurs is far from understood, it is believed that the nervous system 
undergoes some adaptive change to regular, repetitive stimulation (habituation), thus 
reducing analgesia produced by TENS [Pomeranz & Niznick 1987]. Random TENS, 
because of the irregular pulse presentation, may prevent such habituation of the 
nervous system and so prolong the analgesic effect. Although the clinical efficacy of 
this pattern of stimulation has yet to be evaluated, preliminary observations by the 
author suggest that the majority of patients with the availability of random mode 
stimulation on the Xenos stimulator dislike the sensation of 'randomness' of pulse 
delivery when compared to continuous or burst pulse patterns. 
The size of the stimulating electrodes appears to be a further variable in determining 
TENS analgesia. The elevation of pain threshold following 80Hz continuous TENS 
was reduced by doubling the size of electrodes. This finding is somewhat surprising as 
a larger electrode size might be expected to increase the activation of large fibres. 
Nevertheless, smaller electrodes would deliver a higher current density to the point of 
attachment on the skin surface which may produce greater analgesia [Librach 1988]. It 
has been suggested that with the use of large electrodes the stimulator may fail to 
deliver sufficient current to activate peripheral nerves because of the fall off in current 
density with length [Brennen 1976], yet the electrodes used in the present study (2 cm2 
and 4 cm2) were smaller than many commercially available electrodes thus reducing 
such an effect. Furthermore the stimulating current passed to the large electrodes was 
not significantly less than that used with the small electrodes. Additional experiments 
with a range of different electrode sizes are needed. 
Ice pain tolerance was increased by burst, random, continuous and to a small extent 
modulation TENS compared with controls, although the change did not reach statistical 
significance. As with ice pain threshold, larger electrodes reduced the size of response. 
Modes of Stimulation 
In Experiment 3.3 TENS increased experimental pain threshold when applied to: 
(i) produce an electrical paraesthesia within the site of pain, 
(ii) a muscle mass myotomally related to the site of pain only if the intensity of 
stimulation was sufficient to produce strong forceful contractions, i. e. AL-TENS. 
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Thus conventional TENS, intense TENS and AL-TENS significantly increased ice 
pain threshold in the hand. Burst TENS applied at a low intensity to the ipsilateral 
brachioradialis muscle (with respect to the 'painful' hand) also increased ice pain 
threshold, but this increase failed to reach statistical significance. The increase in pain 
threshold associated with conventional and intense TENS fell significantly in the post- 
TENS cycles (when compared to during TENS cycles). However, both intense TENS 
and AL-TENS produced a significant post-TENS analgesia. Although TENS 
significantly increased ice pain threshold, it had a variable effect on the intensity of 
pain (as rated on a visual analogue scale) achieved within 20 seconds after the onset of 
pain threshold. 
The sustained post-TENS analgesia achieved using AL-TENS (>30 minutes), 
compared to the short post-TENS analgesia achieved with conventional (continuous) 
TENS (<10 minutes), is consistent with clinical reports [Sjölund et al. 1990]. 
Nevertheless, clinical reports on the use of AL-TENS are few in comparison to 
conventional TENS. Andersson et al. [1976] found that the production of phasic 
muscle contraction over large muscle nerve bundles segmentally related to the painful 
site, by delivering low frequency single pulses, produced pain relief in only 1 of the 8 
patients. However, the production of fasciculatory muscle contraction within the site of 
pain by high frequency pulses produced pain relief in seven of the 12 patients. 
Delivering pulses in low frequency trains of pulses has been shown to markedly 
increase the intensity of stimulation accepted, and also the degree of analgesia 
experienced, by patients [Eriksson & Sjölund 1976]. Thus, Eriksson and Sjölund 
[1976] found that in a group of 50 patients, 30 did not respond to conventional TENS 
but' 10 of these responded to AL-TENS. Further studies by the same group [Eriksson 
et al. 1979; Eriksson et al. 1984], found that approximately 30 % of 123 patients with 
a variety of chronic pain conditions needed to use AL-TENS to obtain relief of pain, 
and 13 out of 34 patients with facial pain who did not respond to conventional TENS 
required AL-TENS to produce relief. 
Durand et al. [1988] found a marked and lasting increase in muscular (vastus medialis) 
pain threshold to electrical stimulation in healthy subjects, following administration of 
AL-TENS to both ipsilateral and contralateral vastus medialis. Recently, a number of 
newer non-portable stimulating devices have appeared which utilise the principle of 
AL-TENS, including the Codetron [Cheng & Pomeranz 1987] (which also randomises 
pulse presentation) and Likon [1990] although these have yet to be validated. 
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Intense (continuous) TENS has been described by Mannheimer and Lampe [1988a] as 
high intensity (current) and high frequency (100-150Hz) stimulation administered for 
about 5-15 minutes at the highest tolerable level. Such intense TENS produces tetanic, 
fasciculatory muscle contractions. In Experiment 3.3 the stimulating parameters of 
intense TENS were similar to those suggested by Mannheimer and Lampe (i. e. 80Hz, 
200µs, highest tolerable level), and produced a marked increase in ice pain threshold 
during stimulation, which fell rapidly on TENS switch off, although not back down to 
baseline levels. Although the effects of intense TENS have been previously reported 
[Melzack 1975b; Jeans 1979], stimulating characteristics were different to those 
applied in the present study. Intense TENS may have a value clinically during minor 
surgical operations [Strassburg et al. 1977]. 
Differences in the analgesic effects of stimulation modes may be attributed in part to 
differing mechanisms of action. Conventional TENS, acting via segmental inhibition 
of nociceptive input by the excitation of large diameter afferent fibres, would accord 
with a rapid onset and offset of analgesia associated with a neuronal mechanism. By 
contrast, AL-TENS acting via a supraspinal descending pain inhibitory pathway and 
the liberation of neuromodulators such as endorphins, would show a slower onset and 
offset [Sjölund & Eriksson 1985]. This is supported by the naloxone reversibility of 
AL-TENS but not conventional TENS [Sjölund & Eriksson 1979] suggesting a role 
for opioid peptides in analgesia associated with AL-TENS. However, Chung et al. 
[1984a] reported that spinothalamic cells of anaesthetised monkeys were inhibited 
during high intensity (activating C-fibres), low frequency (3Hz trains of 30Hz pulses), 
peripheral nerve stimulation. This inhibition outlasted stimulation by 20-30 minutes, 
and occurred in intact, decerebrate and spinalised monkeys. This suggests that 
antinociception associated with high intensity low frequency stimulation depends to 
some degree upon spinal cord neuronal circuitry. Sjölund [1988] found that low 
frequency (0.1-5Hz trains of pulses) peripheral stimulation of dissected muscle rather 
than skin nerves was more effective in suppressing the C-fibre evoked flexion in 
lightly anaesthetised rats. Furthermore, pulse train repetition rates of around 1Hz, and 
activation of Group I-III rather than Group I-II muscle afferent fibres, produced the 
greatest reduction of C-fibre response. Thus, analgesia associated with AL-TENS may 
be produced by a number of interactive peripheral, spinal and supraspinal mechanisms. 
It has been suggested that brief intense TENS produces peripheral blockade of 
nociceptive transmission [Mannheimer & Lampe 1988b]. Thus high intensity TENS 
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would activate both small and large diameter fibres and produce antidromic block of 
nociceptive impulses transmitted in A-delta and C-fibres [Campbell & Taub 1973; 
Ignelzi & Nyquist 1979]. Moreover the rapid decline in analgesia on 'TENS switch- 
off with brief intense TENS, as observed in Exp. 3.3, substantiates the findings of 
previous reports using similar TENS characteristics [Janko & Trontelji 1980; 
Pertovaara & Hamalainen 1982]. 
The effect of TENS on sensory and affective components of 
pain 
An interesting finding of the three experiments was the reproducible increase in ice 
pain threshold produced by TENS, in comparison to the variable effects of TENS on 
pain tolerance and pain intensity rating measured on a visual analogue scale. This 
suggests that TENS exerts its primary effects on the sensory components (i. e. pain 
threshold) rather than affective components (i. e. intensity/tolerance) of pain. Clinical 
observations are consistent with such findings as patients often report increased 
mobility during TENS which may be associated with an elevation in pain threshold. 
Thus TENS may prove successful in conditions where a lowering pain threshold is the 
common cause of pain as in arthritis. 
Summary 
The results of this systematic investigation into analgesic effects of different electrical 
characteristics of TENS has found that: 
(i) TENS, when applied to produce a'strong but comfortable' electrical paraesthesia 
within the painful area, increased in ice pain threshold but had variable effects on ice 
pain tolerance and pain intensity rating. 
(ii) Differential TENS effects occur across a range of pulse frequencies, and pulse 
frequencies between 20-80Hz produced the largest elevation of ice pain threshold. 
(iii) Although no significant differential effects were observed with a variety of 
pulse patterns, continuous mode TENS produced the largest elevation of ice pain 
threshold. 
(iv) Burst mode TENS, when applied over a muscle mass myotomally related to the 
site of pain, produced an increase in ice pain threshold only when the intensity of 
stimulation was sufficient to produce phasic muscle contraction (i. e. AL-TENS). 
(v) AL-TENS (and intense TENS) produced a prolonged post-TENS analgesia. 
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These results may be helpful to clinicians in selecting pulse frequencies, pulse patterns 
and stimulating modes for TENS treatment in patients with pain. Thus, continuous, 
80Hz stimulation, producing a'strong but comfortable' paraesthesia within the painful 
site, should be the primary TENS treatment choice in the clinic. In certain 
circumstances, where such stimulation is ineffective, aggravates the pain or cannot be 
applied within the painful site, other stimulating characteristics (i. e. AL-TENS) should 
be tried before dismissing a patient as a'TENS failure'. 
Large inter-individual variation in response to TENS was observed in both pain 
patients (Chapter 2) and healthy volunteers experiencing experimental pain (Chapter 
3). However, the cause and site of pain (Study 2.1,2.2 and 2.3), and/or psychological 
variables (Study 2.2, Exp. 3.1,3.2) were not shown to be related to the degree of 
TENS response. Experiments investigating electrophysiological changes (evoked 
potentials (EPs)) during TENS suggest that TENS affects the processing of sensory 
information. Thus, changes in electrophysiological activity may be related to patient 
response to TENS. To examine this possibility, an investigation into the effects of 
TENS on spontaneous EEG and cortical evoked potentials was performed, as 
described in the next chapter. 
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CHAPTER 4 
THE EFFECT OF TENS ON THE 
SPONTANEOUS ELECTROENCEPHALOGRAM 
(EEG) AND SOMATOSENSORY EVOKED 
POTENTIALS 
INTRODUCTION 
The recording of the electrical activity of the brain via electrodes applied to the-surface 
of the scalp is termed electroencephalography (EEG). EEG has proved a useful 
research tool in the investigation of gross brain function and is of increasing 
importance in psychopathology and psychopharmacology for clinical assessment. It 
has been suggested that ongoing electrical activity of the brain, or spontaneous EEG, 
reflects states of arousal and relaxation, and more recently that pain may cause changes 
in spontaneous EEG [Chen et al. 1989]. To date, TENS effects on spontaneous EEG 
remain unknown. Studies utilising somatosensory evoked potentials (i. e. the response 
to a somatosensory stimuli, SEP) suggest that TENS affects the processing of sensory 
information at several levels in the nervous system (i. e. peripheral, spinal, subcortical 
and cortical). Moreover, the peak-to-peak amplitudes of the waveform components of 
baseline SEPs may be related to individual response to TENS. Since brain activity may 
reflect response to TENS a study of the effects of TENS on spontaneous EEG and 
SEPs was undertaken. 
EEG variables 
A variety of EEG measures are now used routinely to assess cerebral activity of which 
spontaneous EEG and cortical evoked potentials are most commonly used. 
Spontaneous EEG: "The electric potential field on the scalp has been likened to the 
surface of the sea on which floats a number of buoys - the electrodes - the varying 
vertical displacements of which represent fluctuations of electrical potential. " [Cooper 
et al. 1980b). In its spontaneous or ongoing state EEG is rhythmic (Fig. 4.1) and this 
rhythmicity enables quantification. 
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Fig. 4.1 Spontaneous EEG recorded from 01 (left occipital 
referenced to linked mastoids) with (a) eyes open and (b) 
eyes closed in a healthy subject. Top trace shows Spontaneous 
EEG in'raw' form. Note the difficulty in detecting and measuring changes 
in EEG activity despite the occurrence of alpha spindles with eyes closed. 
Thus, spontaneous EEG is split into epochs and transformed from the 
time domain into the frequency domain by the calculation of the power 
spectrum for each epoch using Fast Fourier Transform (middle trace). The 
average of these individual epochs is calculated and averaged power 
spectrum is measured across traditional frequency bands (lower trace). Note 
the increase of alpha activity with eyes closed. 
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Methods of EEG analysis are now aided by computers and based on the calculation of 
EEG power (pV2/Hz) within traditionally fixed frequency bands (power spectrum). 
For review see Kunkel [1984]. Although the division between frequency bands is 
arbitrary, each band seems to reflect different types of brain activity (Table 4.1) and 
characteristic changes in the amplitude and frequency of spontaneous EEG are 
associated with different states of arousal (Table 4.1). 
Wave band Frequency Approximate Characteristic Associated 
(Hz) amplitude (µV) activity 
Delta 0- 3.5 100 deep sleep 
Theta 4- 7.5 100 some pathological states 
Alpha 8-13.5 50 awake relaxation, 
eyes closed 
Beta 14-40.0 20 increased arousal, 
Slow beta 14-25.5 mental activity 
Fast beta 26-40.0 
Table 4.1 Electroencephalographic wavebands. From Ashton [1987]. 
Slow, high voltage synchronous waves, characterise the relaxed state and are 
prominent in normal subjects when eyes are closed (Fig. 4.1b). Fast, low voltage 
unsynchronised waves characterise high arousal states and are prominent in normal 
subjects when eyes are open (Fig. 4. la). It has been suggested that spontaneous EEG 
is the average of the multifarious activity of many small zones of the cortical surface 
beneath the electrode, and reflects local currents flowing in dendrites of the superficial 
cortex [Cooper et a]. 1980a]. 
Cortical Evoked Potentials (EP): EPs reflect the cortical response to external 
stimuli (auditory (AEP), somatosensory (SEP), visual (VEP)). In practice, stimuli are 
presented several times so that the cortical response is enhanced in contrast to the 
background activity and signal averaging is used to produce an averaged evoked 
potential. Thus, despite variation in the shape and size of an evoked response elicited 
by single stimuli, a consistent waveform is created from the averaged response of a 
number of stimulus presentations (Fig. 4.2a). 
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Fig. 4.2 Average Somatosensory Evoked Potential (SEP). 
Recorded at Cz (vertex) to the delivery of 35 monophasic square wave 
electrical pulses at a 'strong but comfortable' intensity to the index finger 
of the left hand. (a) The recording of individual trials, (b) averaged 
response of the individual trials, (c) graph to show the relationship 
between peak-to-peak N1P2 amplitude of individual trials and growing 
averaged response. Note the large variability of individual SEPs. Pre- 
stimulus spontaneous EEG averages to zero and post-stimulus time 
locked SEPs enhance to create a characteristic waveform. 
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Measurement of latencies and peak-to-peak amplitude of the waveform components 
following the stimulus allows quantification of the EP. Hence, EPs are categorised into 
[Desmedt & Cheron 1982]: 
(i) Far-field EPs - which occur <20 ms post-stimulus and reflect peripheral and 
spinal transmission of the afferent nerve volley. 
(ii) Early near field EPs - which occur 20-80 ms post-stimulus and reflect initial 
thalamo-cortical processing. 
(iii) Late near field EPs - which occur 80-500 ms post-stimulus and reflect 
generalised cortical processing. 
For reasons of brevity EP waveform components occurring within 80 ms post- 
stimulus are referred to as early latency EPs and those occurring later than 80 ms as 
late latency EPs. Following an evoking stimulus the early latency waves are labelled 
according to polarity and latency of occurrence (i. e. P14=positive wave occurring 
14ms post-stimulus), whereas late latency waves are labelled according to polarity and 
order of occurrence (P1=1st positive wave, N1=1st negative wave). In general peak- 
to-peak amplitudes of SEPs increase and latencies decrease in states of heightened 
arousal and increasing stimulus intensity. Opposite changes occur during relaxation, 
distraction and decreasing stimulus intensity. 
EEG changes related to pain 
Spontaneous EEG: Recent studies have examined changes in spontaneous EEG 
during pain and analgesic intervention. In studies utilising the cold-pressor pain 
technique in healthy subjects, Chen et al. [1989] found that the induction of pain 
increased both delta and beta activity; Gotliesbsen and Arendt-Nielsen [ 1990] reported 
increases in delta and decreases in alpha power, while Backonja et al. [1990] recorded 
increases in alpha activity. Differences in these reports may be attributed in part to the 
variety of electrode positions used and the 'fluid' nature of electrical brain activity. 
Evidence suggests that centrally acting analgesics increase delta and theta activity and 
reduce alpha activity in spontaneous EEG, although it is not clear whether these 
changes are specifically due to analgesic effects [for review see Martin & Kay 1977]. 
Aspirin has also been reported to reduce alpha activity [Fink & Irwin 1982], although 
contrasting reports exist [Sulc et al. 1973]. 
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Somatosensory Evoked Potentials: It has been claimed that certain waveform 
components of the somatosensory evoked potential (SEP) recorded from the human 
scalp can serve as correlates of laboratory pain and analgesia [for review see Chapman 
et al. 1979; Chapman & Jacobson 1984; Bromm, 1985]. Peak-to-peak amplitudes of 
late waveform components of the SEP (N1P2 - 150-400 ms post-stimulus) have been 
shown to increase with increasing stimulus intensity and the subjective report of pain 
intensity. Electrical [Joseph et al. 1991], thermal [Carmon et al. 1978] and laser CO2 
[Bromm et al. 1983] stimuli are commonly used to elicit such 'pain potentials', 
although much work has centred on tooth pulp stimulation [Chatrian et al. 1975; 
Harkins & Chapman 1978; Chen et al. 1979]. However, objections have been raised 
to the interpretation of the results of experiments using tooth pulp stimulation, as they 
do not control for SEP changes at stimulation intensities below the painful range 
[Cruccu et al. 1983]. Recent investigations, using non-painful and painful SEPs, have 
shown no significant changes in SEP amplitudes at the point of pain perception 
[Miltner et al. 1989]. Hence, the relationship between EPs and the subjective report of 
pain may be relative rather than absolute, and late components of the SEP (150-400 ms 
post-stimulus) may represent a perceptual processing of stimulus intensity irrespective 
of pain perception. Bromm et al. [1983] have also suggested that ultra-late components 
of SEPs, with peak latencies around 1260ms, correlate with C-fibre activity in man. 
However, it is likely that such potentials would also be affected (and even swamped) 
by emotional and cognitive influences involved in the processing of pain perception. 
Further investigation is therefore necessary to confirm the existence of these ultra-late 
potentials. 
Analgesics reduce both the subjective report of a painful evoking stimuli, and the 
amplitudes of late SEP components [Rohdewald et al. 1982]. Opiates produce a 
reduction in the late components of pain induced SEPs [Buchsbaum 1984], although it 
is not possible to determine whether these changes were due to analgesic, 
psychotropic, attentional or expectational processes. Moreover, aspirin has been 
shown to reduce SEP components during painful [Chen & Chapman 1980] and 
possibly non-painful stimuli [Ashton et al. 1984b], suggesting that changes in the 
amplitudes of these components may not be specific to the pain system. 
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EEG changes related to TENS 
Spontaneous EEG: No effects of TENS on spontaneous EEG have been previously 
reported, although acupuncture has been found to decrease delta and theta activity, and 
increase alpha and beta activity during relief of tension headache [Manna et al. 1984]. 
The same group found that ischaemic experimental pain increased theta activity in 
healthy subjects, and that acupuncture increased alpha activity and decreased pain 
rating [Varrassi et al. 1986]. Whether these changes in spontaneous EEG were 
primarily due to the reduction of pain remains to be determined. Nevertheless, it seems 
unlikely that the EEG changes observed during acupuncture were produced by opioid 
release as opiates have been shown to increase delta and theta power, and to decrease 
alpha power [Martyn & Kay 1977; Bromm 1989]. Furthermore, Rosenblatt et al. 
[1982] and Saito et al. [1983] suggest that changes in spontaneous EEG observed 
during acupuncture, may be due to changes in arousal, rather than to changes in pain. 
Somatosensory Evoked Potentials: TENS, when applied at a site dermatomally 
related to the evoking stimuli, has been shown to reduce the peak-to-peak amplitudes 
of both early and late waveform components of the SEP in healthy subjects [Chapman 
et al. 1983; Salar et al. 1980; Francini et al. 1982; Golding et al. 1986; Nardone & 
Schieppati 1989]. This reduction in SEP amplitude during TENS has been attributed to 
changes in the processing of sensory information at all levels in the nervous system 
(i. e. peripheral, spinal, subcortical or cortical). It has also been suggested that 
naloxone can reverse this reduction in late latency SEP amplitude [Salar et al. 1980]. 
Furthermore, Golding et al. [ 1986] suggested that the baseline peak-to-peak amplitude 
of an individuals SEP may be related to response to TENS. Healthy subjects with 
small SEPs showed smaller elevations in experimental pain threshold than subjects 
with large baseline SEPs. Hence Golding et al. suggested that patients with small 
SEPs were less likely to respond to TENS. 
Aims of Chapter 4 
Although TENS has been found to reduce the amplitudes of both early and late latency 
SEPs in healthy subjects, no studies have examined the effects of TENS on 
spontaneous EEG. 
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The aim of Chapter 4 was to investigate the effects of TENS on: 
(i) Late waveform components of the SEP. 
(ii) Power spectrum of spontaneous EEG. 
It was hoped that the results would provide information on the mechanisms of TENS 
action. Furthermore, the utility of baseline SEP and spontaneous EEG in predicting 
response to TENS was examined. Thus, three experiments were designed to: 
(i) Examine the effects of TENS on late latency components of the SEP (Exp. 4.1). 
(ii) Examine the effects of TENS on spontaneous EEG in healthy subjects 
(Exp. 4.2). 
(iii) Examine the effects of TENS on pain intensity rating and spontaneous EEG in 
pain patients (Exp. 4.3). 
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THE EXPERIMENTS 
EEG Recording Techniques-General Methods 
General EEG recording techniques are described below. Figure 4.3 gives an overview 
of the EEG recording system and the functions of individual components in the system 
are described in Appendix C. 
Electrode placement 
The number and placement of scalp electrodes used during recording varies depending 
upon the experimenter's requirements and the equipment available. The initial 
description of standard electrode positions (called the 10-20 system for electrode 
placement) was given by Jasper [1958] and used by the International Federation of 
Societies for Electroencephalography and Clinical Neurophysiology (Fig. 4.4). 
Nosion 
Inion 
Fig. 4.4 The 10-20 system of electrode positions as 
originally described by Jasper 1958. For full description see 
Cooper et al. [1984]. 
A reference electrode is chosen as a point to which brain potentials are compared and in 
the experiments that follow electrodes attached to the mastoid process of both sides of 
the head were linked (termed linked mastoids - LM) and used as reference, (although 
other reference points (ears) can also be used). Such a derivation is termed common 
reference and is placed so as to minimise the possibility of picking up potentials from 
the brain. 
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Fig. 4.3 Overview of recording system (see text and Appendix C for full description of the 
function of the components of the recording system). 
Chapter 4: The effects of TENS on spontaneous EEG and SEPs 105 
In the experiments that follow EPs were recorded at Cz (vertex - somatosensory 
cortex), and spontaneous EEG at C3 (left somatosensory cortex - for high frequency 
activity) and 01 (left occipital - for low frequency activity). These commonly used 
sites were chosen to optimise the recording of the respective EEG variables. A nasion 
electrode (Nz), placed between the eyes, was used to monitor electro-oculographic 
(EOG) activity. 
Recording procedure 
Subjects or patients sat in a temperature controlled (21°C) room and the experimenter 
in an adjoining laboratory; communication was by means of a two-way intercom and 
observation by a one-way window (Fig. 4.5). 
Fig. 4.5 EEG recording. Subject sitting during an experiment with 
experimenter in adjoining laboratory. Under normal recording conditions 
the subject would be unable to see the experimenter due to differential 
lighting. 
Silver-silver chloride cup electrodes filled with a conductive gel (hypertonic saline jelly 
- Dracard), were attached to the surface of the scalp by adhesive. The resistance (or 
more correctly the impedance) between electrodes and scalp was small (below 
2Kohms) and matched with respect to a reference electrode on the forehead (used as a 
zero potential reference), thus reducing electrical artefact (see Appendix Q. 
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Scarification of the surface of the skin underlying the electrode, using a syringe with a 
blunted needle, was performed to reduce impedance, which was measured by an 
impedance meter. 
Electrode leads were connected to the amplifier via a headbox (which selects recording 
channels, i. e. the comparison of primary (Cz, C3 or 01) and reference (LM) 
electrodes). High and low pass filters were set to improve signal to noise ratio (see 
Appendix C), and signals amplified to a range of 100µV. The Microlink 3 converted 
the EEG signal from analogue (voltage) to digital (numerical) prior to storage in the 
Apricot Xen computer (Analogue-to-Digital Conversion (ADC) sampling rate=128 
samples/sec/channel with 8 bit resolution). Biodata CEAN 400 computer software 
(Computerised Electroencephalographic ANalysis) was used to collect and analyse 
spontaneous EEG and SEP data. EEG signals were simultaneously monitored on-line 
using a cathode ray oscilloscope and recorded onto FM tape (Racal) for subsequent 
off-line analysis. 
Spontaneous EEG and SEP recordings generally lasted 1.5 minutes during which 
subjects were asked to sit as still as possible with either: 
(i) eyes closed to optimise the recording of low frequency activity, 
(ii) eyes open to fixate on a dot (to reduce eye movements) and optimise the 
recording of high frequency activity. 
Artefact 
After recording, but prior to EEG analysis, an experienced EEG technician (Mr V. R. 
Marsh - VRM) examined raw EEG off-line (tape replay) for signs of artefact due to: 
(i) the patient, i. e. eye movements (Electro-oculographic - EOG) or muscle 
potentials (Electromyographic - EMG), 
(ii) electrical interference external to patient, i. e. TENS and recording equipment. 
A full description of the problems of EEG artefacts is given in Appendix C. 
As EOG is a main source of artefact, a nasion electrode was placed between the eyes 
used to monitor EOG. Correction of primary recording channels (i. e. Cz-LM; C3-LM; 
O1-LM) for EOG artefact was performed by an experienced EEG technician (VRM) at 
the end of the experiment using methods described by Verleger et al. [1982], and 
Thom and Andersen [1984] as follows: 
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(i) In spontaneous EEG recording, EOG contaminated epochs were rejected. No 
EOG artefact was noted when recording spontaneous EEG with eyes closed (Exp. 
4.2 and 4.3b). 
(ii) In SEP recording (Exp. 4.1) primary recording channels were compensated for 
EOG artefact by subtracting a proportion of EOG recorded at the nasion electrode. 
EMG artefact was monitored on-line via a cathode ray oscilloscope and was reduced 
by relaxing or changing the posture of the patient prior to recording. TENS artefact, 
due to the electrical pulses of TENS, was readily identifiable both on-line and in the 
graphical display of the power spectrum (Fig. 4.6). The results of 2 patients were 
omitted from statistical analysis in Experiment 4.3 due to TENS artefact.. 
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Fig. 4.6 TENS artefact contamination of spontaneous EEG. 
Identification of TENS artefact is made simple because of the large peaks 
occurring in power spectrum recorded at both Cz and Nz electrodes. Of 
note is the large power recorded at Nz. 
EEG analysis 
Spontaneous EEG: The Biodata CEAN 400 computer software (and other EEG 
computer programs) subdivides a length of spontaneous EEG into a number of shorter 
segments of equal duration called 'epochs'. Thus, an epoch is a basic period of time 
during which the EEG is sampled, and may be anything from a few seconds to 
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minutes. Epochs are separated by a small time interval to allow the computer to store 
the large volume of incoming data, and although sampling is not continuous the fact 
that epochs are equally spaced throughout the recording makes it unlikely that any 
alteration in the steady state spontaneous EEG activity will go undetected. 
Once collected, the spontaneous EEG needs to be analysed. A powerful and widely 
used method of EEG analysis is based on the calculation of the Fast Fourier Transform 
(FF1') from which a graph of power (JV2/Hz) against frequency (Hz), termed power 
spectrum, is created. Power spectrum is extremely useful in identifying the 
components of complex waveforms, thus making comparisons of EEG portions (i. e. 
pre- and post -drug) possible. The FFT is a mathematical procedure (algorithm) used 
to re-organise the EEG from its conventional form in the time domain into the size and 
distribution of the frequencies that make it up (i. e. the frequency domain). Creating 
power spectrum involves substantial computations which are not possible to perform 
in real-time by the CEAN 400 system. Thus, when all the data had been collected it 
was saved on the winchester disk of the Apricot computer and analysed off-line using 
FFT [for review see Kunkel 1984]. 
The power spectrum for each epoch and for every channel is calculated and then 
averaged, to give an averaged power spectrum. The power in each of the 
conventionally defined EEG frequency bands can be calculated and the power at any 
particular frequency found using interactive cursors (see Fig. 4.1). 
Cortical Evoked Potentials: An averaged evoked potential is created by the 
repeated presentation of a stimulus in order to enhance the cortical response in contrast 
to spontaneous EEG activity. Thus, EEG data is collected during several recording 
'sweeps' (or cycles). The Apricot computer (via CEAN 400 software) coordinates a 
sequence of time locked events (triggered by the digitimer), to present the stimulus (via 
the stimulating unit), collect EEG data (via the Microlink) and create the average 
evoked response on-line. Random or irregular inter-stimulus intervals are used to 
reduce habituation. The latencies and peak-to-peak amplitudes of respective component 
waves of the averaged evoked potential are measured as indices of response (see 
Fig. 4.2, for review see Bromm [1984]). 
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Experiment 4.1 
The effect of TENS on late components of the somatosensory 
evoked potential. 
The aim of Experiment 4.1 was to investigate the effects of TENS on the latency and 
peak-to-peak amplitude of the Ni and P2 components of the SEP, elicited by 'strong 
but non-painful' electrical stimuli administered to the index finger. 
Subjects and procedure 
Twenty healthy university students (female n=12, male n=8; age range=20-23 years of 
age) participated in the present study. All were naive to the experimental procedure, 
and each was randomly allocated into either (i) active TENS, or (ii) sham TENS 
groups. 
SEP recordings were made in the morning. Electrode positions were Cz (vertex) and 
Nz (nasion) referenced to LM (linked mastoids); amplifier settings; high pass filter=ls, 
low pass filter=lkHz, range 100µV; compensation of primary electrodes (Cz-LM) for 
EOG artefact was performed off-line (by VRM) using a method of subtraction 
[Verleger et al. 1982; Thom & Andersen 1984]. 
SEPs were recorded during 7,10 minute experimental cycles (i. e. 2x pre-TENS; 3x 
during TENS; 2x post-TENS) with subjects sitting in a relaxed awake state while 
fixating a dot. SEPs were elicited by 35 square wave electrical stimuli (pulse width 
200µs), randomly delivered (in time 1.2-5 s) to the index finger of the left hand via 
two carbon rubber electrodes (2 x1 cm2) at a 'strong but non-painful' intensity. The 
intensity of the evoking stimulus was determined prior to the start of the experiment by 
increasing stimulus intensity (pulse frequency=3Hz) until rated as 7 on a verbal rating 
scale where 0=imperceptible and 10=painful. Subsequent stimulus intensity ratings 
were measured on a visual analogue scale (VAS) immediately after each SEP 
recording. 
A Microtens 7577 was used to produce TENS, via 2x4 cm2 carbon rubber electrodes 
placed lcm apart on the ventral surface of the left arm overlying the median nerve, 3cm 
above the first wrist crease. TENS was switched on prior to the start of cycle 3 and 
switched off at the end of cycle 5. 
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The electrical characteristics of TENS were monitored using the Frye Analyser and set 
by the experimenter as follows: 
(i) pulse intensity -'strong but comfortable' with no observable muscle activity, 
(ii) pulse pattern - continuous, 
(iii) pulse frequency - 80Hz, (iv) pulse width - 200µs. 
Sham TENS was administered as described in Chapter 3 by a modified stimulator (no 
current output) and a coloured suggestion, re-inforced with a digital display on the 
Frye Analyser. 
Results of Experiment 4.1 
Marked inter-subject variability in the intensity of the evoking stimulus to achieve a 
'strong but non-painful' level was observed (range=0.5-21mA above sensory 
detection threshold - SDT). The SEP was characterised by a series of positive and 
negative waves P1, Ni and P2 as shown in Fig. 4.7 (Mean±SD latency: P1=not 
measured, N1=144.4±29.8ms, P2=210.3±36.3ms, n=20). Mean±SD N1P2 
amplitude and stimulus intensity ratings are shown in Table 4.2. 
Mean±SD TIME (mins) 
Pre 1 Pre 2 Drg Drg 2 Drg 3 Post I Post 2 
-10 -01 +10 +20 +30 +40 +50 
NIP2 (NV) 
TENS 23.5±8.4 22.3±7.4 17.2±6.6 16.3±5.5 16.5±7.3 15.0±6.7 15.4±5.9 
Sham 17.8±10.1 17.9±9.2 15.7± 10.1 15.2±9.7 15.1 ±8.9 13.3±6.1 15 . 4±7.0 
STIMULUS 
INTENSITY 
TENS 6.2±1.9 6.2±1.8 4.9±3.0 4.6±2.9 4.6±2.8 4.5±2.3 4.8±2.3 
Sham 6.7±1.5 6.4±1.8 6.3±1.6 6.1±1.6 6.0±1.6 6.0±1.6 6.1±1.8 
Table 4.2 Mean±SD results of Exp. 4.1. Mean NIP2 peak-to- 
peak amplitudes and evoking stimulus intensity rating for TENS and 
sham groups. Pre=pre-treatment, Drg=during-treatment, Post=post- 
treatment N1P2=Peak-to-peak amplitude of N1P2 (µV), Stimulus 
intensity=Intensity of evoking stimulus measured on a visual analogue 
scale (VAS) where O=imperceptable and 10=painful 
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A pre-treatment mean of cycle 1 and 2 was calculated as pre-treatment baseline (no 
significant differences in pre-treatment cycles 1 and 2 for (i) N1P2 amplitudes, P=0.7; 
(ii) intensity rating of the evoking stimulus, P=0.4, paired t-test). No significant 
differences in baseline N 1P2 amplitudes or intensity rating of the evoking stimulus 
were observed between sham and TENS groups (unpaired t-test); thus the change in 
N1P2 and intensity rating during treatment was calculated for each cycle and individual 
by subtracting the pre-treatment mean from subsequent during and post-treatment 
cycles (Fig. 4.8). 
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Fig. 4.8 Mean change in peak-to-peak N1P2 amplitude from 
pre-treatment baseline in active and sham TENS groups 
(Exp. 4.1). Unpaired t-test TENS v sham mean change across during- 
Drg- (n=3 cycles, Pß. 04) and post (n=2 cycles, Pß. 02) treatment cycles. 
Mean change in N1P2 amplitude and VAS across the (i) 3 during treatment and (ii) 2 
post-treatment cycles, for each individual, were used as summary measures of 
response (Table 4.3). 
TENS produced a significant reduction in N1P2 amplitude when compared to sham 
both: 
(i) during treatment cycles (Mean change in N1P2 amplitude: TENS=-6.2µV, 
sham=-2.4µV, P=0.04, unpaired t-test), 
(ii) post-treatment cycles (TENS=-7.7µV, sham=-3.5µV, P=0.02, unpaired t-test). 
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TENS also reduced the intensity rating of the evoking stimulus, although this failed to 
reach significance. (Mean change (VAS units): (i) during treatment cycles, TENS=- 
1.5, sham=-0.4, P=0.19; (ii) post-treatment cycles, TENS=-1.5, sham=-0.5, P=0.15, 
unpaired t-test, see Table 4.3). No relationships (Pearson correlation coefficients) were 
observed between baseline N1P2 and either: (i) change in the intensity rating of the 
evoking stimuli during TENS, or (ii) change in N1P2 amplitude during TENS. 
Mean Ni and P2 latencies were calculated for each individual for pre-, during and 
post-treatment cycles, and subjected to the same statistical analysis as above. No 
significant changes in latencies were found between TENS and sham groups (Mean 
change in latency during treatment: Ni, TENS=2. lms, sham=0.9ms, P=0.7; P2, 
TENS=3. Oms, sham=3.9ms, P=0.84, unpaired t-test) 
Main findings of Experiment 4.1 
(i) Marked inter-subject variability in the current intensity necessary to produce a 
'strong but comfortable' evoking stimuli was observed. 
(ii) TENS produced a significant reduction in N1P2 peak-to-peak amplitude when 
compared to sham. However sham also reduced N1P2 amplitude but to a lesser 
magnitude. 
(iii) The reduction in N1P2 amplitude was not dependent upon pain perception as 
the evoking stimulus was non-painful. Thus, TENS effects may not be specific to 
the pain system. 
(iv) No significant changes Ni or P2 latency were observed during TENS. 
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Experiment 4.2 
The effect of TENS on resting awake EEG in healthy 
subjects. A preliminary report. 
The TENS-induced reduction in peak-to-peak amplitudes of late waveform 
components of the SEP (Exp. 4.1) suggests that TENS affects the processing of 
sensory information. By implication TENS may also produce changes in spontaneous 
EEG. Although the effects of TENS on spontaneous EEG are unknown, it has been 
suggested that pain and analgesics may induce changes in spontaneous EEG [Bromm 
et al. 1989]. Hence, acupuncture has been shown to increase alpha activity during the 
reduction of tension headache [Manna et al. 1984]. The aim of Experiment 4.2 was to 
examine the effects of TENS on spontaneous EEG in healthy pain-free subjects. 
Conditions were optimised for the recording of alpha activity by recording EEG at 01 
(left occipital electrode position), with eyes closed and filters set to reduce the 
recording of high frequency activity. 
Subjects and procedure 
Sixteen healthy paid students (female n=6, male n=10; age range=21-33, mean=25.6 
years of age) participated in the study. All were naive to the experimental procedure but 
had attended the laboratory for a brief familiarisation session prior to the recording 
session. Subjects were randomly allocated into either (i) active TENS (TENS), or (ii) 
sham TENS (sham) groups. 
Spontaneous EEG recordings were made in the morning; electrode positions were 01 
(left occipital) and Nz (nasion) referenced to LM (linked mastoids); amplifier settings; 
high pass filter=0.2s, low pass filter=30Hz, range=100µV. Each EEG recording was 
re-examined (by VRM) for EOG and/or TENS artefact contamination. No such 
contamination was observed in any subject. 
Spontaneous EEG was recorded in 6,5 minute cycles (i. e. 2x pre-TENS; 2x during 
TENS; 2x post-TENS) with subjects sitting in a relaxed awake state with eyes closed 
to optimise alpha activity. Subjects were requested to make their 'mind as blank as 
possible'. EEG recording lasted 1.5 minutes, separated by a 3.5 minute rest period. 
Active TENS (TENS) or sham TENS (sham) was administered immediately after the 
recording of pre-treatment cycle 2, and switched off immediately upon cessation of the 
recording of during TENS cycle 2 (duration of treatment=21.5 rains). During TENS 
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recordings were taken at +15 min and + 20 min after 'switch on. Each recording 
acquired 25,2 second epochs and averaged spectra were computed off-line using FFF 
(Biodata software) for spectral analysis. Power spectrum (tV2/Hz) was analysed in 
the following (traditional) frequency bands: 
delta, 0.0 to 3.5Hz, 
theta, 4.0 to 7.5Hz, 
alpha, 8.0 to 13.5Hz, 
slow beta, 14.0 to 25.5Hz, 
with a resolution of 0.5Hz. Peak alpha frequency was also measured. 
A Microtens 7757 was used to produce 'strong but comfortable' TENS. Stimulating 
characteristics were monitored using the Frye Analyser and fixed by the experimenter 
as follows: 
pulse pattern=continuous, 
pulse frequency=80Hz, 
pulse width=200 µs, 
electrode impedance <1Kohms . 
TENS was delivered via two 8cm2 carbon rubber electrodes placed 10 cm apart, 
straddling the spinal cord at L1/L2. Subjects in the active TENS group were asked to 
increase the intensity (pulse amplitude) of TENS to a 'strong but comfortable' level 
and to make subsequent adjustments to maintain this intensity during the course of the 
experiment. Sham TENS was administered as described in Chapter 3 and no subjects 
questioned the procedure. 
Results of Experiment 4.2 
Mean±SD power for each cycle and frequency band is shown in Table 4.4. 
Pre-1 
-10mins 
MEAN ±SD POWER 
Prc-2 During-1 
-05mins +15mins 
SPECTRUM 
During-2 
+20mins 
(pV /Hz) 
Post-1 
+25mins 
Post-2 
+30mins 
DELTA 
TENS 21.2±10.2 19.6± 8.9 21.2±11.3 20.4±11.9 20.5±10.0 17.1± 7.8 
Sham 19.5± 6.6 19.0± 7.1 18.5± 6.4 19.0±10.0 20.1± 6.7 20.0± 6.8 
THETA 
TENS 15.0±12.0 14.9±10.2 15.6±11.8 14.1±7.8 15.0± 8.6 14.1± 7.2 
Sham 14.8± 9.1 16.3±10.4 13.8± 8.4 14.3±8.8 15.11 9.4 17.1± 8.2 
ALPHA 
TENS 91.1±37.5 84.0±45.0 99.2±52.5 85.5±58.5 84.2±59.5 78.8±49.5 
Sham 101.8±59.7 105.3±74.2 106.3±65.4 91.1±39.1 102.9±58.1 104.6172.8 
BETA 
TENS 15.4± 8.4 14.1± 6.6 21.2±12.3 16.7± 6.7 15.4± 9.3 25.9±20.0 
Sham 19.3±15.8 20.2±17.3 18.0±14.3 17.8±10. s 20.4±17.5 19.5±13.1 
Table 4.4 Mean±SD power spectrum during active (n=8) 
and sham TENS (n=8) in pain-free healthy subjects. N. B. 
Beta = slow beta. 
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No significant differences were observed in the 2 pre, during or post-treatment cycles 
for any frequency band (paired t-test). Thus mean pre, during and post treatment 
power was calculated for each individual (Table 4.5). Fig. 4.9 shows a graphical 
display of the power spectrum for a subject receiving active TENS and a subject 
receiving sham TENS. 
The following range of pre-treatment baseline power for respective frequency bands 
were recorded: 
Delta 
Theta 
Alpha 
Slow beta 
9.5 to 39.5 µV2/Hz 
3.0 to 35.0 µ. V2/Hz 
11.5 to 310.2 µV2/Hz 
3.4 to 57.8 µV2/Hz 
Although wide inter-subject variability in pre-treatment power were observed 
(especially in alpha power), no significant differences in pre-treatment power was 
found between sham and TENS groups for any frequency band (unpaired t-test TENS 
v sham). Therefore changes in power during treatment were calculated for each 
individual and used as a summary measure of treatment effect. Because of the wide 
inter-individual variability in pre-treatment baseline power spectrum, percentage 
change during treatment (from pre-treatment baseline) was also calculated for each 
individual. This percentage change in power spectrum would account for subjects with 
low baseline power showing small absolute changes in power spectrum during 
treatment. 
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Fig. 4.9 Graphical display of power spectrum in (a) one 
subject receiving active TENS and (b) one subject receiving 
sham TENS. Individual epochs (50 pre- during and post-) and averaged 
spectra are shown. 
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Delta and Theta: No significant change in delta or theta activity occurred during 
TENS when compared to sham (Mean change in power during treatment: Delta; 
TENS=+0.40gV2/Hz, sham=-0.5. tV2/Hz, P=0.6; Theta; TENS =-0.06gV2/Hz, 
sham=-1.5tV2/Hz, P=0.4, unpaired t-test). No significant differences between 
groups were found when the data was transformed to percentage changes (Fig. 4.10a 
and b). 
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Fig. 4.10a Percentage change in delta power (compared to 
pre-treatment baseline) during active TENS and sham TENS 
(Exp. 4.2). Unpaired t-test on TENS v sham percentage change for 
during and post-treatment cycles P=0.6 (mean of 2 cycles per individual). 
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Fig. 4.10b Percentage change in theta power (compared to 
pre-treatment baseline) during active TENS and sham TENS 
(Exp. 4.2). Unpaired t-test on TENS v sham percentage change for 
during and post-treatment cycles, P=O. 4 (mean of 2 cycles per individual). 
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Alpha: Although a rise in alpha activity was observed during active TENS (Table 4.4) 
this failed to reach significance (Mean change; TENS=+4.8tV2/Hz, sham=- 
4.9µV2/Hz, P=0.45). The 21.3% rise in alpha activity during active TENS, when 
compared to the 2.1% reduction during sham, just failed to reach statistical significance 
(P=0.064, unpaired t-test, Fig. 4.10c). 
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Fig. 4.10c Percentage change in alpha power (compared to 
pre-treatment baseline) during active TENS and sham TENS 
(Exp. 4.2). Unpaired t-test on TENS v sham percentage change for 
during and post-treatment cycles (mean of 2 cycles per individual). 
Examination of individual results found that alpha activity increased (by more than 
ljV2/Hz) in 6 out of 8 subjects during TENS, compared to 4 out of 8 during sham 
(Table 4.5). 
Peak Alpha Frequency: Pre-treatment peak alpha frequency ranged from 9-11.5Hz 
and no significant changes in peak alpha activity were observed during or post- 
treatment (with respect to pre-treatment baseline). 
Slow Beta: A significant increase in beta power was observed during TENS (Mean 
change; TENS=+4.2 µV2/Hz, sham=-1.9 LV2/Hz, P<0.05, unpaired t-test). A rise in 
beta activity (of more than 1gV2/Hz) was observed in 6 out of 8 subjects during 
TENS, compared to 2 out of 8 during sham. A 40.1 % increase in beta power was 
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observed during TENS and was attributed to large increases by subjects 2 and 8 
(Table 4.5, Fig. 4.10d). 
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Fig. 4.10d Percentage change in power spectrum (compared 
to pre-treatment baseline) during active TENS and sham 
TENS (Exp. 4.2). Unpaired t-test on TENS v sham percentage change 
for during and post-treatment cycles, P=0.1 (mean of 2 cycles per 
individual). 
Main findings of Experiment 4.2 
(i) Wide inter-individual variation in baseline power was observed across all 
frequency bands, although inter-cycle variation within subjects was small. 
(ii) A significant increase in absolute beta activity was observed during TENS 
(Table 4.5). 
(iii) Although no significant changes in absolute alpha power were observed during 
TENS, a hint of an increase in alpha activity was found when data was transformed 
to percentage change from baseline. 
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Experiment 4.3 
The effect of TENS on spontaneous EEG and pain intensity 
in chronic pain patients during TENS. 
The results of Experiment 4.2 suggest that beta and possibly alpha' activity increase 
during TENS in pain-free healthy volunteers. No significant changes in EEG power 
were observed in other frequency bands. The aim of Experiment 4.3 was to extend the 
findings of Experiment 4.2 by investigating the effects of TENS on spontaneous EEG 
of patients who use TENS to control a chronic pain condition. Furthermore, 
relationships between baseline SEP and spontaneous EEG with chronic pain intensity 
and response to TENS were examined. 
Patients and procedure 
The experiment was split into two parts: 
Exp. 4.3a. High frequency activity - to optimise the recording of beta activity (at C3 
with eyes open), 
Exp. 4.3b. Low frequency activity - to optimise the recording of alpha activity (at 
01 with eyes closed). 
Thirty one patients using TENS to successfully control their chronic pain condition, 
were randomly selected from NPRC files to participate in either Exp. 4.3a (n=15, 
female n=11, male n=4; age range=37-66, mean=52.1 years of age), or Exp. 4.3b 
(n=16, male n=7 female n=9; age range=42-77, mean=61.1 years of age). Patients 
receiving anxiolytics, psychotropics, neuroleptics or centrally acting analgesics were 
excluded from the study. Patients were requested not to take any analgesics 24 hours 
prior to the experiment. Patients were classified according to the International 
Association for the Study of Pain (IASP) classification of chronic pain conditions [for 
full explanation of terms see IASP 1986] and an author's diagnostic classification 
[Johnson et al. 1991a] as follows: 
Experiment 4.3 
Anatomical 
Region 
ababab 
(n) (n) Aetiology (n) (n) Diagnostic (n) (n) 
Head or face 1 
Cervical 0 
Upper limb 3 
Thoracic 1 
Lower back 6 
Lower limb 3 
Two sites or more 1 
Clusters 
0 Trauma 56 Deafferentation 31 
1 Infective 01 Entrapments 54 
3 Inflammatory 11 Neuralgia 13 
2 Toxic 21 Spondylosis 33 
3 Degen. /mechan. 62 Myofascial 12 
6 Dysfunctional 13 Sympathetic 23 
1 Other/unknown 02 
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Spontaneous EEG recordings were made in the morning; electrode positions were 
either; C3(Exp. 4.3a) or 01 (Exp. 4.3b), referenced to LM (linked mastoids). 
Amplifier settings; high pass filter=0.2s, low pass filter=100Hz, (Exp. 4.3a); 30Hz 
(Exp. 4.3b), range=100 µV. All recordings were examined off-line (by VRM) for 
signs of EOG and/or TENS artefact. 
EEG was recorded in 6 (2 x pre-TENS; 2x during TENS; 2x post-TENS), 5 minute 
cycles each lasting 1.5 minutes and separated by a 3.5 minute rest period. Patients sat 
in a relaxed awake state either, fixating a dot with eyes open (Exp. 4.3a), or with eyes 
closed (Exp. 4.3b). Patients were requested to make their minds 'as blank as possible' 
during EEG recording. Twenty five, 2 second epochs were acquired and averaged 
spectra computed off-line using fast fourier transform. EEG power (. tV21Hz) was 
analysed in the same frequency bands as Exp. 4.2, although fast beta activity (26.0- 
40.0Hz) was also measured in Exp. 4.3a. 
TENS was administered immediately after pre-treatment cycle 2, and remained 
'switched on' for 21.5 minutes. During TENS recordings were taken at +15 min and + 
20 min after 'switch on'. Patients were asked to rate the intensity of their pain on a 
visual analogue scale (where 0=no pain and 10=worst pain imaginable) at the end of 
each cycle. 
Patients were in possession of either a Microtens 7757 or a Tiger Burst stimulator, and 
prior to the start of the experiment patients applied TENS electrodes to the site 
normally used to control the pain condition. The stimulator remained switched off until 
the during TENS cycles. All patients administered TENS to achieve a 'strong but 
comfortable' electrical paraesthesia within the painful site, and subsequent adjustments 
to maintain this intensity of stimulation were made during the course of the experiment. 
Patients used the following electrical characteristics of TENS as recorded by the Frye 
Analyser: 
Experiment 4.3a 4.3b 
Continuous mode TENS n=12 n=11 
Burst mode TENS n=3 n=5 
Pulse width 200Ns 200µs 
Pulse frequency median 29 29 
(Hz) range 10-128 16-176 
Pulse intensity median 11 20 
(mA above SDT) range 2-23 4-44 
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Results of Experiment 4.3a and b 
Exp. 4.3a and Exp. 4.3b were analysed in an identical manner. Thus, mean±SD was 
calculated for each cycle and frequency band. No significant differences were observed 
in the two pre-, during or post-treatment cycles for any frequency band (paired t-test), 
therefore mean pre-, during and post-treatment power was calculated for each 
individual. TENS effects were examined by subtracting pre- from during TENS power 
for each individual. Percentage change in power from pre-treatment baseline was also 
calculated as in Exp. 4.2. Paired t-tests were performed to examine differences 
between pre- and during TENS recordings. 
Pre-treatment baseline power spectrum 
The range of pre-treatment baseline power recorded for respective frequency bands are 
shown below: 
Delta 
Theta 
Alpha 
Slow beta 
Fast beta 
Exp. 4.3a 
17.4 to 64.2µV2/Hz 
5.1 to 43. OµV2/Hz 
3.8 to 58.8µV2/Hz 
7.1 to 43.6µV2/Hz 
2.5 to 55.9µV2/Hz. 
Exp. 4.3b 
9.4 to 146.8pV2/Hz 
6.5 to 49.9jV2/Hz. 
7.0 to 197.9pV2/Hz. 
9.0 to 54.6jV2/Hz. 
not measured 
Wide inter-patient variability in baseline power was observed in both Exp. 4.3a and 
Exp. 4.3b. Of note was the large increase in inter-patient variability in alpha power in 
Exp. 4.3b when recording conditions were optimised to record low frequency activity. 
The large and spurious delta activity observed in patient 10 in Exp. 4.3b remains 
unexplained, although examination of raw EEG discounted artefact contamination due 
to EOG which can manifest in this frequency range. 
Baseline power spectrum was not correlated to either: 
(i) baseline pain intensity rating, 
(ii) change of pain intensity during TENS, 
(iii) change in spontaneous EEG during TENS, 
for any of the frequency bands measured (Pearson correlation coefficient) in either 
Exp. 4.3a or Exp. 4.3b. 
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Exp. 4.3a High frequency activity 
Two patients (no. 7 and 11) were omitted from statistical analysis due to the 
occurrence of TENS artefact (see Fig. 4.6). Mean pain intensity rating decreased during 
TENS with concurrent increases in mean theta, alpha, and slow beta activity, and a 
decrease in delta activity (Table 4.6). 
Pre- 
-10mins 
MEAN±SD 
Pre-2 
-05mins 
POWER 
During-1 
+15mins 
SPECTRUM (µV /Hz) 
During-2 Post-1 
+20mins +25mins 
Post-2 
+30mins 
DELTA 33.6±13.2 31.1±11.7 29.6±13.9 27.4± 9.0 31.9±12.8 32.1±12.4 
THETA 12.5±10.6 12.0± 9.0 13.2± 9.6 13.7±10.6 13.6±12.1 13.7±12.7 
ALPHA 17.8±16.5 16.1±12.6 20.4±16.7 20.0±15.7 19.4±17.9 18.7±16.6 
SLOW BETA 17.8±12.0 16.3± 8.7 19.2± 9.5 16.7± 8.4 16.0± 8.7 16.6± 8.6 
FAST BETA 14.0±17.5 10.6±10.3 12.7±11.3 7.0± 3.6 9.1± 6.7 8.2± 6.4 
PAIN RATING 4.5± 2.3 4.5± 2.3 2.8± 1.8 2.4± 1.9 3.8± 2.7 4.4± 2.7 
Table 4.6 Mean±SD power spectrum of chronic pain 
patients during treatment with TENS (n=13). Part 1 High 
frequency activity (Exp. 4.3a). 
Pain Intensity Rating: Baseline pain intensity rating ranged from 1.4-9.7 units on 
the visual analogue scale (VAS units). A significant reduction in pain intensity rating 
was observed during TENS (pre v during: =-2.0 VAS units, P<0.01, paired t-test) 
which began to return to pre-treament baseline in post-TENS cycles (pre v post: =-0.4 
VAS units, P=0.08, paired t-test). 
Delta and Theta: No significant changes in either delta or theta power was observed 
during TENS (Delta=-1.2RV2/Hz, P=0.5; Theta=+0.9. V2/Hz, P=0.3, paired t-test). 
Similarly no significant differences were found when the data was transformed to 
percentage changes (Fig. 4.1 1). 
Alpha: There was a hint of an increase in alpha activity during TENS (+2. l jV2/Hz, 
P=0.09, paired t-test, see Table 4.7). When data was transformed to percentage 
changes this rise in alpha activity of 13.3% reached statistical significance (P=0.01 
paired t-test, see Fig. 4.1 1). Examination of individual results showed that an increase 
in alpha activity during TENS (of lgV2/Hz or more) was observed in 8 out of 13 
patients (Table 4.7). 
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DELTA POWER THETA POWER ALPHA POWER 
SUB TMT V V V 
Mean Mean Mean Mean Mean Mean Mean Mean Mean 
PRE DURING POST PRE DURING POST PRE DURING POST 
(n=2) (n=2) (n=2) (n=2) (n=2) (n=2) (n=2) (n=2) (n=2) 
I TENS 46.5 61.7 66.4 10.0 12.9 11.9 11.7 14.4 12.0 
2 TENS 26.0 24.6 26.7 5.1 6.2 4.6 3.8 4.8 3.7 
3 TENS 37.9 36.4 40.8 12.1 13.7 14.5 33.2 44.0 52.5 
4 TENS 19.3 19.3 22.3 10.3 17.5 16.3 27.0 36.3 34.9 
5 TENS 24.9 23.9 25.6 43.0 42.2 53.8 58.8 58.2 60.4 
6 TENS 28.5 22.2 25.5 7.0 7.1 6.6 5.3 5.9 5.4 
7 TENS 64.2 " 43.1 13.0 " 9.8 4.7 " 3.9 
8 TENS 24.9 24.9 21.7 6.4 7.4 8.1 17.5 20.0 19.0 
9 TENS 31.5 29.0 29.2 8.9 10.1 9.6 17.6 17.7 18.2 
10 TENS 30.0 22.4 39.4 6.3 6.2 7.2 9.2 10.4 10.7 
11 TENS 35.3 " 31.5 7.7 " 6.4 13.4 " 11.0 
12 TENS 33.6 29.7 29.6 8.7 8.1 8.5 7.1 9.5 6.8 
13 TENS 42.4 29.8 30.4 22.3 17.6 19.9 21.1 16.6 14.4 
14 TENS 17.4 16.0 17.7 5.7 5.3 53 9.4 8.8 10.8 
15 TENS 22.8 30.0 29.9 17.5 20.4 22.2 14.4 16.2 22.4 
MEAN 32.4 28.5 32.0 12.3 13.5 13.7 16.9 20.2 19.1 
=0S =03 =0.09 
SLO W BETA PO WER FAST BETA POW ER PAIN INTENSITY RATING 
SUB TMT (µV2/Hz) ÜIV2/Hz) 4+ 
(no pain 0->10 worst Imaglnable) 
Mean Mean Mean Mean Mean Mean Mean Mean Mean 
PRE DURING POST PRE DURING POST PRE DURING POST 
(n=2) (n=2) (n=2 (n=2) (n=2) (n=2) (n=2) (n=2) (n=2) 
1 TENS 11.5 12.3 11.8 4.8 5.6 6.2 7.6 6.8 7.5 
2 TENS 7.3 8.3 7.6 2.5 3.1 3.0 3.2 2.9 3.3 
3 TENS 23.3 30.6 27.4 8.6 15.0 10.0 2.1 1.0 0.7 
4 TENS 18.3 25.9 23.3 7.9 11.7 12.6 1.7 0.9 1.0 
5 TENS 11.4 13.8 11.5 5.0 6.2 3.9 3.7 3.1 4.0 
6 TENS 7.1 6.3 6.2 4.3 3.2 3.1 5.3 1.4 4.0 
7 TENS 8.8 " 7.5 9.5 " 7.9 1.4 0.5 0.5 
8 TENS 17.4 19.8 17.8 6.3 4.4 3.4 5.4 0.9 6.1 
9 TENS 7.8 6.0 5.8 7.6 4.7 4.7 4.7 4.3 5.4 
10 TENS 22.5 25.9 25.5 7.9 5.6 10.6 5.6 4.7 6.3 
11 TENS 20.1 " 15.6 26.0 " 16.4 4.4 3.4 3.3 
12 TENS 8.5 14.2 10.4 7.4 15.6 9.5 4.3 3.5 4.5 
13 TENS 43.6 25.9 19.0 55.9 23.1 6.3 9.7 2.4 9.5 
14 TENS 30.1 27.6 33.1 7.4 7.3 7.7 6.5 1.5 4.2 
15 TENS 17.5 16.7 21.5 23.0 22.0 24.4 1.9 1.4 0.7 
MEAN 17.0 18.0 16.3 12.3 9.8 8.6 4.5 2.6 4.1 
p=0.8 p=0.6 P<0.01 
Table 4.7 Individual change in power spectrum during TENS in pain 
patients. Part 1 High frequency activity (Exp. 4.3a) SUB = Subject no.: TMT = 
treatment Group: TENS = Transcutaneous Electrical Nerve Stimulation: SHAM= Sham 
TENS Mean PRE = Mean of two pre-treatment measures: Mean DURING = mean of three 
during treatment measures: Mean POST = mean of two post-treatment measures. Mean was 
calculated for each group. Statistical analysis was performed by calculating changes during 
treatment (by subtracting PRE from DURING for each individual) and performing a paired t- 
test between groups. 
Beta: No significant changes in either slow or fast beta power was observed during 
TENS (Mean change in power pre v during: Slow beta=+0.5 iV2/Hz, P=0.8; Fast 
beta=-1.6 tV2/Hz, P=0.6, paired t-test). 
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Fig. 4.11 Percentage change in power spectrum and pain 
intensity rating (compared to pre-treatment baseline) during 
TENS treatment of chronic pain conditions (Exp. 4.3a). 
Paired t-test on pre- v during (mean of 2 cycles/individual) TENS 
treatment (n=13). 
Exp. 4.3b Low frequency activity. 
No patients were omitted from analysis as no observable TENS artefact were noted in 
either raw EEG or power spectrum. As observed in Exp. 4.3a the decrease in mean 
pain intensity rating during TENS was accompanied by increases in theta, alpha and 
slow beta power and a decrease in delta activity (Table 4.8). 
Pre- 
-10 
MEAN±SD 
Pre-2 
-05 
POWER SPECTRUM (gV2 /Hz) 
CYCLE (TIME MINS) 
During-1 During-2 Post-1 
+15 +20 +25 
Post-2 
+30 
DELTA 28.8±27.6 27.8±30.2 24.0 ±19.4 23.7±15.7 22.5±17.1 24.3±20.0 
THETA 17.4±14.0 17.1±13.5 18.4±15.3 19.4±14.4 18.2±14.7 16.0±10.8 
ALPHA 78.4±57.1 74.9±51.4 87.1±57.8 87.5±59.9 81.5±60.1 83.1±59.1 
BETA 28.1±16.4 25.5±12.8 30.5±18.0 32.5±23.7 27.6±14.6 30.1±19.7 
ALPHA FREQ. 9.5±0.8 9.7±0.9 9.5±0.7 9.5±0.7 9.5±0.8 9.4±0.7 
PAIN RATING 4.5±1.9 4.5±1.8 2.9±1.9 2.8±1.9 2.9±2.2 3.0±2.3 
Table 4.8 Mean±SD power spectrum of chronic pain 
patients during treatment with TENS (n=16). Part 2 Low 
frequency activity (Exp. 4.3b) 
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SUB 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
TZUIT 
DELTA POWER 
(µV2/Hz) 
Mean Mean Man 
PRE DURING POST 
(n=2) (n=2) (n=2) 
THETA POWER 
(µV2/Hz) 
Mean Mean 1"iean 
PRE DURING POST 
(n=2) (n=2) (n=2) 
SLOW BETA POWER 
(µV2/Hz) 
Mean Mean Mean 
PRE DURING POST 
(n=2) (n=2) (n=2) 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
MEAN 
SUB 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
TMT 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
TENS 
17.9 22.0 20.2 
13.6 15.4 14.8 
16.1 16.0 15.9 
13.1 12.9 13.2 
13.7 14.6 15.3 
9.4 10.6 10.1 
30.1 22.3 18.5 
10.0 8.8 9.8 
33.0 33.7 30.7 
146.8 78.4 83.5 
14.9 14.0 15.0 
26.8 30.3 28.6 
30.9 30.5 35.1 
16.3 17.5 14.2 
48.3 42.6 36.4 
11.5 12.1 13.1 
28.3 23.9 - 23.4 
p=03 
ALPHA POWER 
(µV2/Hz) 
Mean Mean Mean 
PRE DURING POST 
(n=2) (n=2) (n=2) 
53.9 78.4 71.9 
84.0 84.6 81.8 
31.6 29.2 36.2 
71.7 92.3 58.7 
133.2 142.9 139.3 
31.7 41.2 58.1 
61.9 71.8 43.9 
24.0 25.3 33.5 
197.9 186.1 182.3 
88.6 123.5 68.9 
32.8 35.2 36.3 
7.0 8.0 8.3 
100.1 105.7 121.2 
37.9 49.4 53.2 
165.4 208.9 196.9 
104.2 113.8 126.1 
22.2 25.1 
9.3 9.1 
12.2 14.0 
13.6 16.0 
14.4 20.7 
7.1 8.1 
8.5 8.1 
6.5 5.1 
49.9 56.7 
19.0 19.3 
7.9 7.9 
7.0 8.2 
29.5 30.8 
6.3 9.5 
45.9 46.5 
16.1 17.4 
17.2 18.9 
P<0.01 
24.6 
9.6 
13.9 
13.3 
16.4 
9.0 
7.7 
4.9 
39.5 
15.4 
7.1 
8.2 
36.2 
7.5 
42.0 
18.4 
17.1 
ALPHA FREgUENCY 
(Hz) 
Mean Mean Mean 
PRE DURING POST 
(n=2) (n=2) (n=2) 
8.0 8.5 8.0 
11.0 10.7 10.5 
9.0 8.5 8.2 
10.0 10.0 10.0 
10.5 10.0 10.5 
9.2 9.2 9.5 
11.0 10.2 10.2 
10.5 10.0 9.7 
9.0 9.2 9.2 
9.7 9.7 10.0 
9.7 10.0 9.7 
ssf 
9.0 8.7 8.5 
9.2 9.2 9.5 
9.0 9.0 9.0 
9.0 9.0 9.0 
MEAN 76.6 87.3 82.3 9.6 9.5 9.4 
P=0.01 p=0.2 
32.1 31.2 36.5 
11.6 9.5 13.9 
41.6 75.8 64.3 
38.0 39.3 38.7 
25.4 24.4 25.6 
9.0 8.6 6.5 
26.4 22.0 22.2 
54.6 53.1 54.0 
46.4 63.4 45.8 
12.6 13.6 11.7 
13.5 14.4 17.9 
22.7 23.0 24.5 
29.5 34.6 25.6 
30.1 46.7 31.6 
10.3 12.4 13.7 
26.9 31.5 28.9 
n=0.1 
PAIN INTENSITY RATING 
(No pain 0 -> 10 worst imaginable) 
Mean Mean Mean 
PRE DURING POST 
(n=2) (n=2) (n=2) 
2.8 1.5 1.7 
4.5 2.2 2.3 
3.7 2.2 1.1 
6.1 5.5 5.0 
3.2 2.0 2.5 
3.7 3.0 2.4 
5.5 2.0 3.2 
5.7 0.3 0.3 
8.4 7.0 9.1 
1.6 0.6 0.9 
5.3 3.9 2.6 
5.9 5.0 5.0 
4.5 2.0 1.8 
5.7 5.1 5.3 
3.3 2.4 3.1 
1.0 0.7 0.8 
4.4 2.8 3.0 
P=0.01 
Table 4.9 Individual change in power spectrum during 
TENS in pain patients. Part 2 Low frequency activity 
(Exp. 4.3b) SUB = Subject no.: TMT = treatment Group: TENS = 
Transcutaneous Electrical Nerve Stimulation: SHAM= Sham TENS Mean 
PRE = Mean of two pre-treatment measures: Mean DURING = mean of 
three during treatmnent measures: Mean POST = mean of two post- 
treatment measures. Mean was calculated for each group. Statistical 
analysis was performed by calculating changes during treatment (by 
subtracting PRE from DURING for each individual) and performing a 
paired t-test between groups. 
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Pain Intensity Rating: Baseline pain intensity rating ranged from 1.0-8.4 VAS 
units and a significant decrease in pain rating was observed during (-1.6 VAS units, 
P<0.01), and post-TENS treatment cycles (-1.5 VAS units, P>0.01, paired t-test). All 
patients showed a decrease in pain intensity rating during TENS (Table 4.9). 
Delta and Theta: No significant change in delta power was observed during TENS 
(mean change=-4.4 JV2/Hz, P=0.3, paired t-test). A small but significant rise in theta 
power (+1.7pV2/Hz, P>0.05) was observed during TENS and 9 out of 16 patients 
showed an increase (of over IRV2/Hz) in theta power (Table 4.9). This finding was 
confirmed when the data was transformed to percentage change (+10.6%, P>0.05) 
(Fig. 4.12). 
Alpha: A significant increase in alpha power (+10.6pV2/Hz, p>0.01, see Table 4.9) 
was observed during TENS. This was confirmed when data was transformed to 
percentage changes (Mean percentage change=15.8%, P>0.01, paired t-test, see 
Fig. 4.12). Examination of individual results showed that 13 out of 16 patients showed 
an increase in alpha power (of over 1. V2/Hz) during TENS. 
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Fig. 4.12 Mean percentage change in power spectrum and 
pain intensity rating (compared to pre-treatment baseline) 
during TENS treatment in chronic pain patients (Exp. 
4.3b). (a) Delta, theta and slow beta activity. (b) alpha power and 
frequency (n=16) P=paired t-test pre v during. 
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Peak Alpha Frequency: Baseline peak alpha activity ranged from 8.0-1 LOHz and 
no significant changes occurred during TENS (Mean change=-O. 1Hz, P=0.2). 
Beta: A hint of an increase in slow beta power (+4.6. tV2/Hz, P=0.1) was observed 
during TENS and 6 out of 15 patients showed an increase in slow beta activity of 1 
9V2/Hz or more. 
Main findings of Experiment 4.3 
(i) Wide inter-patient variability in baseline power was observed in all frequency 
bands. Variability between baseline cycles 1 and 2 was small and non significant. 
(ii) No relationships were found between baseline power and either baseline pain 
intensity rating, or the change in pain intensity during TENS. 
(iii) A significant reduction in pain intensity rating was observed during TENS 
when compared to pre-treatment baseline. 
(iv) General increases in theta, alpha and slow beta and decreases in delta activity 
were observed in both parts of the experiment during TENS, although these 
changes were small (less than lOpV2/Hz). 
(v) Under conditions to optimise the recording of fast wave activity (Exp. 4.3a) no 
significant changes in any of the power spectrum indices were observed during 
TENS, although there was a hint (P=0.09) of an increase in alpha activity. 
(vi) Under conditions to optimise the recording of low frequency activity (Exp. 
4.3b) a significant increase in alpha activity during TENS was observed (P=0.01). 
(vii) No relationships were found between the magnitude of this increase in alpha 
activity with the magnitude of reduction in pain intensity rating. A small but 
significant (P=0.05) increase in theta activity was also observed. 
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DISCUSSION 
Three experiments were performed to examine the effects of TENS on SEPs and 
spontaneous EEG. TENS was found to reduce the peak-to-peak amplitude of the 
N1P2 (140ms-260ms) SEP complex in healthy subjects, confirming previous reports. 
No significant changes in latency of these components were observed. TENS 
produced changes in spontaneous EEG in both healthy pain-free subjects and chronic 
pain patients. Thus, a significant increase in beta activity (and possibly alpha activity) 
was observed during TENS (compared to sham) in healthy subjects. TENS also 
produced significant increase in alpha activity in chronic pain patients, although no 
change in beta activity was noted. A small but significant increase in theta activity 
during TENS was also observed in pain patients, when conditions were optimised to 
record low frequency activity (Exp. 4.3b). No relationships between baseline power 
spectrum and either baseline pain intensity ratings, or the change in pain intensity 
during TENS were found to occur in the pain patients. These findings will now be 
discussed in detail. 
The effect of TENS on late components of the SEP 
The finding that TENS reduced the N1P2 peak-to-peak amplitude of the SEP confirms 
previous reports [Francini et al. 1982; Ashton et al. 1984b; Golding et al. 1986; 
Nardone & Schieppati 1989]. No significant changes in N1 or P2 latencies or intensity 
rating of the evoking stimulus occurred during TENS. 
Desmedt [1989] suggests that evoked potentials represent compound profiles built up 
of a sequence of distinct components of neuronal activity. The early waveform 
components of an EP reflect transmission of the afferent nerve volley, and initial 
thalamo-cortical processing and anticipatory mechanisms which prime the cortex for 
stimulus identification and evaluation. Later components (>80 ms) are involved with 
the perceptual processing that leads to stimulus identification. Distraction of attention 
can markedly reduce the size of these late SEP components and may therefore 
influence the effect of TENS on the SEP. Miltner et al. [1989] has shown that 
distraction can reduce the amplitude of late components of somatosensory evoked 
potentials elicited by both painful and non-painful stimuli and such attentional 
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manipulations can provide a powerful method to decrease the perception of pain. Sham 
TENS also reduced the N1P2 amplitude of the SEP, although to a lesser magnitude 
than active TENS, which suggests that the effects of placebo have played only a minor 
role. 
Golding et al. [1986] reported a reduction of the amplitude of both early and late 
components of SEPs during TENS, and as early potentials are less susceptible to 
changes in attention they suggested that TENS disrupted the flow of sensory 
information (i. e. the evoking stimuli) at a number of levels in the sensory nervous 
system. 
Recent evidence from Nardone and Shieppati [1989] suggests that TENS 'gates' 
somatosensory volleys both in the periphery, through a 'busy-line' effect on large 
diameter afferent fibres, and centrally at the level of cuneate nucleus. The group 
recorded far field and early near field SEPs at: (i) Erb's point, (ii) the spinous process 
of the sixth cervical vertebra (C6), and (iii) the scalp at C4 and C3. SEPs were elicited 
by electrical stimulation of the median nerve at the wrist or index finger in 15 healthy 
subjects and TENS was applied 1 cm proximal to the electrodes used to elicit the SEP. 
TENS reduced the amplitudes of incoming afferent volleys recorded at Erb's point 
which suggested a peripheral blockade of transmission of the SEP volley. This was 
attributed to a'busy line' effect in large diameter fibres, in which impulses evoked by 
the SEP stimulus may: (i) be in the absolute refractory period of those produced by 
TENS, or (ii) collide (antidromic collision) with those induced by TENS. To measure 
the central contribution of TENS, unconditioned reference SEPs were evoked by 
stimulating with a current strength yielding an Erb's point potential of an amplitude 
equal to that obtained during TENS. In this case the amplitudes of the early near field 
components of the SEP (N14 and N18) were greater than those recorded during TENS 
which Nardone and Schieppati attributed to the effects of TENS in the central nervous 
system (CNS), possibly at the level of the cuneate nucleus. 
In contrast, Golding et al. [1986] found reductions in amplitudes of both early and late 
SEP components but reported no change in wave amplitudes recorded at the median 
nerve, which suggested that TENS produced no peripheral blockade. However, no 
data in support of this statement was presented. Furthermore, no changes in the 
amplitudes of early components of the SEP were found by Francini et al. [1982]. 
However, difficulty in recording and identification of these small amplitude early 
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potentials from both Erb's point and the surface of the scalp may account for such 
discrepancies. As a reduction in N1P2 amplitude can be elicited from non-painful as 
well as painful stimuli, it appears that TENS effects at the cortical level are not 
exclusive to the pain system. 
Although the utility of the evoked response as a measure of treatment effects on the 
response to sensory stimuli has been demonstrated, marked inter-subject variability in 
both baseline SEP amplitudes and response to TENS were observed. Golding et al. 
[1986] suggested that baseline SEP amplitudes may be predictive of an individual's 
response to TENS and that individuals with large peak-to-peak N1P2 amplitudes 
produce greater response to TENS. No such relationships were observed in the present 
study. However, in this and the Golding et al. study, the intensity of the evoking 
stimulus was fixed subjectively (at a 'strong non-painful' level), and therefore subjects 
received different absolute current intensities. As peak-to-peak amplitudes of the SEP 
are dependent on the intensity of evoking stimuli, this makes comparisons of inter- 
subject baseline amplitudes difficult. The value of baseline SEP amplitudes as a 
predictive measure of response is examined in more detail in Chapter 6. 
The effect of TENS on spontaneous EEG 
Large inter-subject variability in both baseline spontaneous EEG measures and changes 
in spontaneous EEG during TENS, were found in both pain-free patients and chronic 
pain patients. However, some generalised TENS effects were found. These are 
summarised below: 
Exp. 4.2 Exp. 4.3a Exp. 4.3b 
(<->=no change) Pain-free subjects Pain patients Pain patients 
Delta <--> <--> <--> 
Theca <--> <--> Increase 
Alpha ? Increase? ? Increase? Increase 
Alpha frequency <--> not measured <--> 
Slow beta Increase <--> ? Increase? 
Fast beta <--> not measured <--> 
Pain intensity not measured decrease decrease 
Thus, a significant increase in alpha activity and a reduction of pain intensity rating 
occurred during TENS in chronic pain patients. This increase in alpha activity also 
occurred, although to a lesser extent, in pain-free subjects. Slow beta activity was 
found to increase during TENS in pain-free subjects and possibly in pain patients 
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under conditions optimising low frequency activity. A small but significant increase in 
theta activity was also found to occur during TENS in pain patients. 
Nevertheless, changes in power spectrum indices were small (less than 10IV2/Hz) 
across all frequency bands in both Experiments 4.2 and 4.3 and such small changes in 
power spectrum, accompanied with large inter-subject variability in baseline spectral 
indices, can hinder statistical comparisons. Hence, subjects with low baseline EEG 
activity may show smaller absolute changes in spontaneous EEG. Therefore 
percentage changes in power were calculated in an attempt to account for this inter- 
individual variability in baseline activity. This problem was highlighted in Experiment 
4.2 where subject 12 showed an decrease in alpha activity of -221V2/Hz (-22% of 
baseline power) whereas subject 6 showed an increase of +3.5pV2/Hz (+30.5% of 
baseline power). 
Furthermore, changes in spontaneous EEG appear to be more readily detected when 
conditions are optimised to increase low frequency activity by recording from occipital 
region with eyes closed. 
(a) Pain free subjects 
The effect of TENS on overall power spectrum was small when compared to sham 
TENS, although a significant increase in beta (and possibly alpha) activity was 
observed. The increase in beta activity from 14.7. V2/Hz to 19.0µV2/Hz (Table 4.5) 
was attributed to increases in beta activity in 6 out of 8 subjects in the TENS group 
compared with 2 out of 8 in the sham. However, a spurious increase in beta activity 
which occurred in post-TENS cycle 2 (Fig. 4.10), where mean beta activity rose by 
approximately 80% in the TENS group was attributed to a large increase in beta 
activity shown by subject 7 (Table 4.5). It has been suggested that rises in beta activity 
reflect heightened states of arousal, and that the increase in beta during TENS in pain- 
free subjects may in part be due to a change in arousal associated with the'unfamiliar' 
paraesthesia experienced during TENS. An alternative explanation may be an increase 
in asynchronous high frequency potentials produced by electromyographical (EMG) 
activity, although EMG was not prominent on examination of the raw EEG. 
Contamination with high frequency TENS artefact also seems unlikely as these 
artefacts can be easily identified on power spectrum graphs (Fig. 4.6). 
The general increase in alpha activity which was observed during TENS in healthy 
pain-free subjects was highlighted when data was transformed to percentage change in 
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alpha activity from pre-treatment baseline (P=0.064). Although the majority (6/8) of 
subjects showed some degree of increase in alpha activity during TENS, half (4/8) of 
the subjects receiving sham TENS also showed increases in alpha activity. Thus the 
increase in alpha activity observed during active TENS under these conditions may be 
due in part to placebo effects. 
In summary, increases in beta activity and possibly alpha activity occurred during 
TENS but not placebo in pain-free subjects. These changes may have been due to: 
(i) TENS interfering with general somatosensory processing, 
(ii) TENS activating analgesic mechanisms (i. e. release of opioids), 
(iii) TENS affecting attention/distraction, 
(iv) an overlying TENS placebo response, 
but this remains to be determined. Additional controlled experiments utilising larger 
sample size examining the effects of both acupuncture and TENS will be required to 
confirm these findings. 
(b) Chronic pain patients 
Experiment 4.3 was designed to optimise the recording of (a) beta activity and (b) 
alpha activity in separate populations of patients using TENS successfully to control a 
chronic pain condition. TENS significantly reduced chronic pain intensity in all 
patients coupled with a concurrent rise in alpha activity. This finding is consistent with 
that of Manna et al. [1984] who found an increase in alpha activity during the relief of 
tension headache in patients receiving acupuncture. In contrast to the present findings, 
Manna's group also showed significant reductions in delta and theta activity. 
However, theta activity was found to increase during TENS treatment under conditions 
to optimise the recording of alpha activity (Exp. 4.3b). No significant changes in delta 
or beta (fast and slow) power were observed in Exp. 4.3a and Exp. 4.3b, although an 
increase in slow beta activity occurred (P=0.1) when recording conditions were 
optimal for low frequency activity (i. e. a similar finding to that for healthy pain-free 
subjects, Exp. 4.2). 
TENS produced a significant reduction in pain intensity within 15 minutes in all 
patients, although this reduction was short lived and pain intensity ratings began to 
return to pre-treatment levels within 5 minutes of TENS switch-off. 
Although the increase in alpha, theta (and beta in Exp. 4.3b) activity, and decrease in 
delta activity, followed the same time course as changes in pain intensity rating (Table 
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4.8), no relationships were observed between the degree of increase in alpha and theta 
activity and the degree of pain reduction during TENS in Exp. 4.3b. Moreover, the 
results of Experiment 4.2 imply that alpha activity may increase during TENS 
application in pain-free subjects. Therefore, the effects of TENS on spontaneous EEG 
may be due to a combination of effects unrelated and related to pain. TENS effects 
unrelated to pain may include: 
(i) changes in the quality and quantity of sensory information reaching the cortex 
produced by the electrical paraesthesia, 
(ii) attentional/distractional changes. 
TENS effects related to the pain may include: 
(i) the reduction of the intensity and quality of the pain by sensory modulation 
(spinal 'gating') or the release of neuromodulators (i. e. opioids), 
(ii) TENS placebo effects [Levine et al. 1978]. 
However, as experiments examining the effects of TENS on EEG in pain patients were 
uncontrolled, further studies are necessary to substantiate these suggestions. 
Baseline spontaneous EEG and clinical pain 
No relationships were observed between baseline pain intensity rating and baseline 
power spectrum. Thus, no simple objective measure of clinical pain in its chronic state 
was found by measuring spontaneous EEG under the present conditions. 
Only recently has the effect of pain on spontaneous EEG activity been investigated. 
Three groups have examined the effects of experimental pain (cold-pressor) on power 
spectrum in healthy subjects. During immersion of a limb in cold water, Chen et al. 
[1990] found a rise in delta and beta activity; Gotliesben and Adrent-Nielsen [1990] 
found an increase in delta and a decrease in alpha; Backonja et al. [1990] found an 
increase in alpha. The variability of results obtained during essentially similar 
experiments may be due in part to: 
(i) different changes in power occurring in different regions of the brain, 
(ii) inter-individual variation in response to the pain stimulus, 
(iii) electrophysiological changes due to cold-pressor (circulatory) rather than 'pain' 
effects. 
With the advent of topographical brain mapping [Maurer 1989] measurement and 
analysis of regional changes in spontaneous EEG activity will be made easier. 
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However, experiments measuring EEG changes during an acute intervention of an 
experimental pain stimulus rather than a chronic condition, may represent changes in 
stress and vigilance [Chen et a]. 1990] rather than pain per se. Thus, it seems unlikely 
that an objective measure of pain in its chronic state will manifest in the spontaneous 
EEG due to the complex, 'fluid' nature of the brain's electrical activity, coupled with 
the lack of knowledge on the physiological significance of spontaneous EEG. 
Summary 
In summary, the results of experiments presented in this chapter have shown that: 
(i) TENS reduced the peak-to-peak amplitudes of late components of the SEP 
elicited by a non-painful stimulus in healthy subjects. 
(ii) TENS increased beta activity (and possibly alpha) of spontaneous EEG in pain- 
free subjects. 
(iii) In chronic pain patients, alpha (and possibly theta) activity increased during 
pain reduction by TENS. 
(iv) Wide inter-individual variability in baseline SEP amplitudes and spontaneous 
EEG were observed, although no relationships between the degree of response to 
TENS and these baseline measures were found. 
As the reduction in SEP amplitude did not depend upon a painful evoking stimulus, it 
is suggested that TENS effects are not specific to the pain system. This suggestion is 
supported by the finding that changes in spontaneous EEG activity occur during TENS 
in pain-free subjects. No relationships were observed between baseline EEG variables 
and patient response to TENS, although the patients investigated were long-term 
TENS responders. Differences in baseline measures may be more apparent between 
groups of non-responders and responders and the utility of baseline SEPs and 
spontaneous EEG as a predictor of response to TENS merits further investigation (see 
Chapter 6). 
Because of the rather non-specific changes in SEPs and spontaneous EEG during 
TENS (occurring with and without the presence of pain), it was decided to investigate 
the effects of TENS on neuropharmacological variables. Thus, Chapter 5 examines the 
effects of TENS on concentrations of opioid peptides and 5-hydroxytryptamine which 
may provide a more specific measure of TENS analgesic effects. 
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CHAPTER 5 
THE PHARMACOLOGY OF TENS 
ANALGESIA 
INTRODUCTION 
The pharmacology of the analgesic effects of TENS (and acupuncture) is poorly 
understood [for review see Thompson 1989; MacDonald 1989]. Research on 
antinociceptive mechanisms in the dorsal horn of the spinal cord and descending pain 
inhibitory pathways arising from supraspinal structures (Fig. 1.5) has suggested that 
many neurotransmitters and neuromodulators may be involved. These include 
serotonin (5-Hydroxytryptamine; 5-HT) [Yaksh 1979], noradrenaline [Xie et al. 
1983], dopamine [Fitzgerald 1986], gamma-amino butyric acid (GABA) [Duggan & 
Foong 1985], glutamate [Jensen & Yaksh 1984], opioid peptides [Sjölund & Eriksson 
1979; Mayer et al. 1977], and vasoactive intestinal peptide (VIP) [Kaada et al. 1984]. 
At present it appears that three substances (beta-endorphin, methionine-enkephalin 
(met-enkephalin) and 5-HT) play a fundamental role in antinociceptive mechanisms 
and may therefore be important in the mechanism of TENS analgesia. 
Opioid peptides (beta-endorphin and met-enkephalin) 
There is considerable evidence that endogenous opioids are involved in acupuncture 
analgesia and by implication in acupuncture-like TENS (AL-TENS). Indirect evidence 
is provided by studies using the opioid antagonist naloxone [for review see He 1987]. 
These show that acupuncture analgesia is reversed by naloxone both in patients with 
pain and in normal volunteers subjected to experimental pain [Mayer et al. 1977]. Direct 
measurement of opioid peptides has been hampered by difficulties in assay, but 
Clement-Jones et al. [1980b] demonstrated the release of beta-endorphin but not met- 
enkephalin into the cerebrospinal fluid (CSF) during acupuncture and 
electroacupuncture. A limited number of studies examining biochemical changes in the 
peripheral circulation have given conflicting results. Malizia et al. [1979] found an 
increase in plasma concentration of beta-endorphin during electroacupuncture in 
healthy subjects, while Kiser et al. [1983] reported increased plasma concentrations of 
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met-enkephalin but not beta-endorphin during acupuncture analgesia in 20 chronic pain 
patients. 
Less information is available concerning the involvement of endogenous opioids in 
TENS analgesia. Pain reduction during conventional (high frequency low intensity) 
TENS does not appear to be naloxone-reversible [Woolf et al. 1978; Abram et al. 1981; 
Freeman et al. 1983; Hansson et a1.1986]. However, Sjölund and Eriksson [1979] 
showed that AL-TENS does produce a naloxone-reversible analgesia. The release of 
beta-endorphin into the CSF during high intensity TENS has been reported in patients 
and normal subjects [Sjölund et al. 1977; Salar et al. 1981]. Conflicting reports exist 
on changes in plasma beta-endorphin in healthy subjects. O'Brien et al. [1984] found 
no significant changes in plasma beta-endorphin concentrations before, during or after 
AL-TENS in 42 healthy volunteers subjected to experimental pain subjects. In 
contrast, Facchinetti et al. [1984] found an increase in both plasma concentrations of 
beta-endorphin and beta-lipotrophin during high frequency TENS in 12 healthy 
volunteers. 
5-HT 
A role for 5-HT as a transmitter in the descending pain inhibitory pathways which are 
activated during acupuncture analgesia has been established [for review see Han & 
Terenius 1982]. Reports on 5-HT involvement in TENS analgesia is sparse although 
Woolf et al. [1980] found that analgesia obtained by segmental peripheral stimulation 
in the rat was significantly reduced by pre-treatment with the 5-HT depleting agent 
parachlorophenylalanine (PCPA). 
Aims of Chapter 5 
In view of the sparse and conflicting information outlined above, the aim of the present 
chapter was to measure changes in peripheral and CSF concentrations of beta- 
endorphin, met-enkephalin and 5-HT during TENS and acupuncture. Unfortunately 
ethical and financial restraints made it impossible to measure CSF concentrations 
within the time course of this work, although ethical approval and financial support has 
finally been obtained and an investigation started. Thus, a pilot experiment was 
conducted in collaboration with the Department of Biochemistry at Newcastle General 
Hospital to investigate changes in peripherally circulating opioid peptides and 5-HT in 
patients who obtained relief of chronic pain with TENS and acupuncture treatment. 
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EXPERIMENT 5.1 
The effect of TENS and acupuncture on concentrations of 
beta-endorphin, met-enkephalin and 5-HT in the peripheral 
circulation. 
Patients and subjects 
Thirteen chronic pain patients and 7 pain-free subjects (of similar age) participated in 
the present study (female n=13, male n=7; age range=25-75, mean=52.3 years of 
age). The chronic pain patients were randomly selected from Newcastle Pain Relief 
Clinic files to create the following groups: 
(i) TENS - seven patients whose pain was controlled successfully with TENS. 
(ii) Acupuncture - six patients whose pain was controlled successfully with manual 
acupuncture. 
Patients were requested not to use analgesics (including TENS and acupuncture) 12 
hours prior to the experiment. A third group, pain-free subjects, acted as a time control 
and consisted of seven pain-free members of the public with similar ages to the pain 
patients. These subjects were administered 'sham' TENS. The thirteen patients had a 
variety of chronic pain conditions (classified according to the International Association 
for the Study of Pain classification of chronic pain conditions [IASP 1986] and the 
author's classification [Johnson et al. 1991 a]) including: 
Experiment 5.1 
Anatomical (n) Aetiology (n) Diagnostic (n) 
Region 
Cervical 3 Trauma 
Upper limb 3 Infective 
Thoracic 1 Inflammatory 
Lower back 5 Degen. /mechan. 
Two sites or more I Dysfunctional 
Other/unknown 
Clusters 
4 Deafferentation 2 
2 Entrapment 2 
1 Neuralgia 3 
4 Spondylosis 3 
1 Myofascial 1 
1 Other/Unknown 2 
Procedure 
Subjects lay on a comfortable bed in a temperature controlled (21°C) room. A 12 ml 
sample of venous blood was taken from the antecubital vein, via an indwelling 
butterfly, every 15 minutes. Six experimental cycles (2 x pre-treatment; 2x during 
treatment; 2x post-treatment) were made. Both the TENS and sham TENS groups 
received 30 minutes stimulation (i. e. TENS was switched on immediately at the end of 
cycle 2 and switched off after cycle 4). Acupuncture needles were inserted immediately 
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at the end of cycle 2 and removed after cycle four. Patients completed a visual analogue 
pain rating scale (0 = no pain to 10 = worst pain imaginable) at the end of each cycle to 
assess the intensity of their pain at that particular time. 
Treatment 
TENS: Patients were in possession of either a Microtens 7757 or Tiger Burst 
stimulator and Tenzcare electrodes (3M-no. 6225). Patients were asked to administer 
TENS to the usual anatomical site to control their pain. All patients applied their 
electrodes to achieve a 'strong but comfortable' electrical paraesthesia within the 
painful area. None used AL-TENS. The electrical characteristics of TENS, as 
monitored with the Frye Analyser, were: 
pulse pattern continuous n=5 burst n=2, 
pulse width 200µs 
pulse frequency median=43Hz range=22-204Hz 
pulse amplitude median=l4mA above SDT range=5-37mA above SDT 
electrode impedance <2kohm. 
Pain free subjects: These were used to compare pre-treatment baseline measures 
with pain patients and as time controls. Thus, sham TENS was administered with a 
coloured suggestion that "TENS is stimulating at a subthreshold level which you may 
not feel yet we still expect it to change the levels of substances we are measuring in the 
blood. ", as previously described in Chapter 3. Electrodes were applied to the lower 
back straddling the spinal cord at Ll/L2. No subjects questioned this procedure. 
Acupuncture: Patients were regularly attending Professor J. W. Thompson (JWT), a 
trained acupuncturist, for treatment of chronic pain and were all known to respond. 
Acupuncture was administered by JWT to points normally used to control the pains of 
these patients. One to 7 needles (depending upon the patient) were inserted for a period 
of 30 minutes, and intermittently twirled. 
Collection and preparation of samples 
Twelve ml of venous blood was collected from the antecubital vein, 2 ml of which was 
stored in an Eppendorf tube at -10°C for 5-HT analysis. The remainder of the blood 
was split into two 5m1 plastic EDTA tubes each containing 50 µl of 2.3 M citric acid, 
mixed and centrifuged at 14,000 rpm for 30s. Plasma was decanted into plastic tubes 
containing 150µl glycine HCL buffer (1.6% glycine in 1M-HCL)/ml plasma, and flash 
frozen in liquid nitrogen and stored at -80°C [Clement-Jones et al. 1980b]. 
All opioid peptide assays were performed by Miss A. Weddell (AW) in the Department 
of Biochemistry at Newcastle General Hospital. Mrs S. Wright-Honari performed 
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5-HT assays in the Department of Psychiatry at the University of Newcastle upon 
Tyne. The following procedures were employed. 
Beta-endorphin: Beta-endorphin was assayed by a two-site, solid phase 
immunoradiometric method supplied by Nichols Institute, San Juan Capistrano, USA 
[for reference see Allegro], employing antibodies recognising two separate epitopes on 
the beta-endorphin molecule - one immobilised on to a plastic bead and the other radio- 
labelled with 1251 thus forming a 'sandwich' complex with the peptide [Wardlaw & 
Frantz 1979]. 
200µl of plasma were incubated with l00µ1 of labelled antibody in the presence of the 
antibody coated bead for 24 hours at room temperature. Samples and control plasma 
were assayed simultaneously using a standard curve. After aspiration and twice 
washing with 2.5m1 of phosphate buffered saline to remove any unbound labelled 
antibody, the tubes were counted for two minutes in a NE 1600 gamma counter and 
values read from the computer generated IRMA-SPLINE curve fitting. The assay has a 
sensitivity of 2.9 pmol/1 and a normal range of 3 to 11 pmol/l. It shows a cross- 
reactivity of 16% with beta-lipotrophin. 
Met-enkephalin: Met-enkephalin was assayed by radioimmunoassay (RIA) using 
reagents supplied by Incstar Corp., Stillwater, USA [for reference see Immuno 
Nuclear Corporation], after an initial extraction technique. Plasma samples were 
acidified with 1M HCL (100µl) and allowed to thaw at 4°C before addition to a C18 
Sep-pac cartridge activated with methanol and washed with water. Samples were 
applied under reduced vacuum ensuring contact with the ODS silica for a minimum of 
3 minutes. After washing with acetic acid (4%) the sample was eluted with methanol 
(1.6m1) dried at 37°C to 500 µl and freeze dried then reconstituted in RIA buffer 
(500µl of 25% human serum albumin in 0.05M phosphate pH 7.4) prior to RIA. 
Frozen aliquots of the top aqueous standard (2175 pmol/1) were serially diluted with 
buffer for the standard curve. Standards and samples (200µ1) were incubated with 
antisera (100µl of 1/900) and tracer (100µl) for 24 hours at 4°C before separation of 
bound from free tracer by precipitation with rabbit gamma globulin (100µ1) and 
saturated ammonium sulphate solution (500µ1). After decanting, the tubes were 
counted for two minutes in a NE 1600 gamma counter; the amount of antibody bound 
label being inversely proportional to met-enkephalin in the tube. Sample concentrations 
were read from the computer generated non-linear standard curve fitting. The assay 
had a sensitivity of 35 pmol/l and a within batch precision of 11.7% at 475 pmol/1 and 
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10.1% at 982 pmol/l (n=15); recoveries above 94% were obtained [Clement-Jones et 
al. 1980a]. 
-5-HT. - A 1ml sample of blood which was kept in the freezer was defrosted and 5-HT 
assay was performed according to Marshall et al. [1987]. 450 µl of distiled water was 
added to 150µ1 of defrosted blood and 100µl of zinc sulphate (10% w/v) was added to 
this aliquot, mixed thoroughly and centrifuged at 12000g for 7 minutes. Sodium 
hydroxide was added (20µl: 20% w/v) to an aliquot (400µl) of the supernatant, mixed 
well and centrifuged at 12000g for 7 minutes. Supernatant was removed to 
autosampler tubes for subsequent assay by HPLC, using electrochemical detector. 
Stock solutions of 5-HT (100mg/1) were prepared in water and kept in aliquots of 
O. lml at -20°C. Standard solutions (final concentration of 100µg 5-HT/1) were 
prepared from the stock solutions in buffer taken through the procedure and assayed 
every fifth sample. All the samples and standards were measured in duplicate. Blanks 
were not included in every assay as no peaks apart from the solvent front appeared on 
the resulting chromatogram. The assay had a sensitivity of 4µg/l. 
Results of Experiment 5.1 
Prior to statistical analysis data was transformed to allow for the sensitivity of the 
assay, thus: 
(i) beta-endorphin levels below the sensitivity of the assay (<2.9pmol/1) were 
transformed to 2.9pmol/l, 
(ii) met-enkephalin levels below the sensitivity of the assay (<35. Opmol/1) were 
transformed to 35. Opmol/l. 
No measurements of 5-HT fell below the sensitivity of the assay. A logarithmic 
transformation was performed to take into account the skewed distribution and marked 
heteroscedascity (i. e. increase in SD with increasing mean) of the data as shown in 
Table 5.1. 
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Pre I 
-15mins 
Pre 2 
-0lmins 
CYCLE 
During 1 During 2 
+15mins +30mins 
Post 1 
45n-tins 
Post 2 
60mins 
Beta-endorphin 
1 O 
Pain Free 6.213.3 6.3±2.8 5.3±2.6 4.6±2.1 5.7±2.7 4.4±1.8 
Acupuncture 5.0±1.6 5.5±2.7 5.9±3.6 4.8±1.8 4.1±1.4 5.5±2.3 
TENS 5.8±1.9 4.9±1.0 5.5±1.4 5.7±2.4 5.5±2.3 5.1±1.6 
Met-enkephalin 
1 (P0 L-) 
Pain Free 48.1±17.7 48.6±22.4 47.7±22.0 52.8±39.7 51.4±29.8 54.6±27.2 
Acupuncture 43.7±14.6 44.2±14.0 48.8±18.0 40.0± 7.6 42.5±13.8 41.7±10.9 
TENS 61.5±25.2 49.9±19.4 86.3140.9 84.7±48.8 72.5±43.2 90.4±58.8 
5-HT (ugl-1) 
Pain Free 67.7±32.1 70.7±38.7 74.6±43.2 75.7±39.7 75.3±40.6 67.7±28.4 
Acupuncture (n=5) 91.8148.8 99.4±56.8 98.8±51.7 113.0±54.8 105.4±51.9 103.0±57.2 
TENS 81.6t5 1.0 79.3±40.6 80.7±45.9 76.3±54.6 90.1±47.6 95.0±46.5 
Pain Intensity 
(VAS units) 
Pain Free 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
Acupuncture 5.5±1.0 5.7±0.9 4.2±2.0 3.4±2.2 3.3±2.2 3.5±2.5 
TENS 3.5±2.6 3.2t2.8 1.5±1.4 0.7±0.9 1.1±1.4 1.2±1.7 
Table 5.1 Mean±SD concentrations of peripherally 
circulating substances during TENS (n=7) and acupuncture 
(n=6) in chronic pain patients (Exp. 5.1). 
No significant differences were observed between the pre-treatment recordings of cycle 
1 and 2 for beta-endorphin, met-enkephalin and 5-HT (Paired t-test irrespective of 
treatment groups). These pre-treatment values were also found to be highly correlated 
(Pearson correlation coefficients, r >+0.8). Thus, pre-treatment baseline mean was 
calculated for each individual for each analyte measured; no significant differences in 
these pre-treatment means were found between treatment groups (one-way ANOVA) 
However, patients in the acupuncture group had higher baseline pain intensity ratings 
than those in the TENS group although this just failed to reach significance (P=0.1 
unpaired t-test, see Table 5.2). General treatment effects were examined by calculating 
the mean of the 2 'during treatment' cycles and the 2 'post-treatment' cycles for each 
individual as shown in Table 5.2. Thus, the pre-treatment mean was subtracted from 
the during and post treatment values for each individual to obtain the change from pre- 
treatment baseline and one-way ANOVA and unpaired student t-tests were used to 
examine differences between groups. 
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Pain Rating: Fig. 5.1 shows a significant reduction in pain intensity rating during 
both TENS and acupuncture, when compared to pre-treatment baseline, which was 
sustained in post-treatment cycles (mean±SD TENS; pre=3.3±2.7, during=1.1±1.0, 
P<0.05: Acupuncture: pre= 5.6±0.9, during= 3.8± 2.0, P<0.05, paired t-test). No 
significant differences were observed between TENS and acupuncture groups 
(unpaired t-test). 
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Fig. 5.1 Mean change in pain intensity rating (measured on 
a VAS) during TENS (n=7) and acupuncture (n=6) in 
chronic pain patients (Exp. 5.1). Pain-free subjects (n=7) received 
sham TENS. Time = minutes. 
Beta-endorphin: Pre-treatment levels irrespective of treatment group (Mean=5.6 
pmol/l, range <2.9-11.3pmol/1) were similar to those reported by the RIA kit 
manufacturers (Mean=8.4 pmol/1 n=83 healthy subjects, [see reference Allegro]). A 
wide range of baseline plasma concentrations of beta-endorphin have been reported in 
healthy subjects (mean±SD): 
(i) 16.7±4.0 pmol/l [Malizia et al. 1979], 
(ii) 6.1±2. lpmol/l [Wardlaw & Frantz 1979], 
(iii) 9.7 pmol/1 [O'Brien et al. 1984]. 
The mean pre-treatment baseline level of beta-endorphin recorded from pain-free 
subjects in the present study was 6.14±3.21pmol/1 and not significantly different from 
pain patients (unpaired t-test). No significant changes in beta-endorphin were observed 
between the treatment groups (one-way ANOVA see Fig. 5.2). 
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Fig. 5.2 Mean change in concentration of peripherally 
circulating beta-endorphin during TENS (n=7) and 
acupuncture (n=6) in chronic pain patients (Exp. 5.1). Pain- 
free subjects (n=7) received sham TENS. 
Met-Enkephalin: Pre-treatment met-enkephalin levels irrespective of treatment 
group (mean=49.2 pmol/l, range=<35.0-100. Opmol/1) were consistent with Clement- 
Jones et al. [1980b] (14-140 pg/ml (7-70pmol/1), but broader than RIA kit 
manufacturers (range=14-61 pmol/l n=9 healthy subjects). Of interest is the 
manufacturer's report of met-enkephalin levels of 14 pmol/l despite the sensitivity of 
the assay being 35pmol/l! [see reference Immuno Nuclear Corporation]. No significant 
differences in plasma met-enkephalin were observed between pain-free subjects and 
pain patients. Met-enkephalin was found to increase in all patients during TENS and 
one subject dominated these results with an increase from <35.0-161pmol/1 (Table 
5.2). The increase in met-enkephalin during TENS just failed to reach statistical 
significance when compared to either pain-free or acupuncture groups (mean±SD 
change in met-enkephalin during treatment: TENS=+32.6±42.9 pmol/l, Pain- 
free=+ 1.9±22. Opmol/l, P<0.1; Acupuncture=-0.9±10.6pmol/1, P<0.09, unpaired t- 
test, see Fig. 5.3). 
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Fig. 5.3 Mean change in concentration of peripherally 
circulating met-enkephalin during TENS (n=7) and 
acupuncture (n=6) in chronic pain patients (Exp. 5.1). Pain- 
free subjects (n=7) received sham TENS. 
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5-HT: Pre-treatment levels (mean=80.3µg/1 range 40-194 µg/1) were similar to those 
reported by Marshall et al. [1987] (90-140µg/1). No significant changes in 5-HT 
occurred during or post-treatment in any groups although all groups showed an 
increase in 5-HT post-treatment when compared to pre-treatment baseline (Fig. 5.4). 
However, examination of individual results showed that a post-TENS increase in 5- 
HT of over 10µg/l occurred in 5 out of 6 patients (see Table 5.2). 
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Main Findings Experiment 5.1 
(i) An increase in peripheral met-enkephalin concentration occurred during TENS 
although this increase just failed to reach statistical significance when compared to 
pain-free subjects who received sham TENS (P=0.1). 
(ii) No significant differences in peripheral concentrations of opioid peptides or 5- 
HT were found between pain-free healthy subjects and chronic pain patients. 
(iii) No significant changes in peripheral concentrations of opioid peptides or 5-HT 
were found after treatment with TENS or acupuncture. 
(iv) During a 30 minute treatment session, TENS and acupuncture significantly 
reduced the intensity of chronic pain in patients. 
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DISCUSSION 
The main finding of the present study was an increase in plasma met-enkephalin which 
occurred in all pain patients during TENS treatment. However, this rise in met- 
enkephalin just failed to reach statistical significance when compared to pain-free 
patients receiving sham TENS. Acupuncture produced no such increase. Both TENS 
and acupuncture had little effect on plasma beta-endorphin or 5-HT. Both TENS and 
acupuncture significantly reduced pain intensity ratings within 15 minutes of 
administration. The possible mechanisms of these changes in relation to analgesic 
effects are discussed below. 
Met-enkephalin 
The increase in met-enkephalin during TENS in chronic pain patients is interesting in 
that no such report has been noted previously. However this finding needs to be 
confirmed in a larger study sample. Met-enkephalin has been implicated in central 'pain 
modulating' mechanisms due to the high concentration of enkephalins localised within 
the substantia gelatinosa of the dorsal horn of the spinal cord [Bennett et al. 1982]. 
Thus, enkephalinergic interneurones may play an important part in TENS analgesia. 
However, it seems unlikely that the peripheral change in met-enkephalin as measured 
in this and other experiments [Clement-Jones et al. 1979; Clement-Jones & Besser 
1983] was due to central release because met-enkephalin cannot cross the blood brain 
barrier as a consequence of poor lipophilic properties. Met-enkephalin is also rapidly 
degraded by a number of circulating, non-specific, amino- and metallo-peptidases 
resulting in a half life of 2 to 3 minutes [Hambrook et al. 1976]. As time from 
venepuncture to flash freezing may take up to 5 minutes it is possible that variations in 
time to flash freezing may seriously alter met-enkephalin concentrations. However 
sample handling was standardised by one individual and it therefore seems unlikely 
that differing degrees of degradation can account for all of the observed increases in 
met-enkephalin concentration during TENS. 
Enkephalins are widely distributed in the peripheral nervous system including high 
concentrations in the adrenal medullary chromaffin cells [Clement-Jones et al. 1980c], 
other sources being the gut, sympathetic ganglia and peripheral autonomic neurones 
[Smith et al. 1981]. It has been suggested that, during stress, enkephalins are released 
along with adrenaline and reach the nervous system through the circulation. Stress is 
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an important and potent activator of the analgesic system and a variety of non-painful 
stressors (restraint, hypoglycaemia) can induce a naloxone-reversible analgesic state 
[Fields 1987b]. Thus, the increase in peripherally circulating met-enkephalin noted in 
this experiment during TENS may be due to a stress-like release mechanism. 
Met-enkephalin has been implicated in acupuncture analgesia and Kiser et al. [1983] 
reported increases in plasma met-enkephalin but not beta-endorphin during 
acupuncture treatment of twenty chronic pain patients. By contrast, Clement-Jones et 
al. [1980b] reported no significant changes in CSF met-enkephalin in 10 pain patients 
successfully treated with low frequency acupuncture. Our findings show no change in 
plasma met-enkephalin levels during symptomatic relief of chronic pain using 
acupuncture, although it is possible that changes may occur outside the time course of 
this experiment. 
Beta-Endorphin 
Studies suggest that chronic pain patients have lower CSF concentrations of beta- 
endorphin-like material than pain-free patients [Sjölund et al. 1977; Akil et al. 1978; 
Almay et al. 1978]. Reports on levels of plasma beta-endorphin in chronic pain 
patients are less readily available. The present study showed no significant differences 
in plasma levels of beta-endorphin between pain-free subjects and chronic pain 
patients. However it has been reported that CSF concentrations of beta-endorphin are 
substantially higher than those found in plasma (i. e. 27-144 pmol/1 n=10, Clement- 
Jones et al. [1980c], for review see Clement-Jones & Besser [1983]). 
It seems unlikely that beta-endorphin would cross the blood brain barrier due to its 
large size. Terenius [1979] suggested that endorphins produced within the peripheral 
circulation would be less likely to be involved with pain reducing mechanisms than 
endorphins produced within the CSF. Our findings lend support to such a theory as no 
peripheral changes in beta-endorphin were detected during symptomatic relief of 
chronic pain by acupuncture and TENS. Thus, the present study does not support the 
findings of Malizia et al. [1979] who reported increased plasma beta-endorphin during 
acupuncture. However it is possible that a delayed increase of plasma beta-endorphin 
may have occurred outside the time course of the experiment. Our findings are 
consistent with those of O'Brien et al. [1984] and contrast with those of Facchinetti et 
al. [1984] in that no changes in plasma beta-endorphin after TENS were observed. The 
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lack of change in CSF levels coupled with the evidence showing the ineffectiveness of 
naloxone to reverse analgesia produced by low intensity high frequency TENS 
suggests that beta-endorphin does not play a role in conventional TENS [Sjölund & 
Eriksson 1979]. 
5-HT 
No change in platelet 5-HT occurred in any group during or post-treatment in the 
present study. No significant differences in pre-treatment 5-HT were observed 
between chronic pain patients and pain-free subjects. Thus, the present findings do not 
support those of Mao et al. [1980] who reported higher baseline peripheral 
concentrations of 5-HT in healthy subjects as opposed to chronic pain patients. 
Although serotonin does not pass the blood brain barrier its precursor tryptophan does 
and thus peripheral 5-HT may reflect central 5-HT [Messing & Lytle 1977]. 
Nevertheless, the relationship between central and peripheral 5-HT remains to be 
determined [Mao et al. 1980]. Cheng and Pomeranz [1981] using mice, suggested that 
high-frequency noxious stimulation (electroacupuncture) did not activate the release of 
endorphins but may result in 5-HT release. Woolf et al. [1980] found that analgesia 
produced by segmental peripheral stimulation in the rat was significantly reduced by 
pre-treatment with PCPA or by spinalisation. It has been established that serotonergic 
neurones form part of descending pain inhibitory pathways in the CNS (see Fig. 1.3). 
However 5-HT is considered as a pain-producing substance in the periphery 
(excitation of tissue chemoreceptors) when liberated as a result of injury. 
Summary 
The main finding of this preliminary study was the first known report of an increase in 
plasma met-enkephalin but not beta-endorphin during TENS analgesia in chronic pain 
patients. Whether this increase is confined to patients who obtain relief of pain during 
TENS, or whether it also occurs during TENS in pain-free subjects remains to be 
determined. Hence it is uncertain if such an increase in met-enkephalin plays a role in 
the relief of pain accompanying TENS. Acupuncture produced no changes in any of 
the biochemical variables measured although a significant reduction in pain intensity 
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was obtained. No differences in any pre-treatment biochemical measures were 
observed between pain-free subjects and pain patients but because of small sample 
numbers these findings need to be substantiated. 
The previous chapters have examined the clinical use of TENS by chronic pain 
patients, the optimal characteristics of TENS to reduce experimental pain and the 
effects of TENS on the electrical activity of the brain and peripheral concentrations of 
opioid peptides and 5-HT. Thus clinical, electrophysiological and 
neuropharmacological factors have been shown to be influenced by TENS. The 
relationship between these factors and patient response to TENS is examined in 
Chapter 6. 
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CHAPTER 6 
FACTORS RELATED TO 
PATIENT RESPONSE TO TENS 
INTRODUCTION 
"After 7 years familiarity with transcutaneous stimulation, the present authors are 
still unable to predict whether or not a particular patient will obtain long lasting 
pain relief. " Bates and Nathan [1980]. 
At present it is still not possible to predict whether a patient will respond to TENS. 
Consequently TENS is administered on an empirical basis. However, the results 
presented in Chapter 2 suggest that 41.4% of patients given a trial of TENS fail to 
respond. Therefore it is important to investigate factors which may be related to patient 
response to TENS in order to elucidate the underlying mechanisms of treatment failure 
and thus to improve clinical efficacy. These factors are discussed below. 
Factors related to pain 
As indicated in Chapters 1 and 2, some pain conditions (e. g. visceral and psychogenic) 
are less likely to respond favourably to TENS than others (see Table 1.2a and b). 
Johansson et al. [1980] searched for predictors of TENS response in 72 patients and 
found that patients with neurogenic or extremity pain showed favourable responses. 
However, only short-term TENS effects were observed and patients were classified as 
responders and non-responders on the basis of a 30 minute treatment session. By 
contrast, Reynolds et al. [1983] found no association between the site and cause of 
pain in 200 patients and treatment outcome, but reported that patients with pain of more 
than one year duration showed less favourable responses to TENS. It is most 
frustrating to both physician and patient when TENS fails to control a pain condition 
which normally responds. This suggests that factors unrelated to pain may influence 
patient response. Despite a large number of trials which have examined TENS efficacy 
Chapter 6: Factors related to patient response to TENS 156 
in the treatment of a variety of pain conditions, few studies have examined factors 
unrelated to pain which may influence patient response. 
Factors unrelated to pain 
A number of pre-existing sociological, psychological, electrophysiological and 
neuropharmacological factors may determine patient response to TENS. 
Sociological 
Reynolds et al. [1983] examined the value of questionnaires which recorded pre- 
existing physical and social factors in determining the response of 200 chronic pain 
patients to TENS. Patients who used tranquillisers, had undergone multiple surgical 
operations, or were unemployed because of the pain condition, were found to respond 
poorly to TENS, although none of these factors reached statistical significance. 
Success with TENS was found in retired patients. Age, sex, and the use of analgesics 
were not found to reflect patient response to TENS, a finding consistent with that of 
Johansson et al. [1980]. 
Psychological 
Nielzen et al. [1982] examined the effects of psychiatric and physical disorders on the 
success of TENS in 66 chronic pain patients and found that mentally ill patients, 
patients with pathological personality traits, and patients without any physical cause for 
pain were failures to TENS treatment. Johansson et al. [1981] found that patients with 
high 'Lie' scores on the Eysenck Personality Inventory (EPI, the forerunner to the 
EPQ) showed favourable responses. The 'Lie' score measures the consistency of 
answering within the questionnaire although it may also reflect social compliance. 
Therefore the EPQ may be of value in predicting patient response to TENS. 
Evoked Potentials 
The results presented in Chapter 4 have shown that TENS reduces the peak-to-peak 
amplitudes of late latency waveform components of the SEPs. No relationships were 
observed between baseline SEP amplitudes and response to TENS although only pain- 
free subjects were examined (Exp. 4.1). The predictive value of SEPs in determining 
TENS response was discussed by Golding et al. [1986] who suggested that subjects 
with large baseline SEP amplitudes (both early and late latency components) produce a 
greater reduction of both SEP amplitudes and experimental pain during TENS. 
However subjects received different current intensities of evoking stimuli to elicit the 
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SEP, which had been fixed perceptually to produce a 'strong non-painful' electrical 
pulse. As baseline SEP amplitudes are related to the current intensity of the evoking 
stimuli, inter-individual differences in SEP amplitudes may have been due in part to 
inter-individual differences in the current intensity of the evoking stimuli. Furthermore 
healthy pain-free subjects rather than patients with a chronic pain condition were 
examined. The utility of SEP amplitudes in predicting patient response to TENS merits 
further investigation. It has been suggested that individuals producing 'augmenting' 
responses to visual evoked potentials may show more favourable responses to TENS 
[Johansson et al. 1981]. 
AugmenterslReducers 
The concept that certain individuals can be described as 'augmenters' or 'reducers' 
according to the way in which they respond to different intensities of sensory stimuli 
was originally proposed by Petrie [1967] to account for individuality in pain and 
suffering. It was suggested that augmenters tend to enlarge their perception of sensory 
stimuli at increasing stimulus intensities while reducers tend to diminish their 
perception at increasing stimulus intensities. The idea of augmenters and reducers has 
received some support from evoked potential studies, and it has been shown that 
augmenters increase peak-to-peak amplitudes of SEP waveform components with 
increasing intensities [Buchsbaum & Silverman 1968; Buchsbaum 1976]. It has been 
suggested that augmenters have a low tolerance to pain and respond favourably to 
analgesic treatment [Buchsbaum 1984]. Johansson et al. [1981], investigated 
augmenting/reducing responses in a group of 30 chronic pain patients and found that 
augmenters to visual evoked potentials (i. e. increase in peak-to-peak amplitude of 
visual evoked potential waveform components with increasing stimulus intensity) 
showed a favourable response to TENS. Reducers responded poorly to TENS. 
Spontaneous EEG 
No previous studies have investigated the relationship between baseline spontaneous 
EEG and response to TENS. However the results presented in Chapter 4 suggest that 
TENS produces variable effects on spontaneous EEG in both pain-free subjects and 
pain patients. Although no relationships were found between baseline spontaneous 
EEG and patient response to TENS (Exp. 4.3), the patient population was biased 
toward responders. A comparison between responders and non-responders is therefore 
necessary. 
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Experimental pain threshold 
The results presented in Chapter 3 found wide inter-subject variability in response to 
TENS in healthy subjects experiencing experimental pain. Although response to TENS 
was not related to an individual's baseline pain threshold, comparisons were made 
difficult as subjects were assigned to different treatment groups and consequently 
received differing electrical characteristics of TENS. Golding et al. [1986] found that 
subjects with low baseline thresholds to experimental pain produced larger responses 
to TENS consistent with the augmenting/reducing concept. Thus, responders would 
correspond to patients with low baseline pain threshold and large baseline SEP 
amplitudes. Unfortunately, Golding et al. did not correct pain threshold measurements 
for inter-individual variations in sensory detection threshold so that high uncorrected 
pain threshold measurements may have been due in part to high sensory detection 
thresholds. 
Neuropharmacological 
The results of Exp. 5.1 suggest that plasma concentrations of met-enkephalin may 
increase during TENS whereas no significant changes in peripheral concentrations of 
beta-endorphin or 5-HT were observed during TENS. Johansson et al. [1981] 
investigated the relationship between baseline CSF endorphin concentrations and 
response to TENS in 22 patients and found that TENS responders had lower levels of 
fraction I level endorphins. This was consistent with the group's previous work [von 
Knorring et al. 1979] which suggested that augmenters had lower levels of endorphins 
in CSF. Although measurement of levels of CSF opioids was not possible in the 
present investigation, plasma levels of opioid peptides may reflect patient response to 
TENS. 
Aims of Chapter 6 
Previous studies in this thesis have examined the effects of TENS on a number of 
clinical, psychological, electrophysiological and neuropharmacological factors in both 
pain-free subjects and chronic pain patients. Hence TENS was found to: 
(i) reduce chronic pain in patients and experimental pain in healthy subjects (Study 
2.2 and Exp. 3.1,3.2,3.3), 
(ii) reduce peak-to-peak amplitudes of late latency components of the SEP in healthy 
subjects (Exp. 4.1), 
(iii) increase a combination of alpha, beta and theta activity of spontaneous EEG in 
chronic pain patients (Exp. 4.3) and pain-free subjects (Exp. 4.2), 
(iv) increase plasma concentrations of met-enkephalin in pain patients (Exp. 5.1). 
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Factors related to patient response to TENS are largely unknown. Therefore, a 
prospective study was undertaken to investigate the relationship between a variety of 
baseline measures and the response to TENS in patients undergoing a trial of TENS 
for the treatment of a chronic pain condition. The study was double-blind in that both 
patient and experimenter did not know whether the patient would respond to treatment. 
Thus the aim of the study reported in Chapter 6 was to investigate the relationships 
between pre-existing: 
(i) psycho-social factors, 
(ii) experimental pain threshold and tolerance measurements, 
(ii) evoked potential amplitudes and spontaneous EEG recordings, 
(iii) plasma concentrations of opioid peptides, 
and patient response to TENS. 
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EXPERIMENT 6.1 
Factors related to patient response to TENS 
Patients and Procedure 
Twenty nine patients (female n=16, male n=13; age range=30-75, mean=52.2 years of 
age) with a variety of chronic pain conditions participated in the study. All new patients 
given a trial of TENS were asked to attend the research unit prior to the follow-up 
appointment at the clinic (between 1-2 months). Patients on psychotropic drugs or with 
mobility problems were excluded from the study. 
TENS Questionnaire: Patients completed a modified TENS multiple choice 
questionnaire designed to record pre-existing sociological variables and the use of 
TENS in the month prior to attending the research unit (see Appendix A). Recordings 
included: patient details, occupation, length of current pain condition, whether 
employment was lost due to the pain, stimulator model and settings used, the number 
of hours of stimulator use, the degree of pain relief obtained, time to onset and offset 
of analgesia and any adverse reactions. In addition visual analogue scales were used to 
assess the patient's: 
(i) opinion on the adequacy of instruction on stimulator use by the clinic, 
(ii) initial confidence in treatment success, 
(iii) opinion on the logic of TENS as a treatment for chronic pain. 
Electrical characteristics of TENS: The electrical characteristics of TENS during 
treatment were recorded on a Frye Analyser as previously described in Chapter 2. 
Patients were asked to apply TENS as they usually would to control their pain. 
Personality, anxiety and depression: All patients completed an Eysenck 
Personality Questionnaire (EPQ) [Eysenck & Eysenck 1975] and a Hospital Anxiety 
and Depression (HAD) scale [Zigmond & Snaith 1983]. 
EEG recording: General recording techniques have been described in Chapter 4. 
The following recordings were made: 
(i) auditory evoked potentials (AEP), 
(ii) somatosensory evoked potentials (SEP) to two intensities of electrical stimuli 
(i. e. 2.5 and 5.0 mA above SDT), 
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(iii) spontaneous EEG with eyes open and closed. 
Recordings were made in the morning; electrode positions were Cz (vertex) and Nz 
(nasion) referenced to LM (linked mastoids). 
(i) Auditory Evoked Potential (AEP): Recorded as a measure of general 
cortical response to sensory stimuli. AEPs were recorded to 30 tones (1000Hz, 60dB, 
200ms) delivered through earphones at randomly varied intervals 1-3s. Patients were 
asked to count mentally the number of tones so as to standardise attention across the 
group. Amplifier settings: high pass filter=0.2s, low pass filter=30Hz, range=100µV 
[for full description of AEP recording see Ashton et al. 1988]. 
(ii) Somatosensory Evoked Potential (SEP): SEPs were recorded as a 
measure of patient response to electrical stimuli at two current intensities: 
(a) 2.5mA above SDT, 
(b) 5. OmA above SDT. 
The evoking stimulus was delivered as a monophasic, square wave electrical pulse 
(pulse width=200µs). Thirty stimuli were delivered randomly in time (inter-stimulus 
interval between 1-3 s) via two electrodes straddling the proximal interphalangeal joint. 
Amplifier settings: high pass filter--1s, low pass filter=1KHz, range =100µV. 
Latencies and peak-to-peak amplitudes of P1N1, N1P2 and the Root Mean Square 
value between 50-550 ms were calculated for each individual. Root Mean Square 
(RMS) value was taken as a general measure of response to stimuli. RMS value was 
calculated as the square root of the mean of the squared deviation of the waveform 
from baseline, for all data points lying between the time window 50-550 ms [Golding 
et al. [1986]. 
(iii) Spontaneous EEG: Spontaneous EEG was recorded with eyes open and eyes 
closed. Each recording acquired 25,2 second epochs and averaged power spectra were 
computed off-line using fast fourier transform. Power spectrum (µV2/Hz) was 
analysed in the traditional frequency bands as described in Exp. 4.2. Amplifier settings 
were set to optimise the recording of slow wave activity as follows: high pass 
filter=0.2s, low pass filter=30Hz, range=100µV. 
Sensory detection threshold, pain threshold and pain tolerance: Sensory 
detection threshold, (SDT), pain threshold and pain tolerance were determined using 
square wave electrical stimuli delivered to the index finger of the left hand, via two 
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0.5cm2 carbon rubber electrodes (the same as used to elicit SEPs) straddling the 
proximal interphalangeal joint. Stimuli were presented at a frequency of 10Hz and a 
5ms pulse width, as such parameters have been found reliable in inducing an aching 
pain sensation (unpublished observations). SDT was recorded as the current at which 
'you can feel the first electrical pulses', pain threshold as the point at which the 
pulses first become painful', and pain tolerance as 'the point at which the pulses 
become unbearable - and the pulses will be terminated immediately'. When stimulus 
strength reached the level of pain tolerance it was switched off immediately. 
Plasma concentrations of opioid peptides: A 10ml venous blood sample was 
collected from the antecubital vein prior to the start of the experiment. Baseline plasma 
concentration of beta-endorphin was measured using a immunoradiometric method 
supplied by Nichols Institute and met-enkephalin by radioimmunoassay using reagents 
supplied by Incstar Corp. as previously described in Chapter 5. 
Four month follow-up: Postal questionnaires were sent to all patients 4 months 
from the date of attendance at the research unit (see Appendix A). Questionnaires 
recorded whether patients continued to use the stimulator. Patient notes were also 
examined at the 4 month interval to ascertain whether stimulators had been returned. Of 
10 patients asked, 8 returned to the unit for follow-up assessment and EEG recording 
(female n=6, male n=2; age range=35-72, mean=50.5 years of age). 
Results of Experiment 6.1 
Classification of responders and non-responders: The degree of pain relief 
achieved during TENS was assessed by two identical visual analogue scales (where 
O=no pain and 10=worst pain imaginable) and a multiple choice question (see 
Appendix A). As no significant differences were found between the two VAS scores 
(P=0.8, paired t-test) the mean VAS score was calculated for each individual. This 
mean VAS measure was found to be highly correlated with the the degree of pain relief 
measured by the MCQ (r=+0.90, P<0.01, Spearman 'rank correlation coefficient). 
Thus, the mean VAS for each individual was used as a measure of response to TENS. 
Seven out of 29 patients (24%) obtained no relief of pain with TENS; the remaining 22 
patients reported pain relief between 2-10 units on the VAS (Fig. 6.1). Therefore, the 7 
patients who achieved no relief of pain during TENS were classified as non- 
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responders. Unpaired t-tests (for continuous data) and Mann-Whitney 2-sample rank 
tests (for categorical data) were performed to examine differences in factors between 
the responders and non-responders; Pearson correlation coefficients were used to 
examine relationships between these factors and degree of pain relief reported with 
TENS. 
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Fig. 6.1 Histogram of pain relief obtained during TENS in 
29 chronic pain patients (Exp. 6.1). Patients with VAS scores of 
<1 (n=7) were classified as non-responders 
TENS Questionnaire: The results of the TENS questionnaire are summarised in 
Table 6.1. Table 6.2 compares the results from the questionnaire, EPQ, HAD and pain 
threshold measures between responders and non-responders. The intensity of the 
patient's pain during the visit to the research unit (i. e. present pain rating) is shown in 
(Fig. 6.2). 
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QUESTION n Median (range) 
Age of study population (years) (a)female (a) 16 (a) 45(35-72) 
(b)male (b) 13 (b) 57(30-75) 
(c)all (c)29 (c) 47(30-75) 
Pain rating during visit to research unit 29 4.3(0-8.6) 
(0 no pain ---> 10 worst pain imaginable) 
Instruction on stimulator use 29 8.0(0-10) 
(0 poor ---> 10 extremely well) 
Confidence in TENS treatment 29 4.5(0-10) 
(0 no confidence ---> 10 extremely confident) 
The logic of TENS in reducing pain 29 5.0(0-10) 
(0 no logic at all ---> 10 extremely logical) 
Degree of pain relief 29 4.8(0-10) 
(0 no relief ---- > 10 total relief) 
Duration of treatment (a)days/week 29 (a)7.0(3- 7.0) 
(b)h/week (b)28(3- >50) 
Time to onset of analgesia (min) 22 30 (0->2h) 
Time to offset of analgesia (min) 22 60(0->2h) 
n No of patients 
Pulse pattern preference (a)continuous 29 (a)20(69%) 
(b) burst (b) 4(14%) 
(c) both (c) 5(17%) 
Change of TENS efficacy (a) increase 27 (a) 5(18%) 
with use (b) unchanged (b)18(67%) 
(c) decrease (c) 4(15%) 
Use TENS in combination with other drugs 29 23(79%) 
Incidence of skin reactions 29 3(10%) 
(ie irritation or rash) 
Table 6.1 Summary of answers to TENS questionnaire 
(Exp. 6.1). 
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VARIABLE RESPONDERS NON- P value (n=22) RESPONDERS (Unpaired t-test) 
(n=7) 
Age (years) 50.4±11.9 57.8±15.3 0.3 
Sex Male n=9 Male n-4 n. s. 
Female n=13 Female n=3 
Duration of pain condition 4.4±5.0 6.9±3.2 0.3 
(years) 
Unemployed due to pain 8 out of 22 1 out of 7 n. s. 
Eysenck Personality P 2.1±1.0 P 2.1±1.7 0.9 
Questionnaire E 10.7±6.3 E 10.8±5.2 1.0 
N 10.8±5.8 N 11.7±5.5 0.8 
L 12.7±4.1 L 9.0±5.6 0.2 
Hospital Anxiety & A 7.8±4.5 A 5.6±3.9 0.3 
Depression scale D 5.6±3.0 D 4.8±4.8 0.7 
Confidence in TENS 5.0 3.3 0.6 
Sensory Detection 2.1±0.7 2.8±1.3 0.2 
Threshold (mA) 
Pain Threshold 2.7±2.2 1.3±0.7 0.1 
(mA above SDT) 
Pain Tolerance 3.0±2.9 3.1±3.1 0.7 
(mA above pain threshold) 
Beta-endorphin 7.4±4.9 11.9±17.4 0.56 
(mow) 
Met-enkephalin 39.6±7.8 41.9±15.7 0.86 
( mol/1) 
Table 6.2 Comparison between responders and non- 
responders for factors measured in Exp. 6.1. Mean±SD, 
n. s. =non significant. 
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Fig. 6.2 Histogram of pain intensity rating in 29 chronic 
pain patients during the visit to the laboratory (Exp. 6.1). 
Although no patients were in the 'worst pain imaginable' category, 13 out of 29 (45%) 
had over 50% pain, and 4 out of 29 (14%) were in no pain. No significant differences 
were found in present pain intensity rating between responders and non-responders. 
The majority of patients (23 out of 29(79%)) were using TENS 7 days a week. Six out 
of 7 non-responders used the stimulator on a daily basis in the hope of development of 
TENS effects during the trial period. Eighteen (62%) patients reported using TENS for 
over 28 h/week, of which 13 (45%) patients reported using TENS on a daily basis for 
over 6 h/day. In the 22 responders the median time to onset of analgesia was 30 
minutes and offset of analgesia 1 hour. The majority of patients used a continuous 
pulse pattern of TENS (20 out of 29(69%)); 5 out of 29 (17%) preferred burst; 4 out 
of 29 (14%) used both continuous and burst equally. None of the patients in 
possession of a Xenos stimulator (which has random mode stimulation) used random 
pulse delivery as the primary stimulating mode. Two out of 9 (22%) patients reported 
using random mode on an occasional basis. No significant differences were found 
between responders and non-responders for any of the variables mentioned above 
(Mann-Whitney U-tests). 
The majority of patients thought that TENS techniques were instructed extremely well 
at the clinic (20 out of 29 (69%) scoring >7 VAS units), although 6 out of 29 (21%) 
reported poor instruction (0 VAS, Fig. 6.3a). 
Chapter 6: Factors related to patient response to TENS 167 
ý 
a ý .ý ý a 
w 0 
0 
Z 
® Non-responders 
Responders 
0 
Poor - 
instruction 
O 
oý oý 
ý 
ö 
ý-; 
0ý v 
d 
v 
clý ý 
N 
Visual Analogue Scale 
ý ý 
ö 
ý 
oý o 
0ö ö ö 
0ö ý 
*Good 
O, 
instruction 
Fig. 6.3a Histogram of adequacy of instruction of TENS 
techniques at the clinic as rated by 29 chronic pain patients 
(Exp. 6.1). 
Few patients (7 out of 29 (24%) scoring >7 VAS units) were confident of the success 
of TENS and 6 out of 29 (21%) reported zero on the VAS (Fig. 6.3b). 
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Fig. 6.3b Histogram of initial confidence of TENS success 
as rated by 29 chronic pain patients (Exp. 6.1). 
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Thirteen out of 29 (45%) patients believed that there was a logical (>7 VAS) reason 
why TENS should reduce their pain (the majority understanding TENS to 'distract' or 
'take their mind off the pain). However, 6 out of 29(21%) believed TENS to be an 
illogical treatment (Fig. 6.3c). 
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Fig. 6.3c Histogram of the logic of TENS as an analgesic 
treatment as rated by 29 chronic pain patients (Exp. 6.1). 
No significant differences were observed between responders and non-responders for 
any of these variables (instruction P=0.54; confidence P=0.71; logic P=0.91, unpaired 
t-test), and no relationships between instruction, confidence or logic with the degree of 
pain relief were found. No significant differences were also noted between age, sex, 
occupation or the duration of the pain condition between responders and non- 
responders (Table 6.2). 
The majority of patients were either retired or housewifes (14 out of 22 responders and 
6 out of 7 non-responders). No significant differences were found between responders 
and non-responders in any of the sociological variables measured. The majority of 
patients (23 out of 29 (79%)) were using TENS in combination with drug treatment 
and 14 out of 29 (48%) patients were using TENS in combination with primary 
analgesics [Thompson 1984]. The incidence of skin reaction was low (3 out of 
29(10%)) and the majority of patients (18 out of 29(60%)) found that the efficacy of 
TENS had remained stable over the trial period. 
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Pain classification: A variety of pain conditions were represented in the study 
(Fig. 6.4 a-c) and of the 7 non-responders, 3 had pains associated with the head and 
face, 2 with the abdomen, 1 lower back and 1 lower limb; 3 had pains of unknown 
aetiology. Careful examination of the population revealed no relationships between the 
classification of the pain condition and response of treatment. 
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Fig. 6.4a Chronic pain conditions classified according to 
Anatomical region, IASP Axis I (Exp. 6.1, n=29). See IASP 
(1986] for full desciption of terms. 
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Fig. 6.4b Chronic pain conditions classified according to 
Aetiology, IASP Axis V (Exp. 6.1, n=29). See IASP [1986) for 
full description of terms. Degen/mech = degenerative/mechanical. 
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n=29). See Johnson et al. 1991a for full description of terms. 
Electrical characteristics of TENS: The majority of patients (23 out of 29(79%)) 
used therapy settings below lOmA above SDT. No significant differences in either 
SDT or therapy levels were found between responders and non-responders and no 
relationships were observed between the degree of pain relief and SDT or therapy 
setting. 
Thirteen out of 29 patients preferred pulse frequencies between 10-30Hz with an 
additional cluster (4 out of 29) at 80Hz (Fig. 6.5). This 'even' distribution (in 
comparison to that found in Study 2.2) may be due in part to the 9 patients using 
Xenos stimulators which have incorporated linear output characteristics on the 
frequency control dial. Furthermore, 3 of the 4 patients using frequencies between 80- 
89.9Hz possessed Xenos stimulators, which has an 80Hz reset facility, and had not 
altered the frequency knob since issue from the clinic. Remaining patients possessed 
Microtens stimulators (with logarithmic output characteristics of the frequency dials). 
One patient used a pulse frequency of 120Hz and possessed a Tiger burst stimulator 
with a maximum frequency output of 120Hz. No significant differences in pulse 
frequency used by the 7 responders and 22 non-responders were observed. 
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Personality, anxiety and depression: EPQ scores were within the range for 
normals [Eysenck & Eysenck 19751, and the mean HAD scores across the group were 
below that expected for clinical anxiety (>10) and depression (>10). Nonetheless 4 
patients had anxiety ratings above 10 (all responders) and 2 had depression scores 
above 10 (both responders). No significant differences in either EPQ or HAD 
measures were found between responders and non-responders (Table 6.2). 
EEG variables 
a) Baseline Evoked Potentials: Peak-to-peak amplitudes and latencies of the late 
waveform components of the auditory and somatosensory evoked potentials are 
summarised in Table 6.3. 
lntenuiY Latency Peak-to-peak amplitude 
MEAN±SD 
of evoking 
nimu1 (ms) (µV) 
(VASunit) Pl NI P2 PIN] PI N2 RMS 
AEP 
Non-responders " 57.0±14.0 114.0±34.8 208.3±27.3 12.4±5.3 16.0±7.5 4.6±1.1 
Responders 57.0±8.5 105.4±14.2 201.8±21.7 14.3±5.1 20.0±7.0 5.4±1.6 
P value 1.0 0.5 0.6 0.4 0.2 0.2 
2.5mA SEP 
Non-responders 2.2 98.2±18.6 129.0±26.7 180.0±41.0 4.0±1.4 5.3±2.9 4.5±1.6 
Responders 3.4 99.4±20.3 139.2±25.5 176.0±103.0 9.4±4.9 12.6±6.5 4.9±2.3 
P value 0.1 0.9 0.4 0.9 0.01 0.01 0.6 
5mA SEP 
Non-responders 5.2 90.2±38.5 117.3±40.3 199.5±32.2 4.1±3.6 7.1±8.2 4.2±2.1 
Responders 5.7 95.1±16.6 139.1±22.4 203.0±45.0 10.5±5.8 14.5±3.5 5.7±2.1 
P value 0.5 0.7 0.3 0.9 0.01 0.01 0.15 
5mA-2.5mA SEP 
Non-responders 2.7 -1.8±33.6 -3.8±24.7 15.7±26.9 0.2±3.3 0.4±3.0 -0.4±1.1 Responders 2.4 -6.0±19.1 -1.2±20.2 -19.2±24.0 1.3±5.8 1.9±6.3 0.8±1.6 P value 0.6 0.3 0.8 0.2 0.6 0.4 0.07 
Table 6.3 Mean±SD latencies and peak-to-peak amplitudes of 
late components of SEPs and AEPs in TENS responders and 
non-responders (n=29 chronic pain patients, Exp. 6.1). P 
value = unpaired t-test non-responders v responders. 
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(i) AEP: The AEP was characterised by a series of waves P1, Ni and P2. Fig. 6.6 
shows a grand mean evoked potential of the 7 non-responders which is compared with 
the grand mean evoked potential for the 22 responders. No significant differences in 
the latencies or peak-to-peak amplitudes of P1, NI or P2 were found between 
responders and non-responders. Nevertheless mean PINI, N1P2 and RMS 
amplitudes were smaller in the non-responders and the amplitude of the P2 component 
is markedly reduced in the non-responders (Fig. 6.6). 
I I 
Stimulus 200ms Tone 
Ni 
200ms 
P2 
Fig. 6.6 Grand average AEP for chronic pain patients 
classified as TENS responders (n=22) and non-responders 
(n=7), Exp. 6.1. Recordings taken at Cz referenced to linked mastoids. 
(ii) SEP: SEPs were recorded to evoking stimuli of 2.5mA above SDT and 5. OmA 
above SDT. In some subjects SEP components were poorly defined and measurement 
of waveform components (especially P1) was often difficult. No significant 
differences in the latency of either P1, Ni or P2 was found between responders and 
non-responders (Table 6.3). 
Responders had significantly larger PIN 1 and N 1P2 amplitudes at both intensity levels 
of SEP (Table 6.3). The SEP was poorly defined in non-responders with the apparent 
absence of the N1 waveform (Fig. 6.7a and Fig. 6.7b). 
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Fig. 6.7 Grand average SEP elicited at (a) 2. SmA above SDT 
and (b) 5. OmA above SDT for chronic pain patients 
classified as TENS responders (n=22) and non-responders 
(n=7), Exp. 6.1. Recordings taken at Cz referenced to linked mastoids. 
Although non-responders had lower RMS (between 50-550 ms post-stimulus) to SEPs 
elicited at the higher intensity, this failed to reach significance (P=0.15). In general, the 
greater the degree of pain relief achieved with TENS the larger the baseline amplitudes 
of the SEP (Fig. 6.8). However, these correlations just failed to reach significance 
(N 1P1; 2.5mA r=+0.36,5. OmA r=+0.36: NIP2; 2.5mA r=+0.34, P=0.1<0.05, 
Pearson correlation coefficient; NIP2 5mA r=+0.2, n. s. ). 
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Fig. 6.8 Relationship between degree of pain relief obtained 
with TENS and the peak-to-peak amplitude of the SEP 
elicited from a 2.5mA above SDT stimulus (Exp. 6.1, 
n=29). Size of SEP=µV, degree of pain relief measured on a VAS where 
O=no relief, 10=total relief. Pearson correlation coefficient r=+0.34, df=29, 
P=0.1<0.05). 
No significant differences in either latency or peak-to-peak amplitudes of P1, N1 and 
P2 were found between the two intensity levels of SEP although responders showed a 
larger incremental increase in RMS between 2.5mA and 5. OmA evoking stimuli than 
responders (P=0.07, see Table 6.3). 
b) Baseline spontaneous EEG: Table 6.4 summarises the results. 
POWER SPECTRUM 
MEAN±SD ( V2/Hz) 
Eyes open Eyes closed Eyes closed-Eyes 
open 
Delta 
Non-responders 167.0±149.0 61.2±28.2 -107.0±125.0 
Responders 89.8± 73.1 114.5±71.1 24.0± 85.7 
P value 0.2 0.01 0.04 
Theta 
Non-responders 34.7±33.0 19.6± 8.2 -15.1±36.2 
Responders 22.6±15.0 50.3±58.6 27.7±58.0 
P value 0.4 0.05 0.03 
Alpha 
Non-responders 44.4±27.8 53.9±51.9 9.5±42.2 
Responders 32.1±26.2 102.2±81.5 70.1±68.4 
P value 0.3 0.08 0.01 
Beta 
Non-responders 17.4± 8.3 18.6±10.8 1.1±15.3 
Responders 21.4±11.6 30.2±13.2 8.8± 8.5 
P value 0.3 0.04 0.2 
Alpha frequency (Hz) 
Non-responders 8.7±0.8 7.8±3.5 -0.8±3.5 
Responders 8.4±2.7 8.7±2.1 0.3±2.3 
P value 0.7 0.6 0.5 
Table 6.4 Mean±SD power spectrum for chronic pain 
patients classified as TENS responders (n=22) or TENS 
non-responders (n=7), Exp. 6.1. Recordings taken at Cz referenced 
to linked mastoids. Unpaired t-tests were performed to examine differences 
between groups. 
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No significant differences in power were found between responders and non- 
responders for any frequency band when recording with eyes open. However, non- 
responders showed significantly less power across all frequency bands when 
recording with eyes closed (Table 6.4). 
Pain threshold and pain tolerance: No significant differences in SDT or pain 
tolerance were found between responders and non-responders. Non-responders were 
found to have lower thresholds to experimental pain although this just failed to reach 
statistical significance (P=0.1, see Table 6.2). No significant relationships in pain 
threshold and the degree of pain relief achieved with TENS measured on the VAS were 
found (r=+2.4, Pearson correlation coefficient). 
Plasma concentrations of opioid peptides: Plasma concentrations of opioid 
peptides were analysed as described in Chapter 5. Thus, beta-endorphin and met- 
enkephalin values recorded below the sensitivity of the assay were transformed to 2.9 
pmol/1 and 35pmol/l respectively (see Chapter 5). Baseline plasma concentrations of 
beta endorphin ranged from <2.9 pmol/l to 47 pmol/l (mean=8.1, median=5.6). No 
significant differences in baseline plasma concentrations of beta endorphin were 
observed between responders and non-responders (Table 6.2). Baseline plasma met- 
enkephalin concentrations ranged from <35 pmol/1 to 79.8pmol/l, and 16 out of 25 
patients had baseline met-enkephalin concentrations below the sensitivity of the assay. 
No significant differences in baseline met-enkephalin concentration between 
responders and non-responders were observed. 
Follow-up: Twenty two (76%) patients replied to a postal questionnaire sent at the 
four month follow-up. Of the 7 non-responders classified in this study by the visual 
analogue scale score, 6 had returned stimulators. The seventh patient reported that the 
stimulator was now effectively reducing the pain. Four patients initially reporting a 
favourable TENS response at the 1 month follow-up were no longer achieving benefit 
at the 4 months follow-up and had returned stimulators to the clinic. One of these 
patients reported a rebound exacerbation of pain post-TENS despite relief during 
stimulation. Whether the declining TENS efficacy observed was due to the 
development of tolerance or an initial placebo response to TENS is not known. 
However, a further 3 patients still using TENS at the 4 month follow-up also reported 
declining effect. 
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Examination of Newcastle Pain Relief Clinic records revealed that 10(34%) patients 
had returned stimulators to the clinic within four months of issue. All of these patients 
reported that TENS was ineffective in reducing their pain, as recorded on the postal 
questionnaire. Hence further statistical analysis was performed as follows: 
All patients who had returned stimulators after 4 months (n=10) were classified as 
non-responders and similar statistics as described above were performed on the data 
collected at the I month period. The following additional information was found: 
(i) No significant differences were found in pain threshold between responders and 
non-responders. 
(ii) Non-responders had a significantly lower peak-to-peak amplitudes of the N1P1 
(P<0.05) and possibly N1P2 (P=0.13) components of the AEP. 
(iii) Non-responders had significantly smaller peak-to-peak N1P1 amplitudes 
(P<0.05) and possibly (RMS values, P=0.13) of the SEP elicited at 5. OmA above 
SDT. 
(iv) No significant differences were found for N1P2 amplitudes of the SEP elicited 
at either 2.5 mA above SDT or 5. OmA above SDT. 
(v) Non-responders had lower power in the delta (P<0.05) and possibly alpha 
(P=0.15) and beta (P=0.11) frequency bands with eyes closed. 
Eight patients (out of ten asked) attended the research unit for EEG recording at the 
four month follow-up. The 2 patients refusing to attend were non-responders; thus only 
I non-responder returned for follow-up. No significant changes in any of the variables 
measured occurred between the two visits (paired t-tests). Hence it appeared that the 
clinical, sociological, psychological, electrophysiological and neuropharmacological 
variables measured during the study remained stable over the four month follow-up 
period. 
Main findings of Experiment 6.1 
(i) Seven out of 29 patients given a trial of TENS to control a chronic pain condition 
failed to obtain satisfactory analgesia with TENS by the 1 month follow-up. 
(ii) Sociological and psychological variables (TENS questionnaire, EPQ and HAD 
scale) were not related to patient response. 
(iii) Poor patient response to TENS was associated with: 
(a) small baseline peak-to-peak amplitudes of the late components of SEPs, 
(b) low spontaneous EEG activity across most frequency bands when recorded 
at Cz with eyes closed. 
Chapter 6: Factors related to patient response to TENS 177 
(iv) Patients with low pain threshold to electrical stimuli also showed poor response 
to TENS although this failed to reach significance. Sensory detection threshold and 
pain tolerance were not related to patient response to TENS. 
(v) At the 4 month follow-up a further 4 patients reported treatment failure and 
another 3 patients reported declining efficacy of TENS. Whether these effects were 
due to the development of tolerance or declining placebo effects remains to be 
determined. 
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DISCUSSION 
In this prospective study of 29 patients undergoing a trial of TENS to control chronic 
pain, the relationship between a number of pre-existing factors and patient response 
was examined. The results have shown for the first time that patients responding 
poorly to TENS have small peak-to-peak amplitudes of late waveform components of 
SEPs, and low spontaneous EEG activity when recorded with eyes closed. Pre- 
existing sociological, psychological, and neuropharmacological factors did not appear 
to reflect response to TENS treatment. These findings suggest that patients who show 
poor cortical response to sensory stimuli (reflected by small amplitude EPs) are less 
likely to respond to TENS. These findings will be discussed below. 
TENS Efficacy 
At the one month follow-up, 7 out of 29 (24%) patients failed to respond to treatment. 
One of these patients reported an increase in TENS efficacy between the 1st and 4th 
month follow-up and therefore continued to use a stimulator. The reasons for this 
delayed analgesic effect are not known, although experimentation with stimulator 
settings may have established more beneficial electrical characteristics for TENS. At 
the 4 month follow-up a total of 10 (34%) patients had reported non-response to TENS 
and all of these patients had returned stimulators to the clinic. The decline in efficacy 
between the 1 and 4 month follow-up may be due to either: 
(i) the decline of an initial placebo response at I month, 
(ii) the development of tolerance to TENS analgesia. 
A further 3 patients still using stimulators had detected a decrease in TENS efficacy 
and were concerned about it. 
Despite the biased nature of the patient population, due to the exclusion of patients with 
mobility problems, those taking psychotropic drugs and an unknown number of 
patients who refused to participate in the study, the findings were similar to those 
reported in Study 2.1 where it was found that approximately 25% of stimulators were 
returned within the first 6 month (see Fig. 2.2). 
TENS Questionnaire 
The answers to the TENS questionnaire (Table 6.1) were similar to those observed in 
the population of responders examined in Study 2.2 (see Table 2.1). The incidence of 
skin reactions was lower in the present study probably due in part to improvements in 
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the teaching of electrode techniques by nurses in the clinic, and the availability of self- 
adhesive electrodes which would reduce the incidence of allergic reactions to 
Micropore adhesive tape. The majority of patients were using TENS on a daily basis 
(for 4 h/day (median)). This included non-responders who used TENS on a daily basis 
in the hope that an analgesic effect might develop with time. This occurred in one 
patient. 
Electrical characteristics of TENS 
All patients applied TENS to produce a 'strong but comfortable' electrical paraesthesia 
within the painful site. No significant differences were noted between the electrical 
characteristics of TENS used by non-responders and responders. Furthermore the 
electrical characteristics of TENS were not related to either the site or cause of pain or 
to the degree of response, a finding consistent with Study 2.2. An even distribution of 
pulse frequencies was used by the patients in the present study (compared with that 
reported in Study 2.2, see Fig. 2.11) due to the incorporation of linear pulse frequency 
output characteristics in Xenos stimulators which were issued to 9 patients. The cluster 
of patients who used pulse frequencies between 80-90Hz were using the 80Hz default 
setting of the Xenos stimulator. 
Factors related to patient response to TENS 
Factors related to pain 
No significant relationships between the site and character of pain with patient 
response to TENS were observed in the present study. However evidence suggests 
that pain of neurogenic origin and/or located at the extremities responds favourably to 
TENS [Johansson et al. 1980]. No such analysis was performed in the present study. 
At the four month follow-up, 4 patients with pains in the vertex region of the head had 
reported poor response to TENS. Loeser et al. [1975] also reported that patients with 
head pains responded poorly to TENS (see Table 2.1). This may be attributed in part 
to the inability to achieve electrical paraesthesia within the scalp because of the 
difficulty of electrode placement within the hair. Sponge electrodes (rather than carbon 
rubber electrodes which require gel and tape) can be applied directly to the scalp, and 
may improve TENS treatment of head pains. 
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Factors unrelated to pain 
Sociological 
No significant differences between responders and non-responders were observed in 
any of the sociological factors measured. Thus, initial confidence in TENS success 
was not related to treatment outcome, and some patients who believed TENS would 
not help their pain were overjoyed at its success. Of the patients who reported poor 
instruction, all (4) had mastered basic TENS techniques by a combination of trial and 
error and reading the manufacturers instruction pamphlet. Although the duration of the 
pain problem was greatest in non-responders, a finding consistent with that of 
Reynolds et al. [1983), this failed to reach statistical significance. Furthermore 
occupation, loss of employment because of the the pain, age, sex and the use of 
analgesics were not related to treatment outcome. 
Psychological 
In contrast to the findings of Johansson et al. [1980] who found that patients with high 
L scores on the EPI showed favourable responses to TENS, no significant differences 
were observed between non-responders and responders in any of the personality traits 
measured by the EPQ (Table 6.2). High L scores are often associated with social 
compliance, indicative of suggestible patients who may report treatment success to 
'please' the experimenter. This may account for the findings of Johansson et al. 
because patients were classified as responders and non-responders according to a short 
(30 minute) TENS treatment session and were therefore more susceptible to placebo 
effects. Nielzdn et al. [1982] found that patients with pathological personality traits 
responded poorly to TENS. The present study revealed no significant differences 
between responders and non-responders with respect to HAD scale scores, which 
measures anxiety and depression. 
EEG variables 
The results of the present study suggest that patients who produce small cortical 
responses to sensory stimuli respond poorly to TENS. Thus, non-responders are 
characterised by small peak-to-peak amplitudes of late latency components (P1N1 and 
NJP2) of the SEP and low baseline spontaneous EEG power when recorded with eyes 
closed. 
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Evoked potentials 
Golding et al. [1986] found a positive correlation between baseline SEP amplitudes 
and response to TENS in alleviating experimental pain in healthy subjects. However, 
as SEP amplitudes are dependent upon the intensity of the evoking stimuli, the inter- 
individual variability in baseline SEP amplitude recorded in the Golding et al. study 
may have been due in part to inter-individual variability in the current intensity of the 
evoking stimulus (which was fixed perceptually across the subject population at a 
'strong but comfortable' level). This problem was addressed in the present study by 
delivering a standard current intensity of evoking stimuli to all patients. 
Although no significant differences in the latency or peak-to-peak amplitudes of AEPs 
occurred Fig. 6.6 shows that the grand mean AEP of non-responders was 
characterised by the absence of the P2 late component. Moreover AEPs and SEPs were 
positively correlated (N1P2 amplitude: AEP v 2.5 mA SEP, r=+0.42, df=28, 
P<0.05), implying that this non-responsiveness to external stimuli occurs across 
sensory modalities within the same individual. Although it has been suggested that 
AEPs and SEPs are reduced in depressed patients compared with normals [Shagass et 
al. 1985], no relationships were found between HAD scores and AEP or SEP 
amplitudes in the present study. This would suggest that depression or anxiety were 
not factors contributing to the small SEP amplitudes under the present conditions. 
In general, patients rated the intensity of the evoking stimuli as 'weak' on the visual 
analogue scale. Consequently the resultant SEPs were small. Utilisation of higher 
intensities of evoking stimuli may have evoked more clearly defined SEPs. A possible 
source of error when using peak-to-peak measures is the correct identification of 
waveform peaks by the experimenter. This problem was minimised in the present 
study by confirmation of correct peak identification by an experienced EEG technician 
(VRM). Root mean squared (RMS) value was used as an overall measure of SEP 
response and does not require peak identification and may reduce experimenter error. 
However no significant differences in RMS (between 50-550 ms) were found between 
responders and non-responders. This was attributed to the large time window used in 
RMS calculation which would encompass a conglomerate of waveform components 
each reflecting separate events; these are more reliably measured using peak-to-peak 
amplitudes (as performed in the present study), or RMS calculation within narrow time 
windows. 
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Spontaneous EEG 
This is the first report to relate baseline spontaneous EEG activity to patient response 
with TENS. Patients showing favourable responses to TENS had significantly greater 
power within all frequency bands while recording with eyes closed, thus maximising 
synchronised slow wave EEG activity. No such differences in spontaneous EEG were 
noted with eyes open. However because of the lack of understanding of the 
physiological significance of spontaneous EEG activity, an explanation for such 
findings is difficult. Nonetheless, changes in states of arousal are reflected in changes 
in spontaneous EEG activity and therefore baseline arousal may influence TENS 
effects. Furthermore it has been suggested that baseline spontaneous EEG correlates 
with personality and certain pathological states [Golding et al. 1985]. With the advent 
of more powerful EEG analytical techniques and topographical brain mapping the 
utility of spontaneous EEG as a predictor of response to TENS (and other treatments) 
merits further investigation. 
Augmenters and reducers 
The concept of augmenters and reducers was originally described by Petrie [1967] to 
account for individuality in pain and response to the external environment. It was 
suggested that augmenters may have a low tolerance to pain and reducers a high 
tolerance to pain. This concept received support from SEP studies where it was 
suggested that augmenters increased the size of the evoked response to increasing 
intensity of stimulation while reducers decreased the size of evoked response with 
increasing stimulus intensity. Further claims that augmenters respond better to 
pharmacological pain-relieving agents such as morphine [Buchsbaum et al. 1981a; 
1981b] and show greater responses to naloxone [Buchsbaum et al. 1983] have yet to be 
validated. 
Johansson et al. [1981] reported that the failure of response to TENS in 24 chronic 
pain patients was related to a tendency of these patients to 'reduce' visual evoked 
potentials. This finding was supported in part by the results of the present study, in 
which patients responding favourably to TENS produced larger incremental increases 
in RMS, and SEP amplitudes (although non-significant) elicited at both low and high 
intensity evoking stimuli (Table 6.3). Unfortunately only two stimulus intensities were 
used and the differences in peak-to-peak amplitude and RMS between these two 
stimuli were small. Such findings merit further study. 
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Sensory detection threshold, pain threshold and pain 
tolerance 
It has been previously suggested that augmenters (and by implication TENS 
responders) have low pain thresholds [Buchsbaum 1984]. Further evidence was 
provided by Golding et al. [1986], who found that healthy subjects with low 
thresholds to experimental pain showed favourable responses to TENS. By contrast, 
the results of the present study suggest that patients who respond favourably to TENS 
may have high thresholds to pain, although this finding failed to reach statistical 
significance. However the failure of the Golding et al. study to correct pain threshold 
values for individual differences in sensory detection threshold may account for this 
discrepancy. Thus, the present study found non-responders to have higher sensory 
detection thresholds (non-significant) which would increase uncorrected pain threshold 
values of non-responders with respect to the TENS responders group. 
Neuropharmacological 
Von Knorring et al. [1978] have suggested that baseline SEPs and 
augmenting/reducing responses may be related to baseline endogenous opioid peptide 
levels. In a population of chronic pain patients they found that augmenters had low 
pain thresholds and low CSF levels of endogenous opioid peptides [Almay et 
al. 1978]. No differences in baseline levels of peripherally circulating beta-endorphin 
and met-enkephalin were observed between responders and non-responders in the 
present study. 
Follow-up 
Four out of 29 patients who initially responded to TENS reported TENS treatment 
failure at the four month follow-up. This may be due either to the development of 
tolerance and/or a decline in an initial placebo response. When the data was re-analysed 
with the inclusion of these 4 patients in the 'non-responding' group, the distinction in 
electrophysiological measures (i. e. spontaneous EEG and SEP) between responders 
and non-responders became less significant. This may suggest that a continuum of 
differing degrees of response rather than distinct patient populations of 
responders/non-responders exists. Unfortunately it was not possible to compare 
changes in electrophysiological measures between the one and four month follow-up. 
Such information may provide the key to understanding the development of tolerance 
to TENS analgesia which has been attributed to central nervous system adaptation (or 
habituation) to peripheral conditioning stimuli [Pomeranz & Niznick 19871. 
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Implications for the mechanism of TENS failure. 
As EPs reflect the cortical response to external stimuli, and TENS is an external 
stimulus, it may be inferred that patients with little CNS response to external stimuli 
are less likely to respond to TENS. This has been shown by: 
(i) the small baseline EP amplitudes observed in non-responders in this and the 
Golding et al. [1986] study, 
(ii) the small incremental rise in EP with increasing stimulus intensity in non- 
responders in this and the Johansson et al. [1981] study. 
It has been suggested that EPs reflect excitatory and inhibitory (post-synaptic) 
potentials related to the processing of an incoming (stimulus-induced) afferent volley. 
Thus, it may be inferred that individuals showing large SEP responses may produce 
greater 'waves of excitation and inhibition' within the CNS with a concurrent release 
of larger amounts of transmitters. These transmitters may in turn be involved in the 
modulation of nociceptive transmission. Furthermore as non-responders show 
'reducing responses' to external stimuli they may be unable to compensate for poor 
cortical responses to TENS as each incremental rise in the intensity of TENS results in 
only a small incremental rise in cortical response. 
Summary 
In this prospective investigation to find factors related to patient response to TENS, 7 
out of 29 patients given a trial of TENS to control a chronic pain condition failed to 
respond at the 1 month follow-up. Patients showing poor response to TENS were 
characterised by: 
(i) small baseline peak-to-peak amplitudes of the late components of SEPs 
(ii) low spontaneous EEG activity across most frequency bands when recorded at 
Cz with eyes closed. 
(iii) low pain threshold to electrical stimuli presented to the index finger, although 
this failed to reach statistical significance. 
Sociological and psychological variables (TENS questionnaire, EPQ and HAD scale) 
were not related to patient response. A further 4 patients reported treatment failure and 
another 3 patients reported declining efficacy of TENS at the 4 month follow-up. 
Whether these effects were due to the development of tolerance or declining placebo 
effects remains to be determined. 
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Despite the possible utility of EEG measurements in predicting patient response to 
TENS, it seems unlikely that such measurements could be employed in the clinic due 
to lack of availability of equipment, trained staff and time to perform the EEG 
recording and analysis. Therefore the quickest and simplest method of assessing 
response to TENS remains to be by a 1-2 month home trial. 
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CHAPTER 7 
DISCUSSION 
OVERVIEW 
Clinical, electrophysiological, neuropharmacological, psychological and sociological 
factors that influence the analgesic effects and clinical efficacy of TENS have been 
examined in this thesis. The results suggest that TENS provides successful long-term 
pain control in 58.6% of patients given a trial (Study 2.1) and that any type of pain 
may respond (Study 2.2). However previous literature suggests that TENS is most 
efficacious for pains of neurogenic (neuropathic) origin. 
Despite the relative success of administering TENS on an empirical basis in which the 
patient determines by trial and error appropriate stimulator settings, 41.4% of patients 
fail to respond and half of these using TENS on a long-term basis achieve less than 
50% relief of pain. Thus, a systematic investigation to examine the analgesic effects of 
different electrical characteristics of TENS was performed on healthy subjects in an 
attempt to determine optimal stimulator settings. It was found that continuous mode 
stimulation at 80Hz producing a 'strong but comfortable' electrical paraesthesia should 
be the primary TENS treatment choice in the clinic. Nevertheless, differential analgesic 
effects were noted using a range of pulse frequencies, with 20-80Hz proving most 
beneficial (Exp. 3.1); no differential effects were observed between a range of pulse 
patterns (Exp. 3.2). However, burst mode TENS applied at an intensity sufficient to 
produce phasic muscle twitches at a site distant yet myotomally related to the site of 
pain (acupuncture-like TENS) produced a powerful analgesia both during and after 
stimulation (Exp. 3.3). The clinical implications of this form of TENS was discussed. 
Electrophysiological factors were found to be influenced by TENS. Thus, TENS 
reduced peak-to-peak amplitudes of the late waveform components (N1P2) of 
somatosensory evoked potentials (Exp. 4.1) and increased alpha, beta and theta 
activity of spontaneous EEG in healthy subjects (Exp. 4.2) and/or pain patients (Exp. 
4.3). Furthermore, as TENS produced changes in SEPs elicited by non-painful 
stimuli, and also changes in spontaneous EEG in pain-free subjects, it was suggested 
that the effects of TENS may be due in part to changes in sensory processing at several 
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levels in the nervous system which may not specific for the perception of pain. The 
surprising finding that TENS increased peripherally circulating met-enkephalin was 
attributed to a stress-like response although this finding remains to be confirmed using 
a larger population sample (Exp. 5.1). 
Patient response to TENS was related to baseline SEP amplitudes and spontaneous 
EEG. Thus, patients with small peak-to-peak amplitudes of the SEP, and low power 
spectrum of spontaneous EEG showed poor response to TENS (Exp. 6.1). 
Deficiencies in stimulator design (Study 2.2) and the under-use of a variety of 
stimulation modes (Exp. 3.3) may be further factors contributing to poor patient 
response. Patient response to TENS was not related to biochemical, psycho-social, 
personality or pain related factors (Exp. 6.1). These points are discussed in detail 
below. 
CLINICAL USE OF TENS 
This thesis has provided much information of benefit to therapists, patients and 
manufacturers concerned with TENS treatment techniques. From the large number of 
previous studies performed to examine the effectiveness of TENS (for summary see 
Table 1.2) it has been shown that superficial somatic, deep somatic and neurological 
pains are more likely to respond than visceral or psychogenic pain. 
Indications and Efficacy: Essentially TENS can be used to treat any localised 
acute or chronic pain. Post-operative pain was the first form of acute pain successfully 
treated with TENS [Hymes et al. 1974] and TENS has been used post-operatively for 
abdominal and thoracic surgery [Cooperman et al. 1977], total hip replacements [Pike 
1978] and lumbar spine operations [Solomon et al. 1980]. It has been shown that 
TENS can reduce labour pain and that optimal analgesia is achieved using two sets of 
electrodes, the first set placed T10/Ll (for the first stage of labour) and the second set 
placed at S2-S4 (for the second stage of labour) [Augustinsson et al. 1977]. Other 
forms of acute pain successfully treated with TENS include traumatic pain (i. e. 
fractured ribs), acute arthritis, acute myalgia and myofascial pain syndrome. 
The results presented in Chapter 2 have shown that a wide range of chronic pain 
conditions may be successfully treated with TENS (Study 2.1 and 2.2), although 
TENS has been shown previously to be particularly suited to the treatment of pain of 
neurogenic origin (Table 1.2a). Chronic pains not responsive to TENS include those 
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poorly localised and/or psychogenic and visceral in origin. However Study 2.2 has 
found that no particular condition should be excluded from a trial of TENS on the 
grounds of a pain that usually fails to respond. Other indications for TENS treatment 
include ischaemic chronic pain states. Kaada [1983] found that TENS not only 
diminished pain in patients with ischaemic leg ulcers but also decreased the size and 
even healed such ulcers. Angina pectoris can also be relieved by TENS administered 
over the chest at the site of the referred pain [Mannheimer et al. 1982]. 
Placebo response: It is difficult to control clinical trials of TENS (and other 
physical treatments) in a double-blind cross-over design, due to the sensory 
differences associated during placebo (sham) TENS compared with active TENS. 
Recently the efficacy of TENS has been questioned by Deyo et al. [1990a] who found 
that TENS produced no statistically significant effect in reducing low back pain in 145 
patients when compared to sham. The group concluded that their results were due to 
successful blinding and that many reports in the literature on the success of TENS 
could be attributed to placebo response. However a number of factors may have 
contributed to the negative findings of Deyo et al.. The use of strong suggestion during 
sham TENS may have markedly increased placebo response, as 42% of patients 
reported improvement in low back pain during sham TENS. This is higher than that 
normally expected for placebo response (i. e. 30%). Hence, the experimenters may 
have administered a stronger suggestion to patients receiving sham TENS to convince 
the patient that the stimulator was functioning correctly. Recruitment of the patients by 
newspaper advertisements was likely to attract an atypical sample of back pain suffers 
who may have shown poor responses to a variety of previous treatments. Thus the 
sample may have been biased toward non-responders [Lancet 1991]. 
Although it is recognised that TENS, in common with all other forms of pain therapy, 
has a significant placebo component, recent double-blind, randomised controlled trials 
have confirmed the earlier uncontrolled studies that TENS is effective in controlling 
pain. The bulk of controlled trials have been performed on patients with acute (post- 
operative) pain due to the convenience of comparing the short-term effects of active 
TENS against sham TENS under experimental conditions in a hospital ward [for 
review see Woolf 1989]. Although fewer controlled studies are available for chronic 
pain, Thorsteinsson et al. [1977] found that active TENS was three times more 
effective in reducing pain from chronic neuropathies than placebo TENS. Taylor et al. 
[1981] also found that active TENS was significantly greater in reducing osteoarthritic 
pain than placebo over a one year period. 
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The results presented in Chapter 3 suggest that the primary effects of TENS cannot be 
attributed to placebo response as significant differences in analgesia were found 
between healthy subjects receiving active TENS and sham TENS. Sham TENS was 
successfully administered to TENS-naive subjects using a combination of verbal and 
visual suggestion. On questioning subjects at the end of the experiment the majority 
were surprised to learn that a'dummy stimulator' had been used. 
Advantages of TENS: Over half of patients given a trial of TENS continue to use 
the therapy on a long-term basis and in general, patients showing an initial favourable 
response continue to use the therapy for many years. Such findings emphasise the 
importance of this treatment in the management of chronic pain, especially as patients 
may have undergone a number of unsuccessful treatments prior to referral to the Pain 
Relief Clinic (by physicians). A major advantage of TENS therapy is that it does not 
interfere with ongoing drug treatment or delay diagnostic investigation. Thus, TENS 
could be administered more frequently by GPs and other 'front-line' therapists in the 
symptomatic control of a wide range of pain conditions. Furthermore TENS is 
relatively cost-effective. After the initial capital outlay for the purchase of the stimulator 
(approximately £65-£85) the running costs (tape, gel, batteries) are low. When the 
stimulator is no longer required by the patient it can be re-issued to another patient 
without any further capital outlay, in contrast to drug therapy. However educating the 
patient about TENS techniques can be both time and labour consuming in comparison 
to writing a prescription. This may deter the use of TENS as a primary treatment. 
The only adverse effects reported by patients in this investigation was due to either 
drying out of electrode gel, which produced a prickly 'mosquito bite' sensation, or an 
allergic reaction to the electrode adhesive tape. Replenishment of gel and the use of self 
adhesive electrodes can overcome these minor problems. Contraindications include 
patients using heart pacemakers of the "on-demand" type as TENS pulses may 
interfere or 'drive' the pacemaker. Manufacturers also recommend that electrodes 
should not be placed on the anterior aspect of the neck to avoid stimulation of the vagal 
nerves on the carotid sinus which may produce hypotension, and stimulation of the 
laryngeal nerves which may produce laryngeal spasm [Sjölund et al. 1990]. No drug- 
TENS interactions were found in Study 2.2 although a reduction in analgesic intake 
was reported by many patients. 
Long-term TENS users: Long-term users of TENS adopt similar operational 
procedures to treat chronic pain. Thus, all patients examined in Study 2.2 applied 
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TENS in its 'conventional' form, to produce a 'strong but comfortable' electrical 
paraesthesia within the painful area as instructed by staff at the clinic. The majority of 
these patients reported a rapid onset and offset of analgesia, with pain relief only 
occurring during stimulation. Therefore to control their pain, patients used stimulators 
over the entire day. Nevertheless about one fifth of patients achieved lengthy post- 
TENS analgesia (>2h) using this technique. The results from Chapter 3 suggest that a 
greater number of patients could achieve lengthy post-TENS analgesia by the 
implementation of acupuncture-like TENS. 
ELECTRICAL CHARACTERISTICS OF TENS 
The finding that half of the patients using TENS on a long-term basis obtained less 
than 50% relief of pain (Study 2.2) suggests that patients may not be utilising the most 
efficacious electrical characteristics of TENS. Chapter 3 systematically examined the 
analgesic effects of different electrical characteristics of TENS in alleviating cold- 
pressor pain in healthy subjects. 
Pulse frequency: Differential TENS effects occur across a range of pulse 
frequencies, with 20-80Hz producing the most beneficial analgesic effects. As 80Hz 
produced a large and reproducible analgesia (Exp. 3.1) and Sjölund [1985] found that 
80Hz produced the greatest reduction in C-fibre reflex in rats, 80Hz may be a good 
reference pulse frequency to use when trying a new patient on TENS in the clinic. 
NEEN Pain Management Systems have incorporated this frequency as a default setting 
on their new Xenos stimulators. Nevertheless the large variation in pulse frequencies 
and pulse preferences used by patients coupled with the consistency of frequency and 
pattern choice on subsequent treatment sessions suggest that patients 'tune in' to their 
particular stimulating preference. However, stimulator design may seriously hinder the 
patients choice as frequencies above 40Hz are difficult to obtain in many commercially 
available stimulators. This may seriously reduce TENS efficacy. Furthermore, the use 
of specific pulse frequencies by patients was not found to be related to the cause and 
site of pain. 
Pulse pattern: No significant differences in the analgesic effects of different pulse 
patterns (when applied at a 'strong but comfortable' intensity) were found in healthy 
subjects (Exp. 3.2). Continuous mode TENS produced the greatest (non-significant) 
elevation of ice pain threshold. However, patients showed preferences for pulse 
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patterns and the majority preferred continuous mode TENS although 23% of patients 
reported that they could only achieve relief of pain when using burst mode TENS. 
With this low intensity TENS, different pulse patterns may be utilised for reasons of 
comfort unrelated to analgesic mechanisms. The use of-continuous mode TENS as a 
primary TENS treatment choice was discussed in Chapter 3. 
Stimulating mode: In certain circumstances where conventional stimulation is 
ineffective, aggravates the pain, or where it is not possible to apply electrodes over the 
painful site, other stimulating characteristics should be used. Acupuncture-like TENS 
produced a powerful analgesic effect in healthy subjects (Exp. 3.3) and should be 
utilised more readily in clinics. Sjölund and Eriksson have demonstrated the value of 
AL-TENS as an additional TENS technique [for review see Sjölund & Eriksson 
1985]. Thus, approximately one third of patients who do not respond to conventional 
TENS show favourable response to AL-TENS. Furthermore AL-TENS produced a 
marked post-TENS analgesia in healthy subjects experiencing experimental pain, in 
comparison to conventional TENS, as shown in Exp. 3.3. This finding implies that 
AL-TENS may benefit patients who can only administer TENS for short periods of 
time. 
MECHANISM OF TENS ACTION 
Although the elucidation of the mechanism of action of TENS was not a primary aim 
of this thesis, a number of important findings have relevance. 
During stimulation: The finding in Chapter 3 that TENS produced a marked 
increase in cold-pressor pain threshold, but had variable effects on pain tolerance and 
pain intensity ratings suggest that the primary effects of TENS are on the sensory 
rather than affective components of pain. Furthermore, as TENS reduced the peak-to- 
peak amplitudes of late waveform components of the SEP elicited by non-painful 
stimuli (Exp. 4.1), it is likely that TENS produces effects on the general processing of 
sensory information irrespective of the presence of pain. The consistent use of specific 
pulse frequencies and pulse patterns by patients on subsequent treatment sessions, and 
the lack of relationships between the cause and site of pain and stimulator settings, 
implies that patients used such settings for reasons of comfort unrelated to specific pain 
mechanisms (Study 2.2 and 2.3). This is further evidence of non-specific TENS 
effects. 
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It was impossible to determine whether the reduction in SEP amplitude was due to 
changes in transmission of afferent information at either peripheral, spinal or 
supraspinal sites (Exp. 4.1). However recent work by Nardone and Schieppati [1989] 
suggests that TENS may inhibit peripheral transmission of the somatosensory volley in 
large diameter fibres and centrally at the level of the cuneate nucleus. Thus, in its 
conventional form, TENS may block (by antidromic collision) transmission of any 
ongoing activity in large diameter peripheral fibres which may occur during injury. 
Furthermore increasing the intensity of TENS may recruit A-delta fibres and 
antidromically block ongoing activity in A-delta fibres [Chung et al. 1984a; 1984b]. 
However, evidence suggests that TENS inhibits the onward transmission of 
nociceptive information by a gating mechanism in the spinal cord as originally 
proposed by Melzack and Wall [1965]. The rapid onset and offset of the analgesia 
associated with conventional TENS, shown both by pain patients (Study 2.2) and 
healthy subjects (Exp. 3.3), is consistent with such a neuronal gating mechanism. 
Further evidence for generalised TENS effects was provided by Exp. 4.2 and 4.3 
where changes in power spectrum during TENS were observed in pain free subjects 
and pain patients. The increase in alpha activity observed during TENS in these 
experiments suggest that TENS may affect states of arousal because an increase in 
alpha activity is often associated with a corresponding increase in relaxation. 
Nevertheless knowledge concerning the physiological significance of spontaneous 
EEG is sadly lacking and a fuller explanation of these changes is not possible. 
No effects of TENS on peripheral concentrations of beta-endorphin or 5-HT were 
found in patients during symptomatic relief of pain during TENS. Of surprise was the 
rise (non-significant) in met-enkephalin. It was suggested that this may be due to 
peripheral release of met-enkephalin following a stress-like response to TENS. 
However only six patients were examined and therefore further studies utilising larger 
sample numbers are needed to confirm this finding. 
Post-TENS analgesia: The short post-TENS analgesia (up to lhour) occurring 
after the prolonged activation of cutaneous afferents associated with conventional 
TENS has been attributed to a post-stimulatory depression (approximately lhour) in 
central excitability [Macefield & Burke 1991]. By contrast, the lengthy (over 2 hour) 
post-TENS analgesia achieved by one fifth of patients (Study 2.2) and during AL- 
TENS (Exp. 3.3) may be due to the activation of descending pain inhibitory pathways 
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and the release of opioid peptides. In this respect, AL-TENS but not conventional 
TENS has been shown to be naloxone reversible [Sjölund & Eriksson 1979]. 
FACTORS RELATED TO PATIENT RESPONSE TO TENS 
The results presented in Chapter 6 suggest that patient response to TENS is related to a 
number of factors which are discussed below. 
Factors related to pain: Previous studies have shown that certain pain conditions 
are more likely to respond to TENS, (i. e. neurogenic) than others (i. e. psychogenic). 
However, the results of Chapter 2 show that any type of pain may respond which 
suggests that factors other than the cause and site of pain may be related to patient 
response to TENS. No relationships were found between social factors related to the 
pain condition (i. e. the duration of the pain condition), or the electrical characteristics 
of TENS adopted during treatment, and response to TENS. 
Psychological: In contrast to the findings of Johansson et al [1980], but consistent 
with the findings of Andersson et al. [1976], the results presented in this thesis 
suggest that traits in personality as measured using the EPQ were not related to TENS 
response in either healthy subjects or pain patients. Furthermore no relationships were 
found to exist between clinical depression and/or anxiety and patient response to 
TENS. 
EEG variables: One of the most important findings within this thesis is the 
relationship between patient response to TENS and baseline EEG measures. Hence, 
patients with small peak-to-peak amplitudes of late components of baseline SEPs and 
low baseline power spectrum show poor response to TENS. As EPs reflect the cortical 
response to external stimuli and TENS is an external stimulus, it may be inferred that 
individuals with little CNS response to external stimuli are less likely to respond to 
TENS. 
Neuropharmacological: The finding that peripherally circulating met-enkephalin 
increases during TENS was surprising and confirmation of these findings in a larger 
patient sample is necessary. However, patient response to TENS was not related to 
baseline levels of peripheral opioid peptides. Opioid peptides produced within the 
periphery are less likely to be involved in pain mechanisms than opioids produced in 
the CNS. Therefore, further experiments are underway to examine changes in CSF 
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concentrations of opioid peptides and GABA during TENS. Unfortunately preliminary 
results are not yet available. 
In summary it appears that an important factor which may influence response to TENS 
is an individual's intrinsic central response pattern to external stimuli. Thus, 
individuals differ in their overall "setting" of nervous system response which may 
account for inter-individual differences in response to TENS. Patients with high 
spontaneous EEG activity and large cortical responses to sensory stimuli show 
favourable responses to TENS. The CNS of these patients appears therefore to amplify 
to a greater extent the incoming afferent barrage (TENS or SEP induced) to produce a 
large SEP response. It has been suggested that cortical responses are related to waves 
of excitatory and inhibitory synaptic potentials [see Cooper et al. 1980a], thus, it may 
be hypothesized that responders to TENS release larger quantities of neurotransmitters 
(some of which may be involved in antinociception) during stimulation. This inter- 
individual variation in response to external stimuli may have implications for inter- 
individual variability in response not only to TENS but to other analgesic treatments 
(i. e. acupuncture). Obviously such a hypothesis needs validation through experimental 
investigation and the author feels that this field of research merits further investigation. 
IMPROVEMENTS IN TENS PROCEDURE 
The results presented in this thesis suggest that improvements in the administration of 
TENS techniques would increase clinical efficacy. Patients, therapists and 
manufacturers could all play a role. 
Patients: The assessment of a patient's response to TENS can sometimes be difficult. 
Thus it is important for patients to understand that TENS is a treatment which may 
symptomatically relieve, rather than cure, the pain problem. Furthermore the analgesic 
effects produced by the electrical paraesthesia of TENS may be qualitatively different 
from those experienced by traditional pharmacological (drug) treatments and patients 
must be made aware of this difference. Patients must learn the correct TENS 
application procedures and be prepared to play an active role in maintaining TENS 
analgesic effects. Thus unlike drug treatment the patient must spend time to find the 
most appropriate stimulation site; and attention should be given to appropriate settings 
and successful treatment regimes for use in future treatment sessions. 
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Therapist: The most important role of the therapist is to administer TENS correctly 
and to provide the patient with appropriate instructions at the initial trial session in the 
clinic. At this trial session it is important to evaluate patient requirements so that: 
(i) elderly patients are not given stimulators which may be-too complicated to use, 
(ii) patients with pains located in regions of the body which are difficult to apply 
electrodes (i. e. back) are supplied with self adhesive electrodes, 
(ii) patients who need to treat two or more sites of pain are supplied with dual 
channel stimulators. 
Patients may readily dismiss TENS as a failure if they feel it is inconvenient to use. 
A two month home trial is necessary to evaluate fully the treatment response. Ideally a 
one month follow-up appointment during this trial could provide the patient with 
additional information on alternative stimulating techniques and advice on improving 
TENS efficacy if the stimulation modes used by the patient are not producing pain 
relief. If this initial follow-up assessment is left too long the patient may have already 
lost faith in the technique and further suggestions by the therapist to improve TENS 
efficacy may prove useless. Regular TENS treatment assessments should then be made 
to monitor progress and to instruct fully the range of stimulating techniques available. 
It is the authors experience (personal observations during Exp. 6.1) that at the one 
month follow-up some patients fail to understand some of the facilities available on the 
stimulators (for example changing pulse frequency). Misconceptions of stimulator use 
do occur and can be remedied at an early follow-up appointment. 
Manufacturers: Possibly the greatest improvements in TENS treatment techniques 
can be made by manufacturers. Manuals accompanying stimulators should provide a 
comprehensive patient orientated guide on TENS application. Appropriate information 
should also be provided for the therapist on different stimulation techniques, and the 
theory behind the incorporation of the multitude of gadgets now appearing on 
stimulators. This is exemplified by burst mode facility incorporated on stimulators for 
the production of AL-TENS, although many company sales representatives and 
therapists are unaware of this fact. 
Inadequacies in stimulator design as reported in this thesis have been noted by TENS 
manufacturers. Recently, a new stimulator'The Xenos', has been designed by NEEN 
Pain Management Systems, and it provides a variety of impressive features including a 
linear frequency and intensity output characteristics (see Table 1.5) and an 80Hz 
frequency reset button. Unfortunately the Xenos stimulator remains deficient by the 
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absence of a visual display for frequency or intensity settings attained during 
stimulation. The stimulator also provides an array of facilities which may appear 
daunting to some patients who may prefer a simple design of stimulator. It has been 
suggested that the analgesic efficacy of TENS may also be improved by concurrent use 
of certain drugs including tryptophan, tricyclic antidepressants and D-phenylalanine 
[Thompson 1989]. Although a number of patients under study in Chapter 2 were using 
TENS in combination with tricyclic antidepressants it was not possible to determine 
any drug-TENS interactions. Clinical trials on the use of these drug-TENS 
combinations may prove useful. 
FUTURE DIRECTIONS 
The findings presented within this thesis support the conclusions of a recent editorial in 
the Lancet [1991] in that ".. it may be irrelevant to subject TENS to further trials. ". 
Thus the long-term efficacy of the technique as a means to control pain has been 
established in an overwhelming number of clinical trials and a wide range of pain 
conditions have been shown to respond to TENS treatment. However, the results of 
Study 2.1 suggest that 41.4% of patients given a trial of TENS fail to respond and of 
those responding about half fail to achieve over 50% pain relief. Future studies should 
aim to elucidate the mechanism of TENS failure. The findings of Exp. 6.1 that 
electrophysiological measures reflect patient response to TENS suggest that a patient's 
intrinsic state of cortical activation to external stimuli, may be an important determinant 
of response. Further studies utilising EPs may improve our understanding of the 
mechanism of TENS effects and inter-patient variability in response. Furthermore, 
studies are underway (by the author) to examine the release of opioid peptides and 
GABA into the CSF during TENS in pain-free patients awaiting hip surgery. The 
findings may be used to improve TENS efficacy by suggesting possible drug/TENS 
combinations. 
Recently a range of non-portable stimulators (i. e. Codetron & Likon), utilising a wider 
range of electrical characteristics (i. e. frequencies up to 5000Hz, multi-electrodes and 
patterns) have been developed. It has been claimed by the manufacturers that these 
stimulators achieve greater analgesic efficacy and also cure a range of ailments. These 
stimulators remain to be validated in the clinic. 
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Despite the extensive use of electrotherapy both past and present, many in the medical 
profession still remain sceptical on the use of electrical stimulators in mainstream 
medicine. In this respect the plea from the Reverend John Wesley which he used to 
end his Desideratwn is as appropriate now as it was in 1759: 
"Before I conclude, I would beg one Thing (If it not be too great a Favour) from 
the Gentlemen of the Faculty, and indeed from all who desire Health and 
Freedom from Pain, either for themselves or their Neighbours. It is That none of 
them would condemn they know not what: That they hear the Cause, before they 
pass Sentence: that they would not pre-emptorily pronounce against Electricity, 
while they know little or nothing about it. Rather let every candid Man take a 
little Pains, to understand the Question before he determines it. Let him for two 
or three weeks (at least) try it himself in the above-named Disorders. And then 
his own Senses will show him, whether it is a mere Play-thing, or the noblest 
Medicine yet know in the World. " 
Quoted from Hymes [1988]. 
CONCLUSION 
The following important findings were presented within this thesis: 
(i) Of patients given a trial of TENS, it was estimated that 58.6% continue to use 
stimulators on a long-term basis (Study 2.1). 
(ii) Any type of pain may respond to TENS treatment (Study 2.2). However, 
certain pain conditions are more likely to respond than others. 
(iii) There were no relationships between the electrical characteristics of TENS used 
by patients during TENS treatment and the cause and site of pain (Study 2.2). 
However, patients utilise specific pulse frequencies and patterns and use these 
settings on subsequent treatment sessions. It was suggested that patients utilised 
specific pulse frequencies and pulse patterns for reasons of comfort (Study 2.3). 
(iv) Pulse frequencies between 20-80Hz were found to produce the greatest 
analgesic effects on experimental pain in healthy subjects (Exp. 3.1). No differential 
effects were found between different pulse patterns (Exp. 3.2). 
(v) AL-TENS provided powerful analgesia during and post-TENS on experimental 
pain in healthy subjects (Exp. 3.3). AL-TENS can be applied at sites distant from 
but myotomally related to, the site of pain. 
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(vi) TENS reduced the amplitude of SEP components in pain-free subjects (Exp. 
4.1), and increased alpha (and beta and theta) activity in spontaneous EEG in both 
pain free subjects (Exp. 4.2) and chronic pain patients (Exp. 4.3). 
(vii) A non-significant increase in peripheral concentration of met-enkephalin was 
found during TENS in pain patients (Exp. 5.1). 
(vii) Patients with small SEP amplitudes and low spontaneous EEG activity show 
poor responses to TENS. 
In conclusion TENS has been shown to be an important therapy for the treatment of 
chronic pain. However certain patients fail to respond or respond poorly to treatment 
and this may be due to a combination of pain-related and pain-unrelated factors. Thus, 
patients with poorly localised, psychogenic or visceral pains are less likely to respond 
to TENS than those with localised pain of neurogenic origin. However, any pain 
condition may respond. Of factors unrelated to the pain, the patient's intrinsic central 
response pattern to external stimuli appears to be related to the response to TENS. 
Furthermore, it appears that TENS effects are mediated, to some extent, via the 
processing of sensory information not specific for the pain system, as changes in 
electrophysiolgical recordings occur in pain-free healthy subjects. 
Clinically, the analgesic efficacy of TENS could be improved by optimising the 
electrical characteristics of TENS utilised by patients and by improving stimulator 
design. Moreover, as TENS does not interfere with the diagnosis or treatment of pain 
conditions, and allows the patient to safely control safely his or her own treatment 
regime, TENS could and should be administered more readily as a primary analgesic 
therapy. 
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APPENDICES 
APPENDIX A 
TENS QUESTIONNAIRES 
The following TENS Questionnaires were used to assess stimulator use and were 
administered by: 
(i) postal communication, 
(ii) the author during a visit by the patient to the research unit. 
The TENS questionnaire was used in Study 2.2,2.3, and Exp. 4.3,5.1. A modified 
version of this questionnaire was used in Experiment 6.1. 
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(1) TENS QUESTIONNAIRE 
Introduction 
We are asking all patients who have previously used a Transcutaneous Electrical Nerve 
Stimulator (TENS) to complete this questionnaire to help us improve existing 
machines. If you no longer use TENS we would still like you to attempt the questions 
as best you can. Please read the instructions carefully. 
(A) PERSONAL DETAILS 
(Please complete) 
NAME 
ADDRESS 
DATE OF BIRTH AGE 
DATE & TIME 
(B) PAIN RATING SCALE 
(not to scale) 
INSTRUCTIONS 
1. Mark with a small cross (x) the point on the 10cm line which represents your pain 
at the moment. 
No Worst pain 
Pain imaginable 
05 
(C) PAIN RELIEF WITH TENS 
(not to scale) 
INSTRUCTIONS 
10 
2. Mark with a small cross (x) the point on the 10cm line which represents the relief 
you have obtained with TENS. 
Relief Complete relief 
of Pain relief of pain 
ý5 10 
Appendix 219 
(D) PAIN DIAGRAM 
INSTRUCTIONS 
1. Please put a line around your affected area and mark: where you have pain 
where you have numbness $COP-$$ ; and where you have pins and needles ;. For example, see over. 
2. If you use a transcutaneous electrical stimulator please indicate with crosses where you place the pads 
(electrodes) 
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(E) MULTIPLE CHOICE QUESTIONS 
INSTRUCTIONS 
Please draw a circle around the number for the answer which is most 
appropriate. There are no right or wrong answers. Please circle only 
one answer unless instructed otherwise. Get a friend to help if 
necessary. 
1. Are you still in possession of a stimulator loaned to you by the clinic ? 
1. Yes 
2. No. I returned it in (year only). 
3. I use a stimulator not given to me by the clinic 
2. If you no longer use a stimulator why did you stop ? 
1. It did not relieve the pain. 
2. It aggravated the pain. 
3. The stimulator was unpleasant. 
4. The electrodes irritated the skin. 
5. Other, please explain 
3. What is the model of your stimulator ? 
1. Cannot remember. 
2. RDG Tiger Pulse. 
3. RDG Tiger Burst. 
4. Spembly. 
5. Microtens. 
6. Other, please specify 
4. Have you, 
1. Used the stimulator at least once within the past 24 hours. 
2. Used the stimulator at least once within the past week. 
3. Used the stimulator at least once within the past month. 
4. Used the stimulator at least once within the past year. 
5. Not used the stimulator for at least a year. 
5. When you were first issued with a stimulator did it relieve your pain, 
1. Better than it does now. 
2. About the same as it does now. 
3. Worse than it does now. 
6. Do you set the switch on the stimulator to, 
1. Always continuous never burst 
2. Occasionally continuous & occasionally burst. 
3. Always burst never continuous. 
7. Does the stimulator reduce your pain, 
1. Not at all 
2. Less than 10% 
3. Between 10-30% 
4. Between 30-60% 
5. Between 60-100% 
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8. When you switch the stimulator on, how long does it take before you start to get 
some pain relief ? 
1. Immediately. 
2. Less than 1/2 hour. 
3.1/2 -1 hour. 
4.1 -2 hours. 5. More than 2 hours. 
9. How long does it take before the original level of pain returns once the stimulator 
has been switched off ? 
1. Immediately. 
2. Less than 1/2 hour. 
3.1/2 -1 hour. 
4.1 -2 hours. 5. More than 2 hours. 
10. How often do you use the stimulator? 
1. Once a month 
2. Once a fortnight 
3. Once a week 
4.2 -4 times a week 
5.5-7times aweek 
6. Everyday 
11. For how long do you normally leave the stimulator switched on at any one time ? 
1. Less than 1/2 hour. 
2. Between 1/2 hr -1 hr. 3. Between 1-2 hours. 
4. Between 2-4 hours. 
5. Between 5-8 hours. 
6. More than 8 hours. 
12. On an average day do you normally use the stimulator at least once between the 
following times, (circle either yes or no). 
1. Between 6.00 a. m. and 9.00 a. m. yes / no 
2. Between 9.00 a. m. and mid-day yes / no 
3. Between mid-day and 3.00 p. m. yes / no 
4. Between 3.00 p. m. and 6.00 p. m. yes / no 
5. Between 6.00 p. m. and 9.00 p. m. yes / no 
6. Between 9.00 p. m. and midnight yes / no 
7. Between midnight and 6.00 a. m. yes / no 
13. How many times do you use the stimulator on a typical day ? 
1. Once. 
2. Twice. 
3. Between 3-6 times. 
4. More than 6 times. 
14. What is the total number of hours that you use the stimulator on a typical day ? 
1. Less than 1. 
2. Between 1-3. 
3. Between 3-5. 
4. Between 5-7. 
5. More than 7. 
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15. While using the stimulator are you normally 
1. Sitting or lying down 
2. Standing or walking around 
3. Sometimes sitting, sometimes standing 
16. Do you ever go outside when wearing the stimulator ? 
1. Often. 
2. Sometimes. 
3. Never. 
17. Do you place the electrodes on the same spot, 
1. Always. 
2. Sometimes. 
3. Never. 
18. Have you ever had any skin complaints (i. e. rash or allergy) due to your 
electrodes, tape or gel? 
1. Yes 
2. No 
3. Don't know 
19. Do you change the rate/frequency (R) button everything you use the stimulator? 
1. Yes 
2. No 
20. Which do you prefer? 
1. Fast pulses 
2. Slow pulses 
SPECIAL QUESTION FOR TIGER PULSE USERS 
Only answer this question if you possess a Tiger Pulse Stimulator. 
21 Which switch setting on the front of the stimulator do you prefer to use 
1. Up. 
2. Down. 
3. Both, up or down depending on the pain. 
4. Both up and down has the same effect. 
Please list the names of any pain killers that you take. 
Thank you for completing this questionnaire. The results will 
hopefully benefit future TENS users. 
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(2) MODIFIED TENS QUESTIONNAIRE 
The following questions were additions to TENS Questionnaire 1 and used in 
Experiment 6.1 
1. What is your occupation ? 
2.. How long have you had the pain for which you were prescribed a stimulator ? 
3.. Did you loose the ability to work because of your pain ? 
4. Do you think the stimulator is too complicated to use ? 
VISUAL ANALOGUE SCALES 
(not to scale) 
PRESENT PAIN RATING SCALE 
1. Mark with a small cross (x) the point on the 10cm line which represents your pain 
at the moment. 
No Worst pain 
Pain imaginable 
05 10 
INSTRUCTION ON TENS TECHNIQUES 
2.. When you were first issued with a stimulator how well were you instructed upon 
its use ? 
Not at Extremely 
all well well 
05 10 
CONFIDENCE IN TENS TREATMENT 
2. When you were first issued with a stimulator how confident were you that it would 
be successful in reducing your pain ? 
Not at Absolutely 
confident confident 
05 10 
THE LOGIC OF TENS AS A TREATMENT FOR CHRONIC PAIN 
3. How logical does this type of treatment seem to you (i. e. do you understand how 
the stimulator relieves your pain) ? 
Not at Very 
logical logical 
os 10 
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(3) TENS follow-up Questionnaire 
NAME 
OCCUPATION 
Does the stimulator help your pain ? 
Do you still use the stimulator ? 
If not why ? 
Have you returned the stimulator to the clinic ? 
Please remember to complete the EPQ and HAD questionnaires. and 
return them in the pre-paid envelope. 
I would like to take this opportunity to thank you for all of your help during the study. 
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APPENDIX B 
Statistical Procedures 
The majority of statistical procedures used in this thesis were performed using Minitab 
Data Analysis Software. Minitab is a general statistical package and was used on an 
Apricot Xen computing system and University mainframe [Ryan et al. 1985]. 
Statistical advice was sort from the Department of Medical Statistics at Newcastle 
University who explored data sets with powerful statistical procedures (i. e. split-plot 
ANOVAs) using "Genstat" data analysis software. No additional relationships were 
found for any of the data sets. For this reason the statistical procedures mentioned 
within the thesis have been restricted to the description of Minitab Data Analysis only. 
Descriptive Analysis: Initial data analysis determined whether the variables 
measured were continuous or categorical. Continuous (or quantitative) variables can be 
defined as those measured on a continuous scale, i. e. age, visual analogue scale 
scores, pain thresholds. Categorical (discrete or qualitative) variables can be defined as 
those measured on discontinuous scales i. e. sex, multiple choice answers. Data sets 
were described by histograms, means, standard deviations and standard errors (for 
continuous variables), and medians (for categorical variables). 
Summary measures: Experiments examining treatment effects were analysed as 
follows. Prior to statistical analysis the data was plotted on a histogram. Continuous 
variables were examined (visually) for normality and data sets with skewed 
distributions were logarithmically transformed prior to statistical analysis. A suitable 
summary measure of response was identified and calculated for each individual i. e. 
total change in ice pain threshold during treatment (Chapter 3) or mean change in EEG 
power during v pre TENS (Exp. 4.2). These summary measures were then analysed 
by simple statistical techniques (i. e. t-tests) as though they were raw data. For a full 
description of the use of summary measures in serially collected data the reader is 
referred to Matthews et al. [1990]. 
Parametric Analysis: Parametric statistical procedures were performed on all 
continuous data sets. Paired student t-tests (2-tailed) were used to compare 
measurements on the same individual, i. e. pre-treatment cycles 1 and 2, or pre- 
treatment mean against during treatment mean. Unpaired student t-tests (2-tailed) were 
used to compare two means when the data was not paired, i. e. differences between 
treatment groups for subjects allocated AL-TENS against subjects allocated 
conventional TENS (Exp. 3.3). One-way ANOVA was used to compare differences 
between three or more groups, i. e. differences in visual analogue scale scores between 
different categories of chronic pain classified according to anatomical region (Study 
2.2). 
Non-parametric Analysis: Non-parametric procedures were used to compare 
categorical variables in a similar manner to that described for parametric analysis. 
Thus, Wilcoxon signed rank test (equivalent parametric test = paired t-test), Mann- 
Whitney U-tests (unpaired t-test) and Kruskal-Wallis (one-way ANOVA) were used to 
examine differences in medians. 
Correlation: The association between two independent variables was measured using 
the Pearson product moment correlation coefficient for parametric analysis and the 
Spearman rank correlation coefficient for non parametric analysis. As correlation 
coefficients test for linear associations, raw data was plotted and exploratory 
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transformations to linearity were performed (i. e. logarithmic, reciprocals square root) 
prior to analysis. 
Heteroscedascity: An important assumption when applying parametric statistical 
procedures is that the variance within groups should be constant (i. e. 
Homoscedascity). Heteroscedascity (from the Greek hetros, other or differently, and 
skedannumi, to scatter or disperse) occurred in the results of Chapter 3 when the 
variance within groups was not constant, i. e. variance increased with increasing mean 
group response. Thus, data was logarithmically transformed prior to statistical analysis 
to make distribution of the data set more symmetrical (normal). 
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APPENDIX C 
(i) Components of the EEG recording system. PA 400 
Amplifier: A4 channel amplifier provides a maximum output for signal amplitudes 
from 10µV (peak-to-peak) to 50 mV (peak-to-peak) and allows a number of frequency 
bands to be selected using high and low pass filters within an overall range of 0- 
10KHz. 
The Microlink Interface: Serves 3 main functions: 
(i) Control of the high speed sampling of EEG signals and their conversion from 
analogue (voltage) to digital (numerical) form. 
(ii) Allows the computer to control other equipment (i. e. stimulator units used 
during EP recording) thus synchronising the start of the sampling of EEG with 
stimulus onset. 
(iii) Allows the computer to sense events from other equipment (i. e. digitimer) thus 
initiating programmed operations remotely. 
The Apricot Computer: This is the heart of the system and controls every aspect of 
operation from the initial stages of data collection through its display and initial 
processing to the printing and storage. of final results. 
The Software: Biodata CEAN 400 software running under MS-DOS (MicroSoft- 
Disk Operating System) provides a variety of special programs for the collection and 
analysis of EEG and evoked potential data i. e. 
(i) Collection and analysis of the background EEG 
(ii) EEG evoked potential averaging 
Digitimer (D4030): Provides (a) series of accurately timed periods which may be 
easily changed and reset during an experiment and (b) an overall recycling function to 
enable repetition of the experiment. Events initiated during EEG recording include the 
triggering of (i) the Microlink to start sampling EEG and (ii) the Grass Stimulator to 
send electrical stimuli or an audiometer to send an auditory tone. The digitimer is also 
interfaced with an Acorn computer with a program providing random stimulus 
presentation during EP recording. 
Grass Dual Pulse Digital Stimulator (S8800): The Grass Stimulator is a 
general purpose, rectangular pulse, dual output electrical stimulator and provides stable 
electrical stimuli. Outputs are referenced to ground and are square wave positive 
voltages. Several accessory units are required. 
(i) Grass Constant Current Unit (CCUI): To convert the constant voltage 
output of the Grass stimulator to a constant current operation and thus maintain the 
current intensity of evoking stimuli. This is important as large changes in resistance 
may occur at the skin electrode-interface. 
(ii) Grass Stimulus Isolation Unit (SIU 5): Isolation of the stimulus signal 
from ground reference reduces the ground current between stimulating and 
recording systems (the primary source of stimulus artefact) and provides greater 
safety for direct human and animal stimulation. 
Acorn computer: Provides a menu driven pseudo random stimulus presentation 
program to trigger the Grass stimulator via the digitimer. 
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Racal Store 4DS FM Tape Recorder: Provides the recording of 4 data channels 
(3 EEG channels and 1 synchronising pulse from digitimer) and 1 voice channel on 
6.25mm (1/4in) magnetic tape for off-line analysis of EEG. 
(ii) Artefacts 
By definition an artefact is any any recorded electrical potential which does not 
originate in the brain and can be produced by: 
(i) EEG equipment, 
(ii) electrical interference external to patient and recording system, (i. e. fluorescent 
lighting) 
(iii) electrodes and leads, (i. e. poor electrode application), 
(iv) the patient (i. e. muscle potentials or eye movements). 
Artefacts due to the stimulus (i. e. an electrical pulse) are produced by the spread of 
stimulus current to the recording electrodes and may obliterate the display of the 
desired response. Stimulus artefacts can be alleviated by: 
(i) isolating the stimulus pulse from ground, using an isolation unit, and thereby 
reducing the circulating ground currents between stimulator subject and recording 
instrument, 
(ii) space stimulating and recording electrodes far apart, 
(iii) use a small stimulator pulse width i. e. (200 µs). 
Nevertheless stimulus artefacts precede the evoked response in time and can be used to 
distinguish the time of the stimulus. 
Artefacts due to muscle potentials manifest as high frequency potentials and can be 
reduced by relaxing or changing the posture of the patient. Eye movement artefacts are 
produced by the potential difference of 100mV existing between cornea and retina and 
are monitored using nasion electrodes placed around the eye. Monitoring eye 
movements at the nasion enables off-line analysis of electro-oculographical (EOG) 
activity and the subsequent rejection of contaminated epochs (in spontaneous EEG 
recording) or compensation of primary electrodes by subtracting a proportion of EOG 
recorded at the nasion electrode (in EP recording) [Verleger et al 1982, Thom and 
Andersen 1984]. 
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APPENDIX D 
Addresses of suppliers 
Microtens 7757 and Xenos TENS units. 
NEEN Pain Management Systems, Old Pharmacy Yard, Church Street, East Dereham, 
Norfolk, NR 19 I DJ, U. K. 
RDG Tiger burst and Tiger Pulse TENS units. Frye Analyser. 
RDG-Electromedical, 429 Brighton Road, Croydon, Surrey, CR2 6UD. 
Spembly 9000 TENS units. 
Spembly Medical Limited, Newbury Road Andover, Hampshire, SP10 4DR, 
England. 
Met-enkephalin 
INC star Ltd., Atlantic Antibodies, Bulldog house, Winnersh, Berks, RG11 5AB. 
Human Beta-endorphin 
Biogenesis Ltd., 12 Yeomans Park, Yeomans Way, Bournemouth, BH8 OBJ. 
CEAN 400 (Computerised Electroencephalographic ANalysis system) 
Biodata Ltd., 10 Stock Street, Manchester, M8 8QG, U. K. 
